FORM 2 THE PATENT ACT 1970 (39 of 1970) & The Patents Rules, 2003 COMPLETE SPECIFICATION (See section 10 and rule 13) 1. TITLE OF THE INVENTION: 'Triple-Targeting, Chiral, Broad-Spectrum Antimicrobial 7-Substituted Piperidino-Quinolone Carboxylic Acid Derivatives, their Preparation, Compositions and use as Medicaments' 2. APPLICANT (S) (a) NAME (b)NATIONALITY (c) ADDRESS Wockhardt Limited Indian : Wockhardt Towers Bandra-Kurla Complex, Bandra (E) Mumbai-400 051, India 3. PREAMBLE TO THE DESCRIPTION The following specification particularly describes the invention and the manner in which it is to be performed. Field of the Invention: The present invention relates to novel antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives and pharmaceutically acceptable salts thereof. Methods' of preparation of the compounds of the invention, compositions of compounds of the invention and their use are also described. Background of the Invention: The fluoroquinolone group of antibiotics available since the early 1960s are valuable as antibacterial agents. There have been synthesized, developed and marketed quinolone carboxylic acid derivatives having various chemical structures. Nalidixic acid, the progenitor of the series, was used primarily as a urinary tract antiseptic. Later development provided agents with broader activity, increased potency against selected pathogens and improved pharmacokinetic and pharmacodynamic properties. From a medical utility viewpoint, the quinolones are classified as first-, second-, and third-generation compounds (Gootz T D et al, Chemistry & Mechanism of Action of the Quinolone Antibacterials. In Andriole VT ed. The Quinolones, San Francisco, Academic Press, 1998, 28-80). First-generation compounds like piromidic acid and pipemidic acid provided coverage for gram-negative Enterobacteriaceae. The second-generation compounds are divided into those with enhanced but predominant gram-negative activity, against pathogens like Escherischia coli and Pseudomonas aeruginosa, and those with balanced broad-spectrum activity (norfloxacin, pefloxacin, enoxacin, fleroxacin, lomefloxacin, ciprofloxacin, ofloxacin, rufloxacin, nadifloxacin). Norfloxacin, ofloxacin and ciprofloxacin have, therefore, been used mainly for treatment of diseases including urinary tract infections, gastrointestinal infections, sexually transmitted diseases and the like. Third-generation drugs (levofloxacin, pazufloxacin, sparfloxacin, clinafloxacin, sitafloxacin, trovafloxacin, tosufloxacin, temafloxacin, grepafloxacin, balofloxacin, moxifloxacin, gatifloxacin) are those with enhanced activity against gram-positive cocci (notably clinafloxacin, sitafloxacin, trovafloxacin for Streptococcus pneumoniae) and, for essentially all the third- generation quinolones, activity also against gram-negative Haemophilus influenzae and Legionella pneumophila, and against anaerobes and atypical pathogens (Ball P, The Quinolone. History 2 2 MAR 2006 and Overview. In Andriole VT ed. The Quinolones, San Francisco, Academic Press, 1998,1-28). Levofloxacin, moxifloxacin and gatifloxacin have, therefore, found use for community-acquired infections such as those of the upper and lower respiratory tract infections (RTI) like pneumonia, sinusitis and pharyngitis, and for skin and soft tissue infections (SSI) caused by gram-positive strains of staphylococci, pneumococci, streptococci and enterococci. The improvements seen in most of the third-generation drugs in current use are generally attributed to their uniqueness in inhibiting the bacterial targets, DNA gyrase and topoisomerase IV. Three categories of quinolone inhibition have been suggested. Type I quinolones (norfloxacin, enoxacin, fleroxacin, ciprofloxacin, lomefloxacin, trovafloxacin, grepafloxacin, ofloxacin and levofloxacin) indicated a preference for topoisomerase IV inhibition. Type II quinolones (nadifloxacin and sparfloxacin) indicated a preference for DNA gyrase inhibition. Type HI quinolones to which some of the third-generation quinolones belong (gatifloxacin, pazufloxacin, moxifloxacin and clinafloxacin) display, however, a dual-targeting property, and equally influence DNA gyrase inhibition and topoisomerase IV inhibition. (Takei M et al, Antimicrobial Agents and Chemotherapy, 2000; 45:3544-49). DNA gyrase is the primary target in bacteria, and thus is explained the weaker activity in gram-positive bacteria of the preferred topoisomerase IV-targeting second-generation quinolones like norfloxacin, ciprofloxacin, ofloxacin, and levofloxacin. The unusual activity of nadifloxacin described by others, and further significantly elaborated for S-(-)-nadifloxacin by us (cf: our pending US application Nos. 09/566,875, 09/850,669, WO 00/68229 and WO 01/85728), specially against gram positive S. aureus, is now better understood in view of its being shown to be DNA-gyrase targeting, which is the first such report for a quinolone in 5. aureus (Oizumi N et al, J . Infect. Chemother, 2001; 7: 191-194). Some, but not all, third generation quinolones being primarily topoisomerase IV-targeting in gram-positive staphylococci, and DNA gyrase-targeting in gram-positive S. pneumoniae, explains the advantages provided by the dual-targeting third-generation quinolones like moxifloxacin and gatifloxacin. The evolution of quinolones from first-generation to second-generation to third-generation compounds has also been guided by structure-activity relationship studies. It has been determined by those in the art that certain structures with specific sites on the quinolone ring functionalised have distinct advantages over others. Structure-activity relationships of the 3 quinolones have been the subject of detailed study for more than a decade (Asahina Y et al, Recent Advances in Structure Activity Relationships in New Quinolones, Prog. Drug Res., 1992, 38, 57-106) As a result of these studies, it has been determined by those in the art that certain structures, with specific sites on the quinolone ring functionalised, have distinct advantages over others. The structural feature that remains constant throughout the drug class is the bicyclic aromatic core consisting of 2 fused 6-membered rings. This core can contain a carbon at the 8-position, yielding a true quinolone, or a nitrogen which provides a ring system technically termed a naphthyridone, or an additional fused ring across the N-l and C-8 positions yielding tricyclic heterocycles, such as pyridobenzoxazines and benzoquinolizidines. In the context of the current invention, the nature of the amine group at the 7-position takes on special relevance. It is notable that in the cited second-generation quinolones the piperazine ring remains relatively constant and undisturbed as a 7-substituent, except for alkylation on the distal nitrogen, or less frequently on the ring carbons. In the third-generation quinolones, the continuing trend of use of a C-7 cyclic amino group is also almost universal. The presence of a second amine, in addition to the nitrogen bonded to C-7 of the quinolone nucleus has been found to be important. However, amongst these new quinolones, too, the frequent employment of mainly a C-7 piperazino or pyrrolidino variant is to be noted, but with only one example of a C-7 piperidino substituent. Only two of the above-cited quinolones, the second-generation nadifloxacin and the third-generation balofloxacin, have a C-7 piperidino substituent. Nadifloxacin with a hydroxypiperidine substituent at the C-7 position is notable for its being the sole marketed modern quinolone without a distal amino group, but is merely a topical agent. Balofloxacin has an unusual 3-methylaminopiperidino substituent, which is, however, said to be the contributing element to its lower activity against Enterobacteriaceae and Mycoplasma pneumoniae. Among the recent fluoroquinolones which have been introduced commercially are moxifloxacin and gatifloxacin. Both these antibacterial agents have an 8-methoxy substituent in the fluoroquinolone core. As 7-substituents in the core, there is for moxifloxacin a bicyclic pyrollidine as the amino moiety, and for gatifloxacin a substituted pyrollidine as the amino moiety. A more recently described olamufloxacin, which has been shown to have activity in murine models of system infections and urinary tract infections, has an 8-methyl substituent in its fluoroquinolone core in which the C-7 substituent is also a substituted pyrollidine. No commercially introduced fluoroquinolone or one that has commercial potential is known in which a piperidino group, substituted or unsubstituted, is introduced at the 7-position of the quinolone structure also having a methoxy group or methyl group at the 8-position. Since the 1960s, in an enormous worldwide effort, well more than 10,000 structurally- related fluoroquinolone agents have been described in many hundreds of patents and journal articles. Despite the understanding of the need of a cyclic amine at the C-7 position, the prior art appears to have discounted the value of having a piperidino moiety, unsubstituted or substituted, as a C-7 substituent. For instance, a 1992 review article (Asahina Y et al, vide infra) indicates the comparative low prior art interest in C-7 piperidino substituents, wherein there are only 21 piperidino moieties cited in comparison to 188 piperazino moieties, and 74 pyrollidino moieties out of a total of 578 C-7 amino moieties. Just as there are structure-activity relationships, there are also structure-side effect relationships that have been determined. Side effects and adverse events related to N-l, C-5, C-8 variants of the quinolone core are generally those that contribute to increase in theophylline interactions, clastogenicity, phototoxicity, hepatotoxicity, cardiotoxicity, arthropathy and tendonitis. Notable is the pattern of (a) the N-l cyclopropyl and C-8 fluorine, chlorine or methoxy substituted quinolone reported to show heightened cytotoxicity (Domagala J M, J. Antimicrob. Chemother., 1994; 33: 655-706), which can be modulated, however, by further structural manipulation (Gootz T D et al, vide infra), (b) the presence of halogen atoms (fluorine or chlorine) at the C-8 position (sparfloxacin, clinafloxacin) enhancing the tendency to induce photosensitivity, (c) the N-l difluorophenyl substituent in trovafloxacin and temafloxacin associated with hepatotoxicity and hemolytic anemia and (d) the C-5 methyl (grepafloxacin) and C-8 methoxy substituent (moxifloxacin, gatifloxacin) contributing to prolongation of the QT interval and the development of a form of ventricular tachycardia known as torsade de pointes. As important, if not more so, than the above-mentioned substituents of the fluoroquinolone core is the amine substituent at the C-7 site. C-7 pyrrolidines tend to show increased cytotoxicity over piperazino substituents, with the combination of 3-substituted pyrrolidines at C-7 and halogens at C-8 providing the most cytotoxic compounds.(Suto N J et al, J Med 5 Chem 1992; 35:4745-50; Mundell L A et al, Clin Infect Dis, 2001; 32(Suppl): S74) In the second most frequently encountered form of quinolone toxicity, namely adverse events involving the CNS, it is the unsubstituted piperazines which correlate best with the degree of GABA-binding inhibition, closely followed by the pyrrolidinyl quinolones. The incremental improvements that have resulted in moving from first- to second- and third-generation quinolones are a consequence of the understanding of the modulation brought about by a combination of a fluoroquinolone core moiety with a C-7 amino substituent. Although certain substituents can impart improvements, whether on one hand in antibacterial potency or on the other in a minimised potential for adverse effect, it is the overall characteristics of each molecule derived from the interaction of all the substituents with each other and with the specific nucleus employed that brings newer gains. Furthermore, characteristics in addition to those of activity and side effects are central to the development of improved human theraputants such as selective molecular mechanisms of action, broader antibacterial coverage to include anaerobes, atypical and resistant pathogens, improved pharmacokinetics and pharmacodynamics, and devoid of class-identified toxicity features. It is, thus, clear that the art has focussed on identifying new quinolones to progress from earlier generation compounds to the next generation compounds. Despite the progress made, the full promise of the quinolones has not yet been exploited. Examples of bacterial infections resistant to antibiotic therapy have been reported in the past; they are now a significant threat to public health in the developed world. The development of microbial resistance is of increasing concern in medical science. "Resistance" can be defined as existence of organisms, within a population of a given microbial species, that are less susceptible to the action of a given antimicrobial agent. This resistance is of particular concern in environments such as hospitals and nursing homes, where relatively high rates of infection and intense use of antibacterials are common. Recent international conferences in 2002 on infectious diseases organised by the Centres for Disease Control and Prevention, USA, World Health Organisation and other groups have highlighted emerging infectious diseases, in which the word "emerging" refers to newly discovered infectious diseases or old ones that have rebounded, turned up in new places, or become drug resistant. The mechanisms of bacterial resistance to fluoroquinolones is generally believed to function by two principal categories, both resulting from chromosomal mutations (DC Hooper, Drug Resis Updat 1999; 2:38-55). One category is the alterations in drug target enzymes. Fluoroquinolone resistance mutations generally occurring stepwise have been localized to specific regions of the parC and parE genes (grlA and grlB in S. aureus) encoding topoisomerase IV, and the gyrA and gyrB genes encoding DNA gyrase. This clustering of mutations has defined the quinolone resistance determining regions (QRDRs) of these genes that are in proximity to the apparent enzyme active site and are thought likely to constitute a domain at which quinolones interact directly with the enzyme-DNA complex. The manner by which the emergence of resistant mutants can be prevented is receiving attention, but is as yet insufficiently understood and continues to be speculative. Studies with the C-8 methoxy fluoroquinolones bearing a C-7 unsubstituted or 3-alkyl substituted piperazino substituent provide support to the concept that attack of both gyrase and topoisomerase IV equally would be ideal. In cases where single point mutation already exists, then a quinolone that would preferably potently inhibit the primary more essential target, whether gyrase or topoisomerase IV, would be better to prevent the resistance (Zhao et al, Proc. Natl. Acad. Sc. 1997; 94: 13991-13996). No similar study, to our knowledge, is available for compounds with a C-7 piperidino substituent, whether unsubstituted or substituted, in any quinolone core. The second category for bacterial resistance to develop is alterations that limit permeation of drug to the target. In S. aureus the elevated expression of the norA gene is responsible for efflux-mediated resistance to quinolones. Factors influencing the decrease in activity of quinolones in efflux-mediated resistant mutants of S. aureus have been suggested not to be hydrophobicity of the whole quinolone molecule, but rather the bulkiness at the C-7 substituent, and bulkiness and hydrophobicity at the C-8 substituent (Takenouchi T et al, 1996; 40:1835-42). Only two of forty quinolones included in this analysis bore a C-7 amino-substituted piperidino substituent. The effect of efflux was more pronounced with the compound bearing the 4-amino substituted piperidino substituent, its MIC value being 8 times more with an efflux pump-bearing strain than with a non-efflux pump-bearing strain, as compared with a 2 times more value for the 3-amino substituted piperidino substituent. Surprisingly, unlike this precedent, the present invention shows that appropriately substituted 4-amino piperidine substituents on different fluoroquinolone cores display potent efflux pump inhibitory/uptake facilitatory properties. 7 Stereochemistry-activity relationships are also of importance in considerations regarding the advancement of quinolones that can exist as isomers. For instance, S-(-)-levofloxacin, as an example of a compound in which the chiral centre is close to the quinolone nucleus, is from 8-128 fold as potent as the R-(+)-enantiomer. Earlier work and our pending US patent application Nos. 09/566,875 and 09/850,669, WO 00/68229 and WO 01/85728 on nadifloxacin, which like levofloxacin has a relatively similar chiral centre, also disclose the superior profile of S-(-)-nadifloxacin over the R-(+)-enantiomer. Chiral centres at C-7 that are at some distance from the quinolone nucleus are said to contribute less significantly to biological activity. However, the relative orientation of the methyl groups on the C-7 piperazine of sparfloxacin is important for bacterial enzymes versus mammalian enzyme selectivity. Sparfloxacin, bearing methyl groups with a cw-stereochemistry essential for its antibacterial activity, displays dramatic differential effects on mammalian topoisomerase-II with no or less interaction with the mammalian enzyme, in contrast to the trans-isomer which does interact with the mammalian enzyme, while however retaining its antibacterial activity (Gootz T D et al., vide infra). Unlike this prior art, the present invention once again surprisingly shows that stereochemical differences of substituents on the C-7 piperidino moiety, while dramatically affecting antibacterial activity, do not significantly influence cytotoxicity of mammalian cell lines, irrespective of whether the differences are enantiomeric or diastereomeric. Both of the third-generation fluoroquinolone market introductions of moxifloxacin and gatifloxacin with improved activity against gram-positive pathogens, have an 8-methoxy substituent in the core fluoroquinolone nucleus. Even their coverage, however, of staphylococci is considered partial, as they possess weak antibacterial activity against most of the methicillin-resistant strains. Moreover, moxifloxacin and gatifloxacin have failed to show therapeutically relevant potency for recent widely reported ciprofloxacin-resistant and levofloxacin-resistant strains of pneumococci. In addition, the potency of newer fluoroquinolones such as moxifloxacin against gram-negative pathogenic bacteria such as E. coli and P. aeruginosa has considerably diminished. Therefore, there is a need for newer orally effective fluoroquinolone antibacterials with superior potency not only against methicillin-resistant, macrolide-resistant and fluoroquinolone-resistant strains, viz. multidrug-resistant strains of gram-positive staphylococci and pneumococci, but also against gram-negative strains with potency 8 comparable to ciprofloxacin and levofloxacin, and against the now so called emerging infectious diseases. Accordingly, numerous studies are being continuously conducted to address the disadvantages of the fluoroquinolones having an 8-methoxy substituent or 8-alkyl substituent or other 8-substituents to make them considerably more potent against bacterial pathogens, to increase their spectrum coverage to include the insufficiently addressed pathogens like mycobacteria, anaerobes, and atypicals, to optimise their action towards bacterial molecular targets, to reduce their efflux or facilitate their cellular uptake, and to improve their oral bioavailability and toxicity profile. Some 1,4-dihydroquinolone related moieties bearing an 8-methoxy substituent are known in the art to have antimicrobial activity and are described in the following references: U.S. Patent No. 4,638,067 to Culbertson, et al. on January 20, 1987; US Patent No. 4,665,079 to Culbertson, et al. on May 12, 1987; European Patent Application 0230295A2 of Kyorin Pharmaceutical Co. pub. July 29, 1987; European Patent Application 0241206A2 of Ube Ind pub. October 14, 1987; U.S. Patent No. 4,822,801 to Domagala et al. on April 18, 1989; U.S. Patent No. 509 7032 to Domagala et al. on March 17, 1992; U.S. Patent No. 5,051,509 to Nagano et al. on September 24, 1991; European Patent Application 0541086A1 of Kaken Pharmaceutical Co. published May 12, 1993; European Patent Application 0572259A1 of Ube Ind. Published December 1, 1993; WO 1993JP 1925 of Japan Tobacco, Inc., dated December 28, 1993; European Patent Specification 0342675B1 of Chugai Seiyaku Kabushiki Kaisha published January 25, 1995; Japanese Patent 6-145167 published May 24, 1994; US Patent No. 5,607,942 of Clive Petersen et al. on March 4, 1997; PCT Patent Application No. PCT/KR94/00005 to Korea Research Institute of Chemical Technology published July 21, 1994; U.S. Patent No. 5,677,316 to Hideki et al. on October 14, 1997; World Patent W098/58923A1 to Hagano et al. on June 23, 1998; US Patent No. 4,777,175 to Warner-Lambert Co. on October 11, 1988; European Patent Application 0919553A1 of Daiichi Pharma Co. published June 2, 1999; US Patent No. 6,121,285 to Takemura et al., on September 19, 2000; US Patent No. 6,329,391 Bl to Benoit Ledoussel et al. On December 11,2001. Similarly some 1,4-dihydroquinolone related moieties bearing an 8-alkyl substituent, in particular an 8-methyl substituent, are known in the art to have antimicrobial activity and are 9 described in the following references: US Patent No. 4,874,764 to Hiraki Ueda et al, on October 17, 1989; US Patent No. 4,935,420 to Hiraki Ueda et al., on June 19, 1990, US Patent No. 5,859,026 to Ito et al., on January 12, 1999 and European Patent application 0919553A1 of Daichi Pharmaceutical Company published June 02, 1999; US Patent No. 6,121,285 to Takemura et al., on September 19, 2000. The methods of producing quinolone carboxylic acids bearing an 8-methoxy substituent are also to be found in the following references: U.S. Patent No. US 5,639,886 to Zerbes et al. on June 17, 1997; U.S. Patent No. 5,869,661 to Ochi et al. on February 9, 1999; and PCT Patent Application No. W0 99/26940 to Bayer Aktiergesellschaft published June 3, 1999. The methods of producing quinolone carboxylic acids bearing an 8-methyl substituent are also to be found in the following references: US Patent No. 5,859,026 to Ito et al., on January 12,1999; US Patent No. 6,121,285 to Takemura et al., on September 19, 2000. European Patent application 0919553A1 of Daichi Pharmaceutical Company published June 02, 1999. A number of compounds having a cyclic amino moiety as substituents at the 7-position of these quinolone carboxylic acids are already known. In addition, many attempts have been made to modify the 7-cyclic amino moiety with various substituents to produce superior compounds, and, for example, a cyclic amino substituent such as 4-amino-l-piperidinyl group or 4-hydroxy-l-piperidinyl group wherein the adjacent carbon atom to the amino or hydroxy substituent is further monosubstituted by an alkyl substituent is known, as hereinbelow described in the identified patent applications and patents. For example PCT Patent Application WO 99/14214 and US Patent No. 6,329,391B 1 discloses a compound having a cyclic amino substituent of the formula wherein each symbol is as defined in the specification of the above-mentioned publication. For the piperidino substituent at the 7-position of the quinolonecarboxylic acid, the compounds having substituents of 3-amino-4-methyl, 3-amino-4-4-dimethyl, 3-amino-4-spirocyclopropyl, 3-amino-6-cycIopropyl, are included in the preferred examples therein. However, specific examples of compounds having a substituent at the 7-position as piperidine of the present invention with a 4-amino or 4-hydroxy substituent with 2-alkyl, 3-alkyl, 5-alkyl or 6~alkyl substituents, or with geminal 3,3-dialkyl, or 3,5-dialkyl, or 3,3,5-trialkyl substituents, located at a position adjacent to the substituent at the 4-position, are not disclosed. What is more, compounds with a piperidine substituent at the 7-position as defined in the cited patent application above with a substituent in the 8-position as a methoxy group (Rs = OCH3) or as an alkyl group (Rg = CH3, C2H5) and the substituent in the 6-position as a fluoro group (R6 = F) are also not disclosed. European Patent Application 241206A2 discloses a compound having a 7-cyclic amino substituent of the formula o with one meaning of Y being , R4—/ N— wherein each symbol is as defined in the specification of the above-mentioned publication at the 7-position of quinolonecarboxylic acid and the compounds having substituents of 4-hydroxy-3-methyl, 4-amino-3-methyl, or 4-methylamino-3-methyl are included as specific examples therein. However, specific examples of the compounds having a substituent at the 7-position as piperidine of the present invention with a 4-amino or 4-hydroxy substituent with 2-alkyl or 6-alkyl substituents, or with 3,3-dialkyl substituents, geminally located at a position adjacent to the substituent at the 4-position are not disclosed. 11 European Patent Application 0394553B1 discloses a compound for the treatment of HTV infections having a 7-cyclic amino substituent of the formula wherein each symbol is as defined in the specification of the above-mentioned publication at the 7-position of the quinolone carboxylic acid with a 4-amino substituent and a single 3-alkyl substituent or a 3-3-dialkyl substituent claimed. However, specific examples of the compounds having a substituent at the 7-position as piperidine of the present invention with a 4-amino or 4-hydroxy substituent with 2-alkyl, 3- alkyl, 5-alkyl or 6-alkyl substituents, or with geminal 3,3-dialkyl, or 3,5-dialkyl, or 3,3,5-trialkyl substituents, located at a position adjacent to the substituent at the 4-position are not disclosed. What is more, compounds with a piperidine substituent at the 7-position as defined in the cited patent application above with a substituent in the 8-position as a methoxy group (Q = C-OCH3) or as an alkyl group (Q = C-CH3, C-C2H5) are also not disclosed. European Patent Application 0304087A2 discloses a compound having a 7-cyclic amino substituent of the formula wherein each symbol is as defined in the specification of the above-mentioned publication at the 7-position of the quinolone carboxylic acid with a 4-amino substituent and a single 3-alkyl substituent is claimed. However, specific examples of compounds having a substituent at the 7-position as piperidine of the present invention with a 4-amino or 4-hydroxy substituent with 2-alkyl, 3-alkyl, 5-alkyl or 6-alkyl substituents, or with geminal 3,3-dialkyl, or 3,5-dialkyl, or 3,3,5-trialkyl substituents, located at a position adjacent to the substituent at 12 the 4-position are not disclosed. What is more, compounds with a piperidine substituent at the 7-position as defined in the cited patent application above with a substituent in the 8-position as a methoxy group (X = C-OCH3) or as an alkyl group (X = C-CH3, C-C2H5) are also not disclosed. European Patent Application 0572259A1 discloses a compound having a 7-cyclic amino substituent of the formula COOH wherein each symbol is as defined in the specification of the above-mentioned publication at the 7-position of the quinolone carboxylic acid with a 4-amino piperidinyl moiety wherein the amino group is substituted with an aryl or aromatic hetero monocyclic group or a fused aromatic group and a single 3-alkyl substituent is disclosed. However, specific examples of compounds having a substituent at the 7-position as piperidine of the present invention with a 4-amino or 4-hydroxy substituent with 2-alkyl, 3-alkyl, 5-alkyl or 6-alkyl substituents, or with geminal 3,3-dialkyl, or 3,5-dialkyl, or 3,3,5-trialkyl substituents, located at a position adjacent to the substituent at the 4-position are not disclosed. What is more, compounds with a piperidine substituent at the 7-position as defined in the cited patent application above with a substituent in the 8-position as a methoxy group (X= C-OCH3) or as an alkyl group (X = C-CH3, C-C2H5) are also not disclosed. European Patent Application 0287951A2 discloses a compound having a 7-cyclic amino substituent as in the following formula in which one of the meanings of R2 is substituent which is a 5- to 9- membered saturated or unsaturated heterocyclic ring which may be substituted, wherein each symbol is as defined in the specification of the above-mentioned publication at the 7-position of the quinolone carboxylic acid with a 4-hydroxy piperidinyl moiety. However, specific examples of compounds having a substituent at the 7-position as piperidine of the present invention with a 4-amino or 4-hydroxy substituent with 2-alkyl, 3-alkyl, 5-alkyl or 6-alkyl substituents, or with geminal 3,3-dialkyl, or 3,5-dialkyl, or 3,3,5-trialkyl substituents, located at a position adjacent to the substituent at the 4-position are not disclosed. What is more, compounds with a piperidine substituent at the 7-position as defined in the cited patent application above with a substituent in the 8-position as a methoxy group (R3 = OCH3) or as an alkyl group (R3 = CH3, C2H5) are also not disclosed. U.S. Patent No. 4,382,892 discloses a compound having a cyclic substituted amino group which is a 4- to 7- membered ring which may be substituted, wherein each symbol is as defined in the specification of the above-mentioned publication at the Z substituted position of the quinolone carboxylic acid with a 4-amino 1-piperidinyl moiety, 4-dimethylamino 1-piperidinyl moiety and 4-hydroxy 1-piperidinyl moiety. However, specific examples of compounds having a substituent at the 7-position as piperidine of the present invention with a 4-amino or 4-hydroxy substituent with 2-alkyl, 3-alkyl, 5-alkyl or 6-alkyl substituents, or with geminal 3,3-dialkyl, or 3,5-dialkyl, or 3,3,5- 14 below, which show potent antibacterial activity against a broad range of pathogenic microorganisms, including both gram-positive and gram-negative strains with advantages of activity against resistant microorganisms, reduced toxicity, and improved pharmacology and pharmacokinetics. It is another aspect of the present invention to provide a process for preparing 7-substituted piperidino-quinolone carboxylic acid derivatives of the formula I. It is a further aspect of the present invention to prepare the intermediates that are necessary to obtain the 7-substituted piperidino-quinolone carboxylic acid derivatives of the formula I. It is a further aspect of the present invention to provide compositions containing 7-substituted piperidino-quinolone carboxylic acid derivatives of the formula I as an active component. It is also an aspect of the invention to use the 7-substituted piperidino-quinolone carboxylic acid derivatives of the formula I of the invention and compositions containing them as medicaments for the treatment of infectious diseases. 16 Summary of the Invention This invention describes fluoroquinolones of the formula I Formula I wherein R1 is C1-5 alkyl, substituted C1-5 alkyl C3.6 cycloalkyl, substituted C3.6 cycloalkyl, aryl; substituted aryl; or when Q is CH and the nitrogen atom to which R1 is linked forms an optionally substituted 5-, 6- or 7-membered ring with the carbon atom of Q, the ring optionally containing one or more hetero atoms selected from nitrogen, oxygen or sulfur atoms, said heteroatom(s) represented by T, preferably R1 is CH2CH2-, CH2T-, CH2CH2CH2-, CH2CH2T-, CH2TCH2-, TCH2T-, TCH2CH2CH2CH2- CH2CH2CH2T-, CH2TCH2CH2., and TCH2CH2T- where T represents NH, O, or S. If the ring is substituted, the substituent is as defined above for Ri. Y is OR3 where R3 is hydrogen; R3 is C1-C20 alkyl, such as straight chain or branched chain aliphatic residues; R3 is aralkyl; R3 is CH2CH(NH2)COOH; R3 is (CH2)„-CHR10-OCOR11 or (CH2)n-CHR10-OC02R11 wherein R10 is H, or CH3; n is 0-3 and Rn is C1-C20 lkyl or substituted C1-C6 alkyl or aralkyl or Rn is CH2 CH3 O O T o or R3 is an alkanoylalkyl group; 17 2.2. MAR 2°06 or R3 is —(CH2)P-A Z wherein A is CH or N, and when A is CH, Z is NH or NCH3, and when A is N, Z is CH, O, NH, S, orNCH3; p is 0 - 2 ; q is 0- 2; or Y is NHR2, wherein R2 is H, C1-20 alkyl, C3.6 cycloalkyl, substituted C3.6 cycloalkyl, aryl or substituted aryl, heteroaryl, all of which heteroaryl residues may be further substituted or unsubstituted; or R2 is the amino acid residue derived from one of the 20 naturally occurring amino acids, or the optically active isomers thereof, or the racemic mixtures thereof; Rs is H, Ci-s alkyl, C1-5 alkoxy, amino, C1.5 alkylamino, or C1.5 acylamino; Q is -N-, -C(R8)- (R8 being H, F, CI, bromo, C1.4 alkyl or unsubstituted or substituted C1-4 alkoxy, wherein when the alkoxy group is substituted it is substituted by one or more halogen atoms such as F, CI, or Br), or when Q is CH and the nitrogen atom to which Ri is linked forms an optionally substituted 5-, 6- or 7-membered ring with the carbon atom of Q, the ring optionally containing one or more hetero atoms selected from nitrogen, oxygen or sulfur atoms, said heteroatom(s) represented by T, preferably Rj is CH2CH2-, CH2T-, CH2CH2CH2-, CH2CH2T-, CH2TCH2-, TCH2T-, TCH2CH2CH2CH2- CH2CH2CH2T-, CH2TCH2CH2., and TCH2CH2T- where T represents NH, O, or S. If the ring is substituted, the substituent is as defined above for R\. X is OR4, wherein R4 is hydrogen, or C1-C20 alkyl, or glycosyl, or aralkyl, or C1-C6 alkanoyl or aminoalkanoyl or an acid residue derived from one of the 20 naturally occurring amino acids, or the optically active isomers thereof, or the racemic mixtures thereof, or R4 is 1- aminocyclohexylcarbonyl or COORn wherein Rn is as hereinbefore defined or R4 is - (CH2)n-CHRio-OCOORn where RJ0 and Rn are as hereinbefore defined, or R4 is CeHnOg, P02(CH3)H, P03H2, P02(OCH3)H or S03H thus giving respectively the gluconic acid, phosphonic acid, phosphoric acid and sulfonic acid ester derivatives of the compounds; or X is NR6R7, wherein R6 is H, C1-20 alkyl, C3-6 cycloalkyl, aralkyl; C1.20 alkanoyl, or C1-20 alkoxycarbonyl, aralkyloxycarbonyl, amino(C1-2o)alkanoyl, or an amino acid residue derived from one of the 20 naturally occurring amino acids or the optically active isomers thereof, or the racemic mixtures thereof. The amino acid residue is derived from a single amino acid or from combinations of amino acids that form dipeptide, tripeptide or polypeptide amino acid unit residues, wherein a terminal carboxy group is optionally protected by C1-4alkyl or aralkyl groups and a terminal amino group is optionally protected by a '-Boc (teritarybutyloxycarbonyl), F-Moc (fluorenylmeth.oxycarbonyl) or Cbz (benzyloxycarbonyl) group R6 may also be COORn wherein R11 as hereinbefore defined or R6 is C6Hn06 thus giving the gluconic acid ester derivative of the compounds. R7 is H, Ci_6 alkyl, C3.6 cycloalkyl, aralkyl; Ci.g alkanoyl, aralkyloxycarbonyl or amino Q 20 alkanoyl; or an amino acid residue derived from one of the 20 naturally occurring amino acids or the optically active isomers thereof, or the racemic mixtures thereof. The amino acid residue is derived from a single amino acid or from combinations of amino acids that form dipeptide, tripeptide or polypeptide amino acid unit residues, or R7 may be CeHnOe. Rs/Rs' are substituents at the 3/3-position of the piperidino ring and are the same or different and represent H, C1-6 alkyl, substituted Q-6 alkyl, alkylamino, or aralkyl. R9 is a substituent at the 4-position or 5-position of the piperidino ring and represents H, C1-6 alkyl, C1.5 alkylamino, Ci_3 dialkylamino or aryl or aralkyl or a trihaloalkyl. This invention also includes optical isomers, diastereomers, enantiomers, polymorphs, pseudopolymorphs, pharmaceutically acceptable salts, hydrates, or biohydrolyzable esters, amides, or solvates of the fluoroquinolones of formula I and prodrugs of these compounds. In addition, compositions incorporating the compounds of the invention, or using compounds of the invention as starting material are also contemplated in this invention. The new compounds of the invention have increased potency and bactericidal activity that can be attributed to the combinations of the respective Rj, Y, R5, Q substituents in the fluoroquinolone cores and the respective X, Rg, Rg>, R9 substituents on the 7-substituted piperidino moieties introduced in the cores. The compounds of the invention thus belong to a new generation of dual-targeting, non-effluxed, diastereomeric, enantiomorphic antimicrobial 7-substituted piperidino-quinolone 19 carboxylic acid derivatives. The compounds of the invention may be rightly called new generation triple-targeting, chiral, broad-spectrum antimicrobial agents. Detailed Description of the Invention The present invention encompasses certain compounds, dosage forms, and methods of administering the compounds, to a human or other animal subject. Specific compounds and compositions to be used in the invention must, accordingly, be pharmaceutically acceptable. As used herein, such a "pharmaceutically-acceptable" compound is one that is suitable for use with humans and/or animals without undue adverse side effects (such as toxicity, irritation, and allergic response) commensurate with a reasonable benefit/risk ratio. This invention describes fluoroquinolones of the formula I COY Formula I wherein Ri is C1.5 alkyl being unsubstituted or substituted with from 1 to 3 fluoro atoms C3-6 cycloalkyl being unsubstituted or substituted with from 1 to 2 fluoro atoms, or aryl being unsubstituted or substituted with from 1 to 3 fluoro atoms; or when Q is CH and the nitrogen atom to which Ri is linked forms an optionally substituted 5-, 6- or 7-membered ring with the carbon atom of Q, the ring optionally containing one or more hetero atoms selected from nitrogen, oxygen or sulfur atoms, said heteroatom(s) represented by T, preferably R, is CH2CH2-, CH2T-, CH2CH2GH2-, CH2CH2T-, CH2TCH2-, TCH2T-, TCH2CH2CH2CH2- CH2CH2CH2T-, CH2TCH2CH2, and TCH2CH2T- where T represents NH, O, or S. This 5- to 7- membered ring may be substituted with 1 or 2 of the same substituents as those defined above for RI, preferably by one C1-C5 alkyl group. Y is OR3 where 20 R3 is hydrogen; R3 is C1-C20 alkyl, such as straight chain or branched chain aliphatic residues such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tertiary butyl, pentyl, hexyl or their branched chain isomers; R3 is aralkyl such as benzyl, phenethyl, phenylpropyl; R3is CH2CH(NH2)COOH; R3 is (CH2)n-CHRio-OCORn or (CH2)n-CHRi0-OCO2R11 wherein R10 is H, or CH3; n is 0-3 and Rn is C]-C2o alkyl as hereinbefore defined, or substituted C1-6 alkyl with substituents such as hydroxy, halogen, amino, mercapto or aralkyl such as benzyl, phenethyl, phenylpropyl or R11 is or R3 is alkanoylalkyl group such as acetoxymethyl, acetoxyethyl, pivaloyloxy-methyl, or pivaloyloxyethyl group; or R3 is —(CH2)P-A Z wherein A is CH or N, and when A is CH, Z is NH or NCH3, and when A is N, Z is CH, O, NH, S, or NCH3; p is 0 - 2 ; q is 0 - 2, preferably R3 is a group such as N-methylpiperidin-4-yl, pyrrolidin-2-yl-ethyl, piperidin-2-yl-ethyl, or morpholin-2-yl-ethyl; or Y is NHR2, wherein R2 is H, C1-20 alkyl such as straight chain or branched chain aliphatic residues as defined above, C36 cycloalkyl, substituted C36 cycloalkyl wherein the substituent is CM alkyl such as methyl, ethyl or trifluoroalkyl such as trifluoromethyl or halogen such as fluorine, chlorine, bromine or aryl such as unsubstituted or substituted phenyl wherein the substituent is C1-3 alkyl, Ci_3 alkoxy, amino, halogen; heteroaryl such as pyridyl, pyrimidinyl, quinolinyl, isoquinolinyl, furyl, oxazolinyl, thiazolyl, or thiadiazolyl, all of which heteroaryl residues may be further substituted or unsubstituted; or R2 is the amino acid residue derived from one of the 20 naturally occurring amino acids viz. alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, 21 histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine and valine, or the optically active isomers thereof, or the racemic mixtures thereof; R5 is H, C1.5 alkyl, C1.5 alkoxy, amino, C1.5 alkylamino such as-NHCH3, N(CH3)2, and the like; or acylamino such as -NHCOCH3, -NHCOC(CH3)3, and the like; Q is -N-, -C(R8)- (R8 being H, F, CI, bromo, methoxy, Ci 4 alkyl, or unsubstituted or substituted Q.4 alkoxy, wherein when the alkoxy is substituted it is substituted by one or more halogen atoms such as F, CI, or Br), or when Q is CH and the nitrogen atom to which Ri is linked forms an optionally substituted 5-, 6- or 7-membered ring with the carbon atom of Q, the ring optionally containing one or more hetero atoms selected from nitrogen, oxygen or sulfur atoms, said heteroatom(s) represented by T, preferably Ri is CH2CH2-, CH2T-, CH2CH2CH2-, CH2CH2T-, CH2TCH2-, TCH2T-, TCH2CH2CH2CH2- CH2CH2CH2T-, CH2TCH2CH2, and TCH2CH2T- where T represents NH, O, or S. If the ring is substituted, the substituent is as defined above for Ri. This 5- to 7- membered ring may be substituted with 1 or 2 of the same substituents as those defined above for RI, preferably by one C1-C5 alkyl group. X is OR4 wherein R4 is hydrogen, or C1-C20 alkyl as hereinbefore defined, or glycosyl, or aralkyl such as benzyl, or C1-C6 alkanoyl such as acetyl, propionyl, pivaloyl, stearoyl, or nonadecanoyl or aminoalkanoyl such as aminoacetyl, aminopropionyl and the like or an acid residue derived from one of the 20 naturally occurring amino acids viz. alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine and valine, or the optically active isomers thereof, or the racemic mixtures thereof; or R4 is 1-aminocyclohexylcarbonyl or COOR10 wherein R11 is as hereinbefore defined or R4 is -(CFbVCFfRio-OCOORii where Ri0 and Rn are as hereinbefore defined, or R4 is CeHnOe, P02(CH3)H, P03H2, P02(0CH3)H or S03H thus giving respectively the gluconic acid, phosphonic acid, phosphoric acid and sulfonic acid ester derivatives of the compounds; or X is NR6R7, wherein R6 is H, C1-20 alkyl as hereinbefore defined, C3-6 cycloalkyl, aralkyl such as benzyl, phenethyl, phenylpropyl; Ci_20 alkanoyl such as COCH3, COCH2CH3, COC(CH3)3, or C1-20 alkoxycarbonyl such as COOCH3, COOCH2CH3, COOC(CH3)3, aralkyloxycarbonyl such as benzyloxycarbonyl, or amino(d-2o)alkanoyl such as aminoacetyl, aminopropionyl and the 22 % 1 \?m 2$& like, or an amino acid residue derived from one of the 20 naturally occurring amino acids or the optically active isomers thereof, or the racemic mixtures thereof. The amino acid residue is derived from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine or valine. The amino acid residue is derived from a single amino acid or from combinations of amino acids that form dipeptide, tripeptide or polypeptide amino acid unit residues wherein a terminal carboxy group is optionally protected by C1-4 alkyl or aralkyl groups and a terminal amino group is optionally protected by a '-Boc (teritarybutyloxycarbonyl), F-Moc (fluorenylmethoxycarbonyl) and Cbz (benzyloxycarbonyl) or group or R6 may also be COORn wherein R11 is as hereinbefore defined or R6 is QHnOe thus giving the gluconic acid ester derivative of the compounds. R7 is H, C1-6 alkyl as hereinbefore defined, C3 -6 cycloalkyl, aralkyl such as benzyl, phenethyl, phenylpropyl; C1-6 alkanoyl such as COCH3, COCH2CH3, COC(CH3)3, aralkyloxycarbonyl such as benzyloxycarbonyl or amino (C1-20)alkanoyl such as aminoacetyl, aminopropionyl, etc.; or an amino acid residue derived from one of the 20 naturally occurring amino acids or the optically active isomers thereof, or the racemic mixtures thereof. The amino acid residue is derived from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine or valine. The amino acid residue is derived from a single amino acid or from combinations of amino acids that form dipeptide, tripeptide or polypeptide amino acid unit residues, wherein a terminal carboxy group is optionally protected by C1-4 alkyl or aralkyl groups and a terminal amino group is optionally protected by a l-Boc (teritarybutyloxycarbonyl), F-Moc (fluorenylmethoxycarbonyl) and Cbz (benzyloxycarbonyl) or group or R7 may be CeHnOg thus giving the gluconic acid ester derivative of the compounds. Rs/Rg' are substituents at the 3/3-position of the piperidino ring and are the same or different and represent H, C1-6 alkyl, substitutedC1-6alkyl wherein the substituent is amino, hydroxy, halogen such as one or more fluorine, chlorine, bromine or alkylamino, or aralkyl such as benzyl. R9 is a substituent at the 4-position or 5-position of the piperidino ring and represents H,C1-6 alkyl, C1-5 alkylamino, C1.3 dialkylamino or aryl, aralkyl such as benzyl, phenethyl or a trihaloalkyl such as trifluoromethyl. 23 Aryl is substituted or unsubstituted phenyl. The phenyl group may be substituted at one or more positions by the usual aromatic substituents such as halogen namely F, CI, or Br; alkyl such as methyl, ethyl, trifluoromethyl, etc. Substituted phenyl groups include such as halophenyl, trifluoromethylphenyl, monofluorophenyl, 2-fluorophenyl, 4-fluorophenyl, or 2,4 difluorophenyl. This invention also includes optical isomers, diastereomers, enantiomers, polymorphs, pseudopolymorphs, pharmaceutically acceptable salts, hydrates, or biohydrolyzable esters, amides, imides, or solvates of the fluoroquinolones of formula I. A pseudopolymorph is a polymorph that differs from a true polymorph by the incorporation of solvent. It has been found that the compounds of this invention, and compositions containing these compounds, are effective antimicrobial agents which are a new generation of antibacterial agents, in particular a new generation of respiratory antibacterials, effective against multidrug-resistant pathogens with broad spectrum coverage of gram-positive and gram-negative microbes, such as sensitive and fluoroquinolone-resistant pneumococci, staphylococci, streptococci, anaerobes, enterococci and atypical pathogens. In addition, the compounds of the invention have potent cidal action for fluoroquinolone-resistant strains. The compounds of the invention have the preferred potential to address the unmet need for orally effective drugs for the treatment of multidrug-resistant pneumococcal infections like life-threatening pneumoniae and meningitis, to which pediatric and geriatric patients are vulnerable. They are unusually cidal for viridans streptococci, which are the causative groups of strains responsible for bacteremias, soft tissue infections, abscesses, sepsis and endocarditis. They are potential antitubercular agents against sensitive and resistant mycobacteria. The combination of physicochemical parameters contributed to the fluoroquinolone molecules by the location, hydrogen-acceptor/-donor properties, spatial bulk, hydrophobicity, stereochemical orientation of the different contributing substituents at the respective positions surprisingly provide compounds of the invention that are not effluxed by efflux pump bearing strains or have better uptake through bacterial cellular membranes. The above described physicochemical parameters also contribute to their unusually favourable drugability properties. They are orally effective with once-a-day potential. They have favourable penetration into tissues like the lung, liver, kidney and heart over serum thus enabling the targeting of organ-specific infections. They are relatively non-phototoxic, with 24 favourable cytotoxicity and cardiotoxicity profiles which are usually the problem toxicities displayed by the fluoroquinolone class of compounds. Among compounds that fall within the compounds of the aforementioned general formula, optically active compounds and diastereomeric isomers, each having the substituent in a specific stereo and three-dimensional spatial orientation have both excellent antibacterial activity and high safety features. The compounds of the invention are sufficiently basic to form acid addition salts. The compounds are useful both in the free base form and the form of acid addition salts, and both forms are within the purview of the invention. The acid addition salts are in some cases a more convenient form for use. Examples of appropriate acid addition salts include, but are not limited to acetate, benzenesulfonate, fumarate, hydrochloride, hydrobromide, hydroiodide, hydrogensulfate, isethionate, lactate, malate, maleate, malonate, methanesulfonate, pamoate (embonate), phosphate/diphosphate, stearate, succinate, sulfate, tartrate, trifluoroacetate, trifluoromethanesulfonate, p-toluenesulfonate, and the like. Preferred acid addition salts include halides, sulfonates, carboxylates, phosphates, and the like. However, other appropriate pharmaceutically acceptable salts within the scope of the invention are those derived from other mineral acids, organic acids and amino acids. The amino acid may be selected from one of the 20 naturally occurring amino acids: alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine or valine or the optically active isomers thereof or the racemic mixtures thereof or dipeptides, tripeptides and polypeptides derived from the monoaminoacid units thereof. The compounds of the invention are also sufficiently acidic to form alkaline/base addition salts. Preferred alkali/base addition salts include the alkali metal salts (such as sodium and potassium), alkaline earth metal salts (such as magnesium and calcium), inorganic salts, such as ammonium, substituted ammonium, choline and organic base salts from basic amines such as diethanolamine, ethylenediamine, guanidine or heterocyclic amines such as piperidine, hydroxyethylpyrrolidine, hydroxyethylpiperidine, morpholine, piperazine, N-methyl piperazine and the like or basic amino acids such as optically pure and racemic isomers of arginine, lysine, histidine, tryptophan and the like. In practice, the use of the salt form inherently amounts to the use of the base form of the active. Acids used to prepare acid addition salts include preferably those, which produce, when combined with the free base, pharmaceutically acceptable salts. These salts have anions that are relatively innocuous to the animal organism, such as a mammal, in pharmaceutical doses of the salts so that the beneficial property inherent in the free base are not vitiated by any side effects ascribable to the acid's anions. The pharmaceutically acceptable acid addition salts of compounds of the formula I are prepared in a conventional manner by treating a solution or suspension of the free base of formula I with about one chemical equivalent of a pharmaceutically acceptable acid such as an inorganic acid or organic acid. Conventional concentration and recrystallization techniques are employed in isolating the salts. For example, the free base can be dissolved in an aqueous alcohol solution containing the appropriate acid and the salt is isolated by evaporation of the solution. Alternatively, they may be prepared by reacting the free base with an acid in an organic solvent so that the salt separates directly. Where separation of the salt is difficult, it can be precipitated with a second organic solvent, or can be obtained by concentration of the solution. Although pharmaceutically acceptable salts of the basic compounds are preferred, all acid addition salts are within the scope of the present invention. All acid addition salts are useful as sources of the free base form, even if the particular salt per se is desired only as an intermediate product. For example, when the salt is formed only for purposes of purification or identification, or when it is used as an intermediate in preparing a pharmaceutically acceptable salt by ion exchange procedures, these salts are clearly contemplated to be a part of this invention. The amino moiety of piperidine is a potential point of formation for the subject compounds of a pharmaceutically acceptable anionic salt; such salts are included in the subject invention compounds. Preferred salts are acid addition salts with, for example, HC1, CH3COOH, CH3SO3H, HCOOH, CF3COOH, gluconic acid,C1-20 straight chain or branched alkanoic acids or one of the 20 naturally occurring amino acids as hereinbefore defined or dipeptide, tripeptide or polypeptide derivatives of the monoaminoacid units thereof. 26 "Host" is a substrate capable of sustaining a microbe, preferably it is a living organism, and most preferably an animal, more preferably a mammal, and more preferably still a human. "Biohydrolyzable amides" are aminoacyl, acylamino, or other amides of the compounds of the invention, where the amide does not essentially interfere, preferably does not interfere, with the activity of the compound, or where the amide is readily converted in vivo by a host to yield an active compound. "Biohydrolyzable imides" are imides of the compounds of the invention, where the imide does not essentially interfere, preferably does not interfere, with the activity of the compound, or where the imide is readily converted in vivo by a host to yield an active compound. Preferred imides are hydroxyimides. "Biohydrolyzable esters" are esters of the compounds of the invention, where the ester does not essentially interfere, preferably does not interfere, with the antimicrobial activity of the compound, or where the ester is readily converted in a host to yield an active compound. Many such esters aire known in the art. Such esters include lower alkyl esters, lower acyloxy-alkyl esters (such as acetoxymethyl, acetoxyethyl, aminocarbonyloxymethyl, pivaloyloxylmethyl and pivaloyloxylethyl esters); lactonyl esters (such as phthalidyl and thiophthalidyl esters) lower alkoxyacyloxyalkyl esters (such as methoxycarbonyloxymethyl, ethoxycarbonyloxyethyl and isopropoxycarbonyloxyethyl esters), alkoxyalkyl esters, choline esters and alkylacylaminoalkyl esters (such as acetamidomethyl esters) and alkyl amino acid esters. The illustration of specific protected forms and other derivatives of the formula 1 compounds are not intended to be limiting. The application of other useful protecting groups, salt forms, etc. is within the ability of the skilled artisan. "Optical isomer", "stereoisomer", "diastereomer" "polymorph" "pseudopolymorph", "hydrates" and "solvates" as referred to herein have the standard art recognized meanings. The compounds of the invention may contain chiral center(s), thus any such compound includes and contemplates each optical isomer, diastereomer or enantiomer thereof, in purified or substantially purified form, and mixtures thereof, including racemic mixtures. The compounds of the invention may have one or more chiral centers. As a result, one may selectively prepare one optical isomer, including diastereomer and enantiomer, over another, for example by use of chiral starting materials, catalysts or solvents, one may prepare both stereoisomers or both optical isomers, including diastereomers and enantiomers at once (a racemic mixture). Since the compounds of the invention may exist as racemic mixtures, mixtures of optical isomers, including diastereomers and enantiomers, or stereoisomers, they may be separated using known methods, such as chiral resolution, chiral chromatography and the like. In addition, it is recognized that one optical isomer, including diastereomer and enantiomer, or stereoisomer may have favorable properties over the other. Thus when disclosing and claiming the invention, when one racemic mixture is disclosed, it is clearly contemplated that both optical isomers, including diastereomers and enantiomers, or stereoisomers substantially free of the other are disclosed and claimed as well. As used herein, a quinolone derivative includes prodrugs of a quinolone. The preferred compounds of the invention are those compounds of Formula I which are composed of on one hand the following core fluoroquinolone moieties displayed below minus the respective 7-amino substituent: 29 2,2 MAR Z0Q6. 30 It is preferred that one of the following amines can be combined with the core fluoroquinolone moieties as shown above. The prefix "c" represents cyclo: ZI MAR 2006, including their optical isomers and diastereomers. The combinations of the above mentioned cores and the above mentioned amines provide the fluoroquinolone compounds of the invention. The following exemplary compounds are made using the procedures described herein and variations thereof which are within the purview of the skilled artisan's practice. The examples below do not limit the invention, but rather serve to illustrate some of embodiments of the invention. In the following tables (Tables 1-16), there are provided some examples of the compounds of the invention. The lower case "c" represents "cyclo". Q = C-H, C-(CrC2) alkyl, C-OCH3, C-F or N, and when Q is CH and the nitrogen atom to which Ri is linked forms substituted 6 membered ring with the carbon atom of Q and Ri are C-CH2CH2C*H(CH3) and C-OCH2CH(CH3). 32 ^ MAR art R1= C2H5, C-C3H5, C6H3F2(2,4), and when Q is CH and the nitrogen atom to which R1 is linked forms substituted 6 membered ring with the carbon atom of Q and R1 are C- CH2CH2C*H(CH3) and C-OCH2CH(CH3). R5 = H, CH3, NH2 Rs = H, CH3 R9 = H,CH3 and optical isomers, pharmaceutically acceptable salts, hydrates, biohydrolyzable esters, 33 11 MAR 2006 polymorphs and pseudomorphs thereof. 35 11 MAR Z006 Q = C-H, C-CH3, C-OCH3, C-F or N, and when Q is CH and the nitrogen atom to which R1 is linked forms substituted 6 membered ring with the carbon atom of Q and R1 are C- CH2CH2C*H(CH3) and C-OCH2CH(CH3). R1 = C2H5, C-C3H5, C6H3F2(2,4), and when Q is CH and the nitrogen atom to whichR1 is linked forms substituted 6 membered ring with the carbon atom of Q andR1 are C- CH2CH2C*H(CH3) and C-OCH2CH(CH3). R5 = H, CH3, NH2 R8 = H,CH3 R9 = H,CH3 and optical isomers, pharmaceutically acceptable salts, hydrates, biohydrolyzable esters, polymorphs and pseudomorphs thereof. 0 R1 R5 R8 R9 Isomers C-H C-C3H5 H H H cis + trans C-H c-C3H5 H H H cis C-H c-C3H5 H H H trans C-H c-C3H5 H CH3 H (±) C-H c-C3H5 H CH3 H (+) C-H c-C3H5 H CH3 H ■(-) C-H c-C3H5 CH3 H H cis + trans C-H c-C3H5 CH3 H H cis C-H c-C3H5 CH3 H H trans C-H c-C3H5 CH3 CH3 H (±) C-H c-C3H5 CH3 CH3 H (+) C-H c-C3H5 CH3 CH3 H (-) C-CH3 c-C3H5 H H H cis + trans C-CH3 c-C3H5 H H H cis C-CH3 c-C3H5 H H H trans C-OCH3 C2H5 H H CH3 mixture A of isomers C-OCH3 C2H5 H H CH3 mixture B of isomers C-OCH3 c-C3H5 H H CH3 mixture A+B C-OCH3 c-C3H5 H H CH3 mixture A of isomers C-OCH3 c-C3H5 H H CH3 mixture B of isomers C-OCH3 C-C3H5 NH2 H CH3 mixture A+B C-OCH3 c-C3H5 NH2 H CH3 mixture A of isomers C-OCH3 c-C3H5 NH2 H CH3 mixture B of isomers C-F C-C3H5 NH2 H CH3 mixture A+B C-F c-C3H5 NH2 H CH3 mixture A of isomers C-F c-C3H5 NH2 H CH3 mixture B of isomers C-F c-C3H5 NH2 CH3 H (±) C-F c-C3H5 NH2 CH3 H (+) C-F c-C3H5 NH2 CH3 H (-) N c-C3H5 H H H cis + trans 36 37 11 MAR 20Q6 Q = C-H, C-CH3, C-OCH3, C-F or N, and when Q is CH and the nitrogen atom to which R1 is linked forms substituted 6 membered ring with the carbon atom of Q and R1 are C- CH2CH2C*H(CH3) and C-OCH2CH(CH3). Ri = C-C3H5, C6H3F2(2,4), and when Q is CH and the nitrogen atom to whichR1 is linked forms substituted 6 membered ring with the carbon atom of Q andR1 are C- CH2CH2C*H(CH3) and C-OCH2CH(CH3). R5 = H,CH3,NH2 R8 = H,CH3 R9 = H,CH3 and optical isomers, pharmaceutically acceptable salts, hydrates, biohydrolyzable esters, polymorphs and pseudomorphs thereof. 38 21 MAR 2006 trialkyl substituents, located at a position adjacent to the substituent at the 4-position are not disclosed. The feature of the known 7-substituted piperidino derived compounds is that they are said to exhibit antimicrobial properties, but either no biological data is provided or in cases where some data is provided, such piperidino derivatives have been found to be inferior in activity to those derivatives bearing 7-piperazino or 7-pyrrolidino substituents. It is only through our on-going studies in recent years as described in our pending US patent applications 09/566,875 and 09/850,669, WO 00/68229 and WO 01/85728 that there has begun to be elaborated the full potential of a fluoroquinolone core bearing an unsubstituted or substituted 4-hydroxy piperidino substituent at the 7th position of the core fluoroquinolone for use in clinical development as medicaments for life-threatening old and new emerging infectious diseases. Thus, the present inventors have extensively studied the subject by introducing various substituted piperidine groups in the 7-position of different fluoroquinolone cores and determining the microbiological/pharmacological properties of the compounds to develop the novel substituted piperidino compounds of the invention, which (a) show a potent hitherto-undescribed antibacterial potency against broad spectrum sensitive and existing/emerging resistant pathogenic strains, including p-lactam-resistant, macrolide-resistant and even fluoroquinolone-resistant strains, mycobacteria, anaerobes and atypical pathogens (b) prevent selection of resistant bacteria by apparently inhibiting both DNA gyrase and topoisomerase IV equally, or by potently inhibiting the enzyme it targets, (c) are not subjected to efflux or have facilitated uptake, (d) do not apparently act to merely form bacteriostatic quinolone-gyrase/topoisomerase-DNA complexes to inhibit cell growth, but also apparently extend the action to release the broken DNA ends to ensure cell death, (d) exhibit high absorption and improved pharmacokinetic properties in a living body, and (e) display a favourable safety profile. As a result, we have identified that the compounds of the general formula I as defined below wherein substituted piperidino groups are introduced into the 7-position of the fluoroquinolone nucleus can satisfy such a purpose. It is therefore, an aspect of the present invention to provide new non-chiral and chiral 7-substituted piperidino-quinolone carboxylic acid derivatives, of the formula I, as defined 15 Table 4 Q = C-H, C-OCH3, C-F or N, and when Q is CH and the nitrogen atom to which Ri is linked forms substituted 6 membered ring with the carbon atom of Q and Ri are C- CH2CH2C*H(CH3) and C-OCH2CH(CH3). R1=rc-C3H5, C6H3F2(2,4), and when Q is CH and the nitrogen atom to which Ri is linked forms substituted 6 membered ring with the carbon atom of Q and Ri are C- CH2CH2C*H(CH3) and C-OCH2CH(CH3). R5 = H, CH3, NH2 R8 = H,CH3 R9 = H,CH3 and optical isomers, pharmaceutically acceptable, salts, hydrates, biohydrolyzable esters, polymorphs and pseudomorphs thereof. Q Ri R5 Rs R9 Isomer C-H C-C3H5 H CH3 H (±) C-H c-C3H5 H CH3 H (+) C-H c-C3H5 H CH3 H (-) C-H c-C3H5 CH3 CH3 H (±) C-H c-C3H5 CH3 CH3 H (+) C-H c-C3H5 CH3 CH3 H (-) C-OCH3 c-C3H5 H H CH3 mixture A+B C-OCH3 c-C3H5 H H CH3 mixture A of isomers C-OCH3 c-C3H5 H H CH3 mixture B of isomers 39 22 MAR 2006 C-OCH3 C-C3H5 H H CH3 mixture A+B C-OCH3 c-C3H5 H H CH3 mixture A of isomers C-OCH3 C-C3H5 H H CH3 mixture B of isomers -C-OCH3 C-C3H5 NH2 H CH3 mixture A+B C-OCH3 C-C3H5 NH2 H CH3 mixture A of isomers C-OCH3 c-C3H5 NH2 H CH3 mixture B of isomers C-OCH3 c-C3H5 NH2' H CH3 mixture A+B C-OCH3 C-C3H5 NH2 H CH3 mixture A of isomers C-OCH3 C-C3H5 NH2 H CH3 mixture B of isomers C-OCH3 C-C3H5 NH2 CH3 H (±) C-OCH3 C-C3H5 NH2 CH3 H (+) C-OCH3 C-C3H5 NH2 CH3 H (-) C-F C-C3H5 NH2 H CH3 mixture A+B C-F C-C3H5 NH2 H CH3 mixture A of isomers C-F c-C3H5 NH2 H CH3 mixture B of isomers C-F C-C3H5 NH2 CH3 H (±) C-F C-C3H5 NH2 CH3 H (+) C-F c-C3H5 NH2 CH3 H (-) N c-C3H5 H H H cis + trans N C-C3H5 H H H CIS N C-C3H5 H H H trans N C-C3H5 H CH3 H (±) N C-C3H5 H CH3 H (+) N C-C3H5 H CH3 H (-) N C6H3F2(2,4) H H H cis + trans N C6H3F2(2,4) H H H cis N C6H3F2(2,4) H H H trans N C6H3F2(2,4) H CH3 H (±) N C6H3F2(2,4) H CH3 H (+) N C6H3F2(2,4) H CH3 H (-) C-CH2C H2C*H(CH3) H CH3 H (±) C-CH2CH2C*H(CH3) H CH3 H (+) C-CH2CH2C*H(CH3) H CH3 H (-) C-OCH2CH(CH3) H CH3 H (±) C-OCH2CH(CH3) H CH3 H (+) C-OCH2CH(CH3) H CH3 H (-) Table 5 2 2 MAR 2006 Q = C-H, C-CH3, C-OCH3, C'F or N, and when Q is CH and the nitrogen atom to which Ri is linked forms substituted 6 membered ring with the carbon atom of Q and Ri are C- CH2CH2C*H(CH3) and C-OCH2CH(CH3). Ri = C-C3H5, C6H3F2(2,4), and when Q is CH and the nitrogen atom to which Ri is linked forms substituted 6 membered ring with the carbon atom of Q and Ri are C- CH2CH2C*H(CH3) and C-OCH2CH(CH3). R5 = H, CH3, NH2 R8 = H,CH3 R9 = H,CH3 and optical isomers, pharmaceutically acceptable salts, hydrates, biohydrolyzable esters, polymorphs and pseudomorphs thereof. Q Ri Rs Rs R9 Isomers C-H C-C3H5 H CH3 H (±) C-H C-C3H5 H CH3 H (+) C-H C-C3H5 H CH3 H (-) C-H C-C3H5 CH3 CH3 H (±) C-H C-C3H5 CH3 CH3 H (+) C-H C-C3H5 CH3 CH3 H (-) C-CH3 C-C3H5 H H H cis + trans C-CH3 C-C3H5 H H H cis C-CH3 c-C3H5 H H H trans C-CH3 c-C3H5 H CH3 H (±) C-CH3 c-C3H5 H CH3 H (+) C-CH3 c-C3H5 H CH3 H (-) C-OCH3 C-C3H5 H H H cis + trans C-OCH3 c-C3H5 H H H cis C-OCH3 C-C3H5 H H H trans C-OCH3 c-C3H5 H H CH3 mixtures A+B C-OCH3 c-C3H5 H H CH3 mixture A of isomers C-OCH3 C-C3H5 H H CH3 mixture B of isomers C-OCH3 c-C3H5 H CH3 H (±) C-OCH3 C-C3H5 H CH3 H (+) C-OCH3 c-C3H5 H CH3 H (-) C-OCH3 C-C3H5 NH2 H H cis + trans C-OCH3 c-C3H5 NH2 H H cis C-OCH3 c-C3H5 NH2 H H trans C-OCH3 C-C3H5 NH2 H CH3 mixture A+B C-OCH3 C-C3H5 NH2 H CH3 mixture A of isomers C-OCH3 c-C3H5 NH2 H CH3 mixture B of isomers C-OCH3 c-C3H5 NH2 CH3 H (±) C-OCH3 C-C3H5 NH2 CH3 H (+) 41 11 MAR 20QS C-OCH3 c-C3H5 NH2 CH3 H (-) C-F C-C3H5 CH3 CH3 H (±) C-F C-C3H5 CH3 CH3 H (+) C-F C-C3H5 CH3 CH3 H (-) C-F C-C3H5 NH2 H H cis + trans C-F c-C3H5 NH2 H H cis C-F c-C3H5 NH2 H H trans C-F c-C3H5 NH2 H CH3 mixtures A+B C-F C-C3H5 NH2 H CH3 mixture A of isomers C-F c-C3H5 NH2 H CH3 mixture B of isomers C-F c-C3H5 NH2 CH3 H (+) C-F C-C3H5 NH2 CH3 H (+) C-F C-C3H5 NH2 CH3 H (-) N c-C3H5 H H H cis + trans N c-C3H5 H H H cis N C-C3H5 H H H trans N C-C3H5 H CH3 H (±) N C-C3H5 H CH3 H (+) N C-C3H5 H CH3 H (-) N C6H3F2(2,4) H H H cis + trans N C6H3F2(2,4) H H H cis N C6H3F2(2,4) H H H trans N C6H3F2(2,4) H CH3 H (±) N C6H3F2(2,4) H CH3 H (+) N C<5H3F2(2,4) H CH3 H (-) C-CH2CH [2C*H(CH3) H CH3 H (+) C-CH2CH2C*H(CH3) H CH3 H (+) C-CH2CH2C*H(CH3) H CH3 H (-) C-OCH2CH(CH3) H H H cis + trans C-OCH2CH(CH3) H H H cis C-OCH2CH(CH3) H H H trans C-OCH2CH(CH3) H CH3 H (±) C-OCH2CH(CH3) H CH3 H (+) C-OCH2CH(CH3) H CH3 H (") COOH Q = C-(C,-C2) alkyl, C-OCH3, C-F or N 42 R, = C2H5, c-C3H5, C6H3F2(2,4), R5 = H, NH2 R8 = H,CH3,C2H5 R9 = H,CH3,C2H5 and optical isomers, pharmaceutically acceptable salts, hydrates, biohydrolyzable esters, 2 2 MAR 2006 polymorphs and pseudomorphs thereof. Q = C-OCH3, C-F, and when Q is CH and the nitrogen atom to which Ri is linked forms substituted 6 membered ring with the carbon atom of Q and Ri is C-OCH2CH(CH3). Ri = C-C3H5 and when Q is CH and the nitrogen atom to which R] is linked forms substituted 6 membered ring with the carbon atom of Q and Ri is C-OCH2CH(CH3). R5 = H,NH2 R8 = H,CH3 and optical isomers, pharmaceutically acceptable salts, hydrates, biohydrolyzable esters, polymorphs and pseudomorphs thereof. Q Ri Rs Rs Isomer C-OCH3 C-C3H5 H H cis + trans C-0CH3 C-C3H5 H H cis C-0CH3 C-C3H5 H H trans 44 2 MAR ZOO Q = C-OCH3 Ri = C-C3H5 R5 = H, NH2 R8 = H,CH3 and optical isomers, pharmaceutically acceptable salts, hydrates, biohydrolyzable esters, polymorphs and pseudomorphs thereof. Q Ri R5 R8 Isomer C-OCH3 c-C3H5 H H cis + trans C-OCH3 C-C3H5 H H cis C-0CH3 C-C3H5 H H trans C-0CH3 C-C3H5 H CH3 (+) C-OCH3 C-C3H5 H CH3 (+) 45 2 2 MAR 2006 C-OCH3 C-C3H5 H CH3 (-) C-OCH3 C-C3H5 NH2 H cis + trans C-OCH3 C-C3H5 NH2 H cis C-OCH3 C-C3H5 NH2 H trans C-OCH3 c-C3H5 NH2 CH3 (±) C-OCH3 C-C3H5 NH2 CH3 (+) C-OCH3 c-C3H5 NH2 CH3 (-) Table 9 COOH Q = C-OCH3 R, = c-C3H5 R5 = H, NH2 R8 = H,CH3 and optical isomers, pharmaceutically acceptable salts, hydrates, biohydrolyzable esters, polymorphs and pseudomorphs thereof. Q Ri R5 Rs Isomer C-0CH3 C-C3H5 H H cis + trans C-0CH3 C-C3H5 H H cis C-0CH3 C-C3H5 H H trans C-0CH3 c-C3H5 H CH3 (±) C-0CH3 C-C3H5 H CH3 (+) C-0CH3 c-C3H5 H CH3 (-) C-OCH3 C-C3H5 NH2 H cis + trans C-0CH3 c-C3H5 NH2 H cis C-0CH3 c-C3H5 NH2 H trans C-0CH3 c-C3H5 NH2 CH3 (±) C-0CH3 c-C3H5 NH2 CH3 (+) C-0CH3 c-C3H5 NH2 CH3 (-) 46 2 2 MAR 2006 Table 10 COOH Q = C-OCH3, C-F R5 = H, NH2 R6 = COCH3, CO-(0-C2-C4 alkyl), COOCH2C6H5, amino C1.4 alkanoyl, carboxy amino CM alkanoyl, dipeptidoalkanoyl wherein the terminal amino group is unprotected or protected with a l-Boc-protecting group. 0 Rs R4) and concentrated to dryness to afford 4-methylamino-3-methyl-piperidine. Yield 1.8 g (77 %), C7H16N2,m/z 129 (M+l), PMR (CDC13): 0.92 (dd, 3H), 1.54-(m, 1H), 2.12 (m, 2H), 2.38 (s, 3H), 2.6 (m, 1H), 2.8 (m, 1H), 3.02 (m,lH), 3.42 (m,lH), 3.68 (m,lH). Preparation 3 4-Ethvlamino-3-methvlpiperidine Ethylamine hydrochloride (5 g, 61.34 mmol) was added to the stirred solution of 1-carbethoxy-3-methyl-4-piperidone (3.5 g, 18.9 mmol) obtained as described in Preparation 1, in methanol (30 ml) followed by 3.43g (61.34 mmol) KOH. Stirring was continued for 3 hr at ambient temperature. The resulting mixture was cooled at 0°C and sodium cyanoborohydride (1.4 g, 22.22 mmol) was added to it. Cooling was removed after 10 min. and resulting mixture was stirred for 16 hr at ambient temperature. The reaction mixture was concentrated to dryness, triturated with water, acidified with cone. HC1 (pH 3-4) and extracted with ethyl acetate to remove impurities. The aqueous layer was basified with 1 M sodium hydroxide solution (pH -10) and extracted with ethyl acetate. Ethyl acetate extract was dried (Na2S04) and concentrated to dryness to give l-carbethoxy-4-ethylamino-3-methylpiperidine. Yield 2.3 g (54 %), C, 1H22N2O2, m/z 215 (M+l). l-Carbethoxy-4-ethylamino-3-methylpiperidine (2.3 g, 10.74 mmol) was suspended in 5 M NaOH solution (15 ml), stirred at 110°C for 120 hr, cooled, extracted with ethyl acetate, dried (Na2S04) and concentrated to dryness to afford 4-ethylamino-3-methylpiperidine. Yield 0.7 g (46 %), C8HigN2,m/z 143, (M+l). Preparation 4 4-Cyclopropvlamino-3-methvlpiperidine Cyclopropylamine (10 g, 169.5 mmol) was added to the stirred solution of l-carbethoxy-3-methyl-4-piperidone (7.0 g, 37.83 mmol) obtained as described in Preparation 1, in methanol (50 ml) and stirring was continued for 12 hr at ambient temperature. The resulting mixture was cooled at 0°C and sodium cyanoborohydride (3.0 g, 46.0 mmol) was added to it. Cooling was removed after 10 min. and stirring was continued for 12 hr at ambient temperature. The reaction mixture was concentrated to dryness, triturated with water, acidified with cone. HC1 (pH 3-4) and extracted with ethyl acetate to remove impurities. The aqueous layer was basified with 1 M sodium hydroxide solution (pH -10) and extracted with ethyl acetate. Ethyl acetate extract was dried (Na2S04) and concentrated to dryness to afford l-carbethoxy-4- 81 cyclopropylamino-3-methylpiperidine. Yield 6.0 g (70 %), C12H22N202, m/z 227 (M+l), PMR (CDC13): 0.38 (m, 4H), 0.88 (dd, 3H), 1.28 (t, 3H), 1.54 (m, 1H), 2.06 (m, 2H), 2.32 (m, 1H), 2.48 (m, 1H), 2.84 (m, 1H), 3.06 (m, 1H), 3.72 (m, 1H), 3.88 - 4.24 (m, 2H). l-Carbethoxy-4-cyclopropylamino-3-methylpiperidine (6.0 g, 26.66 mmol) was suspended in 5 M NaOH solution (20 ml), stirred at 130°C for 120 hr, cooled and extracted with ethyl acetate. Ethyl acetate extract was dried (Na2S04) and concentrated to dryness to afford a mixture of starting material (3.0 g) and 4-cyclopropylamino-3-methylpiperidine, which were separated by silica column chromatography. Yield 1.0 g (35 %), C9Hi8N2, m/z 155, (M+l). Preparation 5 4-Dimethylamino-3-methvlpiperidine Paraformaldehyde (5.1g) was added to the stirred solution of 4-amino-l-carbethoxy-3-methylpiperidine (3.5 g, 18.8 mmol) in methanol (100 ml) at 0°C and sodium cyanoborohydride (1.7 g, 27.0 mmol) was added to it. Then, acetic acid (1 ml) was added to the resulting mixture and stirring was continued for 96 hr at ambient temperature. The reaction mixture was concentrated to dryness, triturated with water, acidified with cone. HC1 (pH 3-4) and extracted with ethyl acetate to remove impurities. The aqueous layer was basified with 1 M sodium hydroxide solution (pH -10) and extracted with ethyl acetate. Ethyl acetate extract was dried (Na2SC>4) and concentrated to dryness to give l-carbethoxy-4-dimethylamino-3-methylpiperidine. Yield 3.5 g (88 %), d^NzO^m/z 215 (M+l). l-Carbethoxy-4-dimethylamino-3-methyIpiperidine (3.5 g, 16.3 mmol) was suspended in 5 M NaOH solution (20 ml), stirred at 110°C for 48 hr, cooled, extracted with ethyl acetate, dried (Na2S04) and concentrated to dryness to afford 4-dimethylamino-3-methylpiperidine. Yield 1.0 g (43 %), C8H18N2, m/z 143 (M+l), PMR (CDC13): 0.96 (dd, 3H), 1.3 (m, 1H), 1.5 (m, 1H), 1.74 (m, 1H), 2.08 (m, 1H), 2.24 (s, 6H), 2.38 (m, 1H), 2.61 (bs, 1H, D20 exchangeable), 2.86 (m, 1H), 3.16 (m, 1H), 3.68 (m, 1H). Preparation 6 4-Amino-3-ethylpiperidine Ethyl chloroformate (37.49 g, 346 mmol) was added to a stirred solution of l-benzyl-3-ethyl-4-piperidone (24.0 g, 110 mmol) in benzene (200 ml) at ambient temperature. The obtained reaction mixture was refluxed with stirring for 16 hr and concentrated to dryness to give 1-carbethoxy-3-ethylpiperidin-4-one as oil. Yield 21 g (96 %), CioHi7N03,m/z 200 (M+l). 82 Ammonium acetate (33 g) was added to the stirred solution of l-carbethoxy-3-ethyl-4-piperidinone (8.2 g, 41 mmol) in methanol (125 ml) and stirring was continued for 3 hr at ambient temperature. The resulting mixture was cooled at 0°C and sodium cyanoborohydride (2.5 g, 39 mmol) was added to it. Cooling was removed after 10 min. and resulting mixture was stirred for 6 hr at ambient temperature. The reaction mixture was concentrated to dryness, triturated with water, acidified with cone. HC1 (pH 3-4) and extracted with ethyl acetate to remove impurities. The aqueous layer was basified with 1 M sodium hydroxide solution (pH -10) and extracted with ethyl acetate. Ethyl acetate extract was dried (Na2S04) and concentrated to dryness to furnish crude 4-amino-l-carbethoxy-3-ethylpiperidine, which was used as such in the next step. 4-Amino-l-carbethoxy-3-ethylpiperidine was suspended in 5 M NaOH solution (36 ml), stirred at 120°C for 120 hr, cooled, extracted with ethyl acetate, dried (Na2SC>4) and concentrated to dryness to afford 4-amino-3-ethylpiperidine. Yield 3.1 g (59.6 %), C7HK5N2, m/z 129 (M+l). , Preparation 7 4-Methvlamino-3-ethylpiperidine Methylamine hydrochloride (17 g, 252 mmol) was added to the stirred solution of 1-carbethoxy-3-ethyl-4-piperidone (10 g, 50 mmol) in methanol (150 ml) followed by 14.1 g (252 mmol) KOH. Stirring was continued for 3 hr at ambient temperature. The resulting mixture was cooled at 0°C and sodium cyanoborohydride (4.72 g, 75 mmol) was added to it. Cooling was removed after 10 min. and resulting mixture was stirred for 12 hr at ambient temperature. The reaction mixture! was concentrated to dryness, triturated with water, acidified with cone. HC1 (pH 3-4) and extracted with ethyl acetate to remove impurities. The aqueous layer was basified with 1 M sodium hydroxide solution (pH -10) and extracted with ethyl acetate. Ethyl acetate extract was dried (Na2S04) and concentrated to dryness to give crude l-carbethoxy-4-methylamino-3-ethylpiperidine. The obtained crude 1-carbethoxy-4-methylamino-3-ethylpiperidine was suspended in 7 M NaOH solution (50 ml), stirred at 110°C for 230 hr, cooled, extracted with ethyl acetate, dried (Na2S04) and concentrated to dryness to afford 4-methylamino-3-ethyl-piperidine. Yield 3.5 g (50 %), C8H18N2, m/z 142 (M+l). 83 Preparation 8 4-Cvclopropylamino-3-ethylpiperidine Cyclopropylamine (14.25 g, 250 mmol) was added to the stirred solution of l-carbethoxy-3-ethyl-4-piperidone (10 g, 50 mmol) in methanol (100 ml) and stirring was continued for 12 hr at ambient temperature. The resulting mixture was cooled at 0°C and sodium cyanoborohydnde (3.9 g, 62 mmol) was added to it. Cooling was removed after 10 min. and stirring was continued for 12 hr at ambient temperature. The reaction mixture was concentrated to dryness, triturated with water, acidified with cone. HO (pH 3-4) and extracted with ethyl acetate to remove impurities. The aqueous layer was basified with 1 M sodium hydroxide solution (pH -10) and extracted with ethyl acetate. Ethyl acetate extract was dried (Na2S04) and concentrated to dryness to afford crude l-carbethoxy-4-cyclopropylamino-3-ethyl piperidine. The obtained crude l-carbethoxy-4-cyclopropylamino-3-ethylpiperidine was suspended in 7 M NaOH solution (30 ml), stirred at 130°C for 160 hr, cooled and extracted with ethyl acetate. Ethyl acetate extract was dried (Na2SC>4) and concentrated to dryness to afford 4-cyclopropylamino-3-ethyl -piperidine. Yield 5.7 g (67 %), C10H2oN2,m/zl69,(M+l). Preparation 9 4-Dimethylamino-3-ethvlpiperidine Sodium cyanoborohydnde (3.2 g, 50.8 mmol) was added to the stirred suspension of N-tert.-butoxycarbonyl-3-ethyl-4-piperidone (8 g, 35 mmol), N,N-dimethylamine hydrochloride (14 g, 172 mmol) and KOH (9.6 g, 172 mmol) in methanol (50 ml) at 0°C. The resulting mixture was stirred for 4 hr at ambient temperature. The reaction mixture was concentrated to dryness, triturated with water, acidified with cone. HC1 (pH 3-4) and extracted with ethyl acetate to remove impurities. The aqueous layer was basified with 1 M sodium hydroxide solution (pH -10) and extracted with ethyl acetate. Ethyl acetate extract was dried (Na2S04) and concentrated to dryness to give 4-dimethylamino-3-ethylpiperidine. Yield 2.3 g (37 %), C9H2oN2,m/zl57(M+l). Preparation 10 4-Amino-3,3-dimethvlpiperidine Step-1: l-Benzvl-3.3-dimethyl-4-piperidone : l-Benzyl-4-piperidone (100 gm, 0.53 mol) diluted with 100 ml THF was added to a suspension of 60% NaH (42 g, 1.05 mol) in 700 ml THF at -10 to -5 °C. The mixture was stirred for 1 hour and methyl iodide (150 gm, 1.06 mol) diluted in 50 ml THF was added, 84 2 2 MAR 2006 maintaining the temperature between -3 to -10 °C. The resultant mixture was stirred. Ethyl acetate (800 ml) was added to the reaction mixture followed addition of 300 ml water. The organic layer was separated washed with 2 x 300 ml water and concentrated under vacuum to obtain a syrup. The syrup was triturated with 200 ml hexane. the mass was filtered at room temperature over celite and the filtrate concentrated to afford a 121 gm of crude compound. The crude compound upon high vacuum distillation afforded 85 g distillate. To the distillate (50 gm) was charged 50 ml of concentrated hydrochloric acid. The suspension was stirred for 15 minutes and hydrochloric acid was evaporated under vacuum to obtain a thick residue. Isopropanol (50 ml) was added to this residue and was evaporated under vacuum to obtain a solid. The solid was dissolved in 200 ml isopropanol under reflux and stirring, and cooled under stirring to effect crystallization. The crystalline solid was filtered under suction at 20-30 °C to give a white crystalline compound as hydrochloride salt of 1-benzyl- 3,3 -dimethyl -4- piperidone. The solid was dissolved in 100 ml water and made alkaline with aqueous ammonia solution to pH 10-11. Alkaline aqueous phase was extracted with 50 ml chloroform thrice. Combined organic extract was washed with water, dried over sodium sulfate and then evaporated under vacuum to afford 28 g (80%) compound as an oil. m/z (M+l) 218. NMR (CDC13): 1.18 (s, 6H,); 2.40 (s, 2H); 2.45(t, 2H); 2.65 (t, 2H); 3.60 (s, 2H); 7.38 (m,5H). Step-2: 4-Amino-3,3-dimethylpiperidine: Ammonium acetate (3.5 g, 45.45 mmol) was added to the stirred solution of l-benzyl-3,3-dimethyl-4-piperidone (2.0 g, 9.2 mmol), in methanol (20 ml) and stirring was continued for 3 hr at ambient temperature. The resulting mixture was cooled at 0°C and sodium cyanoborohydride (0.58 g, 9.2 mmol) was added. Cooling was removed after 10 min. and resulting mixture was stirred for 6 hr at ambient temperature. The reaction mixture was concentrated to dryness, triturated with water, acidified with cone. HCl (pH 3-4) and extracted with ethyl acetate to remove impurities. The aqueous layer was basified with 1 M sodium hydroxide solution (pH -10) and extracted with ethyl acetate. Ethyl acetate extract was dried (Na2S04) and concentrated to dryness to furnish 4-amino-l-benzyl-3,3-dimethyl piperidine. Yield 1.6 g (77 %), C14H22N2, m/z 219 (M+l), PMR (CDCI3): 0.84 (s, 3H), 0.98 (s, 3H), 1.48 (bs, 2H, D20 exchangeable), 1.66 (m, 2H), 2.04 (m, 2H), 2.42 (m, 2H), 2.86 (m, 1H), 3.46 (dd, 2H), 7.32 (m, 5H). 85 A mixture of 20% Pd(OH)2 on carbon (0.3 g) and 4-amino-l-benzyl-3,3-dimethylpiperidine (1.6 g, 7.33 mmol) in methanol (25 ml) was stirred in hydrogen atmosphere (1 atm.) at 30°C for 6 hr. The catalyst was filtered off, washed with methanol and filtrate was concentrated to dryness to afford 4-amino-3,3-dimethylpiperidine. Yield 0.7 g (75 %), C7H16N2, m/z 129 (M+l), PMR (CDC13): 0.9 (s, 6H), 1.5 (m, 2H), 1.58 (bs, 2H, D20 exchangeable), 2.26 - 2.68 (m, 4H), 3.06 (m, 1H), 3.52 (bs, 1H, D20 exchangeable). Preparation 11 4-Methvlamino-3,3-dimethvlpiperidine Potassium hydroxide (12.85 g, 230 mmol) was added to the stirred solution of methylamine hydrochloride (15.5 g, 230.0 mmol) in methanol (100 ml) and stirring was continued for 30 min at 30°C. l-Benzyl-3,3-dimethyl-4-piperidone (5 g, 23.0 mmol), was added to the resulting mixture and stirred for 6 hr. Sodium cyanoborohydride (1.45 g, 23.0 mmol) was added to it and reaction mixture was stirred for 15 hr. The reaction mixture was concentrated to dryness, triturated with water, extracted with chloroform, dried (Na2S04) and concentrated to give l-benzyl-4-methylamino-3,3-dimethylpiperidine. Yield 5.3 g (99 %), Ci5H24N2, m/z 233 (M+l), PMR (CDCI3): 0.9 (s, 3H), 1.0 (s, 3H), 1.38 (m, 2H), 1.54 (bs, 1H, D20 exchangeable), 1.68 - 2.1 (m, 4H), 2.4 (s, 3H), 2.86 (m, 1H), 3.4 (dd, 2H), 7.3 (m, 5H). A mixture of 20% Pd(OH)2 on carbon (0.15 g) and l-benzyl-4-methylamino-3,3-dimethylpiperidine (0.5 g, 2.1 mmol) in methanol (10 ml) was stirred in hydrogen atmosphere (1 atm.) at 60°C for 6 hr. The catalyst was filtered off, washed with methanol and filtrate was concentrated to dryness to afford 4-methylamino-3,3-dimethyl-piperidine. Yield 0.3 g (99 %), C8Hi8N2, m/z 143 (M+l), PMR (CDCI3): 0.88 (s, 6H), 1.24 (m, 2H), 1.8 (bs, 2H, D20 exchangeable), 1.8 (m, 1H), 2.1 (m, 1H), 2.4 (s, 3H), 2.6 (d, 2H), 2.86 (m, 1H). Preparation 12 4-Ethvlamino-3,3-dimethvlpiperidine Potassium hydroxide (4.6 g, 83.0 mmol) was added to the stirred solution of ethylamine hydrochloride (6.8 g, 83.0 mmol) in methanol (70 ml) and stirring was continued for 30 min at 30°C. l-benzyl-3,3-dimethyl-4-piperidone (3.5 g, 16.6 mmol)), was added to the resulting mixture and stirred for 6 hr. Sodium cyanoborohydride (1,0 g, 16.6 mmol) was added to it and reaction mixture was stirred for 15 hr. The reaction mixture was concentrated to dryness, triturated with water, extracted with chloroform, dried (Na2SC>4) and concentrated to give 1- 86 benzyl-4-ethylamino-3,3-dimethylpiperidine. Yield 3.8 g (88 %), Ci6H26N2, m/z 247 (M+l), PMR (CDC13): 0.9 (s, 3H), 1.06 (s, 3H), 1.18 - 1.38 (m, 5H), 1.64 - 2.8 (m, 6H), 2.94 (m, 1H), 3.44 (dd, 2H), 7.2 (m, 5H). A mixture of 20% Pd(OH)2 on carbon (0.4 g) and l-benzyl-4-ethylamino-3,3-dimethylpiperidine (1.3 g, 5.3 mmol) in methanol (10 ml) was stirred in hydrogen atmosphere (1 atm.) at ambient temperature for 15 hr. The catalyst was filtered off, washed with methanol and filtrate was concentrated to dryness to afford 4-ethylamino-3,3-dimethylpiperidine. Yield 0.8 g (97 %), C9H20N2, m/z 157 (M+l), PMR (CDC13): 0.9 (s, 3H), 1.06 (s, 3H), 1.18 - 1.38 (m, 5H), 1.85 (bs, 2H, D20 exchangeable), 1.64 - 2.8 (m, 6H), 2.94 (m, 1H). Preparation 13 4-Cyclopropylarnino-3,3-dimethylpiperidine l-Benzyl-3,3-dimethyl-4-piperidone (10.0 g, 46.0 mmol), was added to the stirred solution cyclopropylamine (13.1 g, 230.0 mmol) in methanol (150 ml) and stirred for 6 hr. Sodium cyanoborohydride (2.9 g, 46.0 mmol) was added to it and reaction mixture was stirred for 15 hr. The reaction mixture was concentrated to dryness, triturated with water, extracted with chloroform, dried (Na2S04) and concentrated. The obtained crude product was purified over silica gel column. Eluted from 5 % ethyl acetate in hexane gave l-benzyl-4-cyclopropylamino-3,3-dimethyl piperidine. Yield 8.0 g (67.3 %), Ci7H26N2, m/z 259 (M+l), PMR (CDCI3): 0.4 (m, 2H), 0.82 (s, 3H), 1.06 (s, 3H), 1.16 (m, 2H), 1.5 (bs, 1H, D20 exchangeable), 1.7 (m, 2H), 1.9 - 2.95 (m, 5H), 3.3 - 3.6 (m, 3H), 7.22 (m, 5H). A mixture of 20% Pd(OH)2 on carbon (0.5 g) and l-benzyl-4-cyclopropyl-amino-3,3-dimethylpiperidine (2.0 g, 7.7 mmol) in methanol (20 ml) was stirred in hydrogen atmosphere (1 atm.) at 60°C for 48 hr. The catalyst was filtered off, washed with methanol and filtrate was concentrated to dryness to afford 4-cyclopropylamino-3,3-dimethylpiperidine. Yield 1.2 g (92 %), C10H20N2, m/z 169 (M+l), PMR (CDC13): 0.42 (m, 2H), 0.84 (s, 3H), 0.9 (s, 3H), 1.22 (m, 2H), 1.7 (bs, 2H, D20 exchangeable), 1.94 (m, 2H), 2.1 - 2.72 (m, 5H), 3.08 (m, 1H). Preparation 14 4-Dimethvlamino-3,3-dimethylpiperidine Formaldehyde solution (47 %, 10 g) was added to the stirred solution of 4-amino- 1-benzyl-3,3-dimethylpiperidine (2.0 g, 9.2 mmol) in methanol (20 ml) at 0°C and sodium 87 mixture was concentrated to furnish 4-acetylamino-l-benzyl-3,3-dimethyl piperidine as an oil. Yield 1.8 g (76 %), C16H24N20, m/z 261 (M+1), PMR (CDC13): 0.84 (s, 3H), 0.98 (s, 3H), 1.64 (m, 2H), 2.02 (s, 3H), 2.12 (m, 2H), 2.44 (d, 1H), 2.84 (d, 1H), 3.44 (d, 2H), 3.7 (m, 1H), 5.3 (bs, 1H), 7.31 (m, 5H). A mixture of 20% Pd(OH)2 on carbon (0.3 g) and 4-acetylamino-l-benzyl-3,3-dimethyl piperidine (1.8 g, 6.92 mmol) in methanol (20 ml) was stirred in hydrogen atmosphere (1 atm.) at 35°C for 6 hr. The catalyst was filtered off, washed with methanol and filtrate was concentrated to dryness to afford 4-acetylamino-3,3-dimethylpiperidine. Yield 1.0 g (90 %), C9Hi8N20,m/zl71(M+l). Preparation 17 3,3-Dimethyl-4-piperidone l-Benzyl-3,3-dimethyl-4-piperidone 275 g (1.26 mol) prepared as per procedure described in US 5,846,980, was dissolved in 1.0 L. methanol. The solution was transferred to a Parr reactor after adding 10% palladium on carbon (25 g). The reaction mixture was stirred under 300 psi hydrogen pressure at 60°C until chromatography showed complete conversion. The reaction mixture was filtered and the residue washed with methanol (200 ml). The filtrate was concentrated to dryness to afford 3,3 -dimethyl-4-piperidone (158 g) which was used as such for the preparation of either 4-benzyloxycarbonylamino-3,3-dimethylpiperidine or 4-t-butyloxycarbonylamino-3,3-dimethylpiperidine. Preparation 18 (±)-4-Benzyloxvcarbonvlamino-3,3-dimethylpiperidine Step-1: 1 -{Butvloxvcarbonvl-3.3-dimethyl-4-piperidone Di-t-butyldicarbonate (430 g, 1,97 mol) was added to a stirred solution of 3,3-dimethyl-4- piperidone (262 g, 2.06 mol) and triethylamine (175 g, 1.73 mol) in 600 ml dichloromethane at 0-10°C over a period of 1 hour. Cooling was removed and the reaction mixture was stirred at 20-30°C for 30 min. The reaction mixture was concentrated to dryness and the residue was triturated with hexane (250 ml) and filtered to give l-t-butyloxycarbonyl-3,3-dimethyl-4- piperidone (352 g) in 76% yield. m/z (M+1) 228. NMR(CDC13): 0.8 (s, 3H); 0.95 (s,3H); 1.50 (s, 9H); 1.5-1.8 (m, 2H); 2.5-2.9 (m, 2H); 3.4- 3.8 (m, 2H); 4.05 (bs, 1H), 4.6 (d,lH), 5.05(s, 2H), 7.4 (s,5H). 89 Step-2: 4-Amino l-[ butyloxvcarbonyl- 3,3-dimethylpiperidine: Ammonium acetate (700 g, 9.09 mol) was added to a stirred solution of l-'-butyloxy carbonyl-3,3-dimethyl-4-piperidone (352 g, 1.55 mol) in methanol (1.0 L). The suspension was stirred for 3 hr at 20-30°C. The reaction mixture was cooled to 0 °C and sodiumcyanoborohydride (45 g, 0.71 mol) was added portion wise over 30 minutes. Cooling was removed and the suspension was stirred for 12 hr at 20-30°C. The reaction mixture was concentrated to dryness, stirred with water (2.0 L) and extracted with 1.0 L X 3 dichloromethane. Combined organic extract was washed with water and dried over sodium sulfate. Evaporation of organic solvent afforded the product. Step-3: 4-Benzvloxvcarbonvlamino-l-tbutvloxycarbonyI-3,3-dimethvlpiperidine: Benzyl chloroformate (50% in toluene, 450 ml, 1.57 mol) was added to a stirred suspension of 4-amino-l-t-butyloxycarbonyl-3,3-dimethylpiperidine (365 g ) as prepared above and NaHC03 (150 g, 1.78 mol) in dry tetrahydrofuran (1.5 L). The reaction mixture was stirred for 20 hr at 35°C. The reaction mixture was diluted with 3.5 L water and was extracted with 2.0 L X 2 ethyl acetate. Combined organic extract was washed with water, dried over Na2SC>4 and concentrated to dryness. The residue was subjected to chromatography on a silica gel column to give 4-benzyloxycarbonylamino-l-'"butyloxycarbonyl -3,3-dimethylpiperidine in 63% (350 g) yield, m/z 363 (M+l). NMR(CDC13): 0.8 (s, 3H); 0.95 (s, 3H); 1.5 (s, 9H); 1.5-1.8 (m, 2H);2.5-2.9 (m, 2H); 3.4-3.8 (m, 2H); 4.05 (bs,lH); 4.6 (d, 1H); 5.05 (s, 2H); 7.4 (s, 5H) Step-4: 4-Benzyloxycarbonvlamino-3,3-dimethvlpiperidine; 6 N HC1 (200 ml) was added to a stirred solution of 4-benzyloxycarbonylamino-l-1-butyloxycarbonyl-3,3-dimethylpiperidine (350 g, 0.96 mol) in dioxane (200 ml). The resulting mixture was stirred for 1 hr and concentrated to dryness. The resultant residue was treated with water (3.0 L) water and was extracted with 1.0 L X 2 ethyl acetate. The aqueous layer was basified with 2 M aqueous NaOH and extracted with 2.5 L X 2 dichloromethane. Combined organic extract was washed with water, dried over NajSCv and concentrated to afford 4-benzyloxycarbonylamino-3,3-dimethylpiperidine in 89% (224 g) yield, m/z (M+l) 263. NMR (CDC13): 0.88 (s, 6H); 1.2-1.5 (m, 2H); 1.6-1.8 (m, 1H); 2.4-2.7 (m, 3H); 2.9-3.1 (m, 1H); 3.4-3.6 (m, 1H); 4.7 (s, 1H), 5.1 (s, 2H); 7.40 ( s, 5H). 90 Preparation 19 (+) and (-)-4-t-Butvloxycarbonvlamino -3,3-dimethvlpiperidine Step-1; 1- Benzvloxvcarbonyl-3,3-dimethyl-4-piperidone: Method A 3,3-dimethyl-4-piperidone (157 g, 1.24 mol) was dissolved in 750 L. tetrahydrofuran and was charged with solid NaHCC^ (115 g , 1.37 mol) . The reaction mixture was stirred and under stirring addition of 50% benzyl chloroformate in toluene (470 ml, 1.37 mol) was made at 0 tol0°C temperature. To the reaction mixture 1.0 L water was added and the resulting mixture was extracted with 500 ml X 3 ethyl acetate. Combined organic extract was washed with water, dried over sodium sulfate and concentrated in vacuo to give a residue which was subjected to silica gel column chromatography to give 272 g titled compound, m/z (M+l) 262. NMR(CDC13): 1.18 (s, 6H); 2.50 (t, 2H); 3.50(s, 2H); 3.80 (t, 2H); 5.20 (s, 2H); 7.40 (s,5H). Method B l-Benzyl-3,3-dimethyl^4--piperidone (255 g , 1.175 mol) was dissolved in 800 ml toluene. To the clear solution was charged 50% benzyl chloroformate in toluene (441 ml, 1.29 mol). The reaction mixture was stirred at temperature between 80-85°C for 4-5 hrs. The reaction mixture was concentrated under vacuum. Crude product was purified by silica gel column chromatograhy to give 292 g (95%) titled compound, m/z (M+l) 262. NMR (CDC13): 1.18 (s, 6H); 2.50 (t, 2H); 3.50(s, 2H); 3.80 (t, 2H); 5.20 (s, 2H); 7.40 (s,5H). Step-2: 4-Amino-l-benzvloxycarbonvl- 3,3-dimethvlpiperidine: l-Benzyloxycarbonyl-3,3-dimethyl-4-piperidone (290 g, 1.11 mol) was dissolved in methanol (1.5 L) and under stirring addition of ammonium acetate (600 g, 7.80 mol ) was made at 30- 35°C. The reaction mixture was stirred for 5 hrs. Sodium cyanoborohydride (35 g, 0.55 mol) was added portion wise to the suspension, over 0.5 hrs by maintaining temperature between 0- 10°C. The reaction mixture was stirred for 6-7 hrs. After completion of reaction, solvent was evaporated under reduced pressure and addition of 3.00 L water was made under stirring. The reaction mixture was stirred for 15 minutes. It was extracted with 1.5 L X 2 CHCI3. Combined organic extract was evaporated under vacuum. The residue was 91 dissolved in 3 N HC1 till pH 1 and was extracted with 500 ml X 2 dichloromethane. The aqueous layer was basified with 300 ml aqueous ammonia solution (23-25%) to pH 10-11 and then was extracted with 1.5 L X 3 dichloromethane. Combined organic extract was washed with water and was dried over sodium sulfate. Evaporation of organic solvent afforded 225 g (77%) title compound, m/z (M+l) 263. NMR (CDC13) D20 exchange: 0.80 (s, 3H); 0.98 (s, 3H); 1.40-1.78 (m, 2H); 2.50 (dt, 2H); 2.90 (m, 1H); 3.80 (t,lH); 4.18 (t, 1H), 5.18 (s,2H); 7.40 (s, 5H). Step-3: (+)-4-Amino-l-benzvloxvcarbonvl-3,3-dimethylpiperidine: 4-Amino-l-benzyloxycarbonyl-3,3-dimethylpiperidine (200 g, 0.76 mol) was dissolved in 2.4 L 2-3% aqueous ethyl alcohol (moisture content 2.6% by Karl Fischer titration) and L-(+)-tartaric acid (110 g, 0.73mol) was added to the solution at 65-70 °C. The reaction mixture was heated under stirring for half an hour at 65-70 °C. The reaction mixture was cooled under stirring between 20-30°C. The solid was filtered and the wet cake was washed with additional 675 ml ethyl alcohol. Resultant 'solid A' was treated separately to obtain (-) isomer of 4-amino-l-benzyloxycarbonyl- 3,3-dimethyl- piperidine as described in Step-4. The filtrate was concentrated under vacuum to obtain a 'solid B'. The 'solid B' was treated with aqueous K2CO3 solution made by dissolving 112 g K2CO3 in 1.2 L water and was extracted with 750 ml chloroform thrice. Combined organic extract was washed with 200 ml water and dried over sodium sulfate. Evaporation of organic solvent afforded 71 g (71% ) as an oil. The compound was subjected to a second resolution by dissolving it ( 70 g, 0.267 mol} in 840 ml 2-3 % aqueous ethyl alcohol (moisture content, 2.6 %) under stirring and resultant solution was treated with (40 g, 0.267 mol) D-(-)-tartaric acid at 60-70°C. The reaction mixture was agitated at 65-70 °C for half an hour. The reaction mass was cooled and was filtered at 20-30°C. The wet cake was washed with 210 ml additional ethyl alcohol to afford a crystalline salt. The resultant wet solid was treated with aqueous K2CO3 solution made by dissolving 81 g K2CO3 in 0.81 L water and was extracted with 750 ml X 3 chloroform. Combine organic extract was washed with 200 ml water and was dried over sodium sulfate. Evaporation of organic solvent afforded 57 g (86%) as an oil. m/z (M+l) 263. 92 NMR(CDC13) D20 exchange: 0.80 (s, 3H); 0.98 (s, 3H); 1.40-1.78 (m, 2H); 2.50 (dt, 2H); 2.90 (m, 1H); 3.80 (t,lH); 4.18 (t, 1H), 5.18 (s,2H); 7.40 (s, 5H). MD25 vaJue +30.60 (c=l, CHCh), percentage of isomers ratio 98.07: 1.93 determined by HPLC of Mosher amide analogue. Step-4: (-)- 4-Amino-l-benzvloxvcarbonvl- 3,3-dimethylpiperidine The 'solid A' obtained in Step-3 was treated with aqueous K2C03 solution made by dissolving 164 g K2C03 in 1.6 L water and was extracted with 750 ml chloroform thrice. Combined organic extract was washed with 200 ml water and dried over sodium sulfate. Evaporation of organic solvent afforded 85 g (85%) as an oil. The compound was subjected to a second resolution by dissolving it (84 g, 0.32 mol} in 1.0 L 2-3 % aqueous ethyl alcohol (moisture content, 2.6 %) under stirring and resultant solution was treated with L-(+)-tartaric acid (46 g, 0.307 mol) at 60-70°C. The reaction mixture was agitated at 65-70°C for half an hour. The reaction mass was cooled and was filtered at 20-30°C. The wet cake was washed with 250 ml additional ethyl alcohol to afford a crystalline salt. The resultant white solid was treated with aqueous K2CO3 solution made by dissolving 93 g K2C03 in 1.0 L water and was extracted with 750 ml X 3 chloroform. Combined organic extract was washed with 200 ml water and was dried over sodium sulfate. Evaporation of organic solvent afforded 71 g (83%) as an oil. [a]D25 value -31.80° (c=l, CHCI3), percentage of isomers ratio 96.37:3.63 determined by HPLC of Mosher amide analogue. Step-5: (+V1- Benzvloxvcarbonvl^butyloxycarbonylamino-S.S-dimethvlpiperidine: To a solution of (+)-4-amino-l-benzyloxycarbonyl-3,3-dimethylpiperidine (55 g, 0.209 mol) was dissolved in 500 L dichloromethane was added triethylamine (22.2 g, 0.209 mol) followed by di-t_butyl carbonate (45.8 g, 0.209 mol) dissolved in 200 ml dichloromethane while maintaining temperature between 5- 10°C, under stirring. The reaction was maintained at 25-35°C. After completion of reaction the reaction mixture was diluted with 1.0 L water and layers were separated. Combined organic extract was dried over sodium sulfate and was evaporated to dryness to obtain 76 g of product, m/z (M+l) 363. 93 NMR(CDC13) D20 exchange: 0.80 (s, 3H); 0.98 (s, 3H); 1.45 (s, 9H); 1.70 (m, 1H); 2.70 (m, 1H); 2.90 (t,lH); 3.40 (t, 1H), 3.80 (t,lH); 4.18 (t, 1H); 4.4 (d,lH), 5.1 (s, 2H); 7.40 (s,5H). [a]D25 value +16.28° (c=l, CHCI3). Step-6: (-)- 1-Benzyloxycarbonyl- -A- butyloxycarbonylamino-3,3-dimethylpiperidine The compound was prepared as per procedure described for its (+) isomer in quantitative yield. [a]D25 value -15.86° (c=l, CHCI3). Step-7: (+)-4-t-Butyloxvcarbonylamino -3.3-dimethylpiperidine: (+)-l- Benzyloxycarbonyl-4-t"butyloxycarbonylamino-3,3-dimethylpiperidme (75 g, 0.207 mol) was dissolved in 500 ml methanol and the solution was transferred to a Parr reactor. Wet 10% palladium on carbon (7.5 g) was added to the solution and was stirred at 200 psi hydrogen pressure. Reaction progress was monitored on TLC and reaction was completed in 3-4 hrs. The reaction mixture was filtered as soon as it was completed. The residue was washed with 100 ml methanol. Fitrate was evaporated to dryness to afford the required product (47 g) in quantitative yield. m/z (M+l) 229. NMR(CDC13): 0.95 (bs, 6H); 1.45-1.6 (m, 10H); 1.6-1.8 (m, 1H); 2.4 (d, 1H); 2.5-2.7 (m, 2H); 3.05 (m,lH); 3.3-3.5 (m, 1H), 4.4 (m,lH). Step-8: (-)-4-t-Butvloxvcarbonvlamino-3,3-dimethylpiperidine The compound was prepared as per procedure described for its (+) isomer. m/z (M+l) 229. NMR(CDC13): 0.95 (bs, 6H); 1.45-1.6 (m, 10H); 1.6-1.8 (m, 1H); 2.4 (d, 1H); 2.5-2.7 (m, 2H); 3.05 (m,lH); 3.3-3.5 (m, 1H), 4.4 (m,lH). Preparation 20 4-Amino-3-ethvl-3-methylpiperidine Ammonium acetate (2.5 g, 32.46 mmol) was added to the stirred solution of l-benzyl-3-ethyl-3-methyl-4-piperidinone (0.9 g, 3.9 mmol) in methanol (20 ml) and stirring was continued for 3 hr at ambient temperature. The resulting mixture was cooled at 0°C and sodium cyanoborohydride (0.2 g, 3.1 mmol) was added to it. Cooling was removed after 10 94 min. and resulting mixture was stirred for 6 hr at ambient temperature. The reaction mixture was concentrated to dryness, triturated with water, acidified with cone. HC1 (pH 3-4) and extracted with ethyl acetate to remove impurities. The aqueous layer was basified with 1 M sodium hydroxide solution (pH -10) and extracted with ethyl acetate. Ethyl acetate extract was dried (Na2S04) and concentrated to dryness to furnish 4-amino-l-benzyl-3-ethyl-3-methylpiperidine. Yield 0.6 g (66 %), C15H24N2, m/z 233 (M+l). A mixture of 20% Pd(OH)2 on carbon (0.2 g) and 4-amino-l-benzyl-3-ethyl-3-methylpiperidine (0.6 g, 2.58 mmol) in methanol (210 ml) was stirred in hydrogen atmosphere (1 atm.) at 30°C for 6 hr. The catalyst was filtered off, washed with methanol and filtrate was concentrated to dryness to afford 4-amino-3-ethyI-3-methyIpiperidine. Yield 0.27 g (74 %), C8H18N2,m/z 143 (M+l). Preparation 21 4-Methylamino-3-ethyl-3-methylpiperidine Potassium hydroxide (15.45 g, 276 mmol) was added to the stirred solution of methylamine hydrochloride (18.54 g, 276 mmol) in methanol (100 ml) and stirring was continued for 30 min at 30°C. l-benzyl-3-ethyl-3-methyl-4-piperidinone (8 g, 34.6 mmol) was added to the resulting mixture and stirred for 6 hr. Sodium cyanoborohydride (2.18 g, 34.6 mmol) was added to it and reaction mixture was stirred for 15 hr. The reaction mixture was concentrated to dryness, triturated with water, extracted with chloroform, dried (Na2S04) and concentrated to give l-benzyl-4-methyIamino-3-ethyl-3-methylpiperidine. Yield 6 g (67 %), C16H26N2, m/z 247 (M+l). A mixture of 20% Pd(OH)2 on carbon (0.7 g) and l-benzyl-4-methylamino-3-ethyl-3-methyl piperidine (6 g, 24.39 mmol) in methanol (60 ml) was stirred in hydrogen atmosphere (1 atm.) at 60°C for 6 hr. The catalyst was filtered off, washed with methanol and filtrate was concentrated to dryness to afford 4-methylamino-3-ethyl-3-methylpiperidine. Yield 2.5 g (66 %), C9H2oN2,m/z 157 (M+l). Preparation 22 4-Cyclopropvlamino-3-ethyl-3-methvlpiperidine l-Benzyl-3-ethyl-3-methyl-4-piperidinone (4.2 g, 18.18 mmol) was added to the stirred solution cyclopropylamine (6.5 g, 115 mmol) in methanol (100 ml) and stirred for 6 hr. 95 2 2 MAR 2006 Sodium cyanoborohydride (1.14 g, 18.18 mmol) was added to it and reaction mixture was stirred for 15 hr. The reaction mixture was concentrated to dryness, triturated with water, extracted with chloroform, dried (Na2S04) and concentrated to furnish crude l-benzyl-4-cyclopropylamino-3-ethyl-3-methylpiperidine. Yield 4g (88%), C18H28N2,m/z 273 (M+l). A mixture of 20% Pd(OH)2 on carbon (0.5 g) and 1 -benzyl-4-cyclopropylamino-3-ethyl-3-methylpiperidine (3.54 g, 13.00 mmol) in methanol (70 ml) was stirred in hydrogen atmosphere (1 atm.) at 60°C for 48 hr. The catalyst was filtered off, washed with methanol and filtrate was concentrated to dryness to afford 4-cyclopropylamino-3-ethyl-3-methylpiperidine. Yield 2.3 g ( 93%), CnH22N2, m/z 183 (M+l). Preparation 23 4-Dimethylamino-3-Ethvl-3-Methylpiperidine Paraformaldehyde (10 g) was added to the stirred solution of 4-amino-l-benzyl-3-ethyl-3-methylpiperidine (8.0 g, 34 mmol) in methanol (100 ml) at 0°C and sodium cyanoborohydride (2.14 g, 34 mmol) was added to it. Then, acetic acid (2 ml) was added to the resulting mixture and stirring was continued for 24 hr at ambient temperature. The reaction mixture was concentrated to dryness, triturated with water, acidified with cone. HC1 (pH 3-4) and extracted with ethyl acetate to remove impurities. The aqueous layer was basified with 1 M sodium hydroxide solution (pH -10) and extracted with ethyl acetate. Ethyl acetate extract was dried (Na2S04) and concentrated to give l-benzyl-4-dimethylamino-3-ethyl-3-methylpiperidine. Yield 6 g (67 %), Ci7H28N2,m/z 261 (M+l). A mixture of 20% Pd(OH)2 on carbon (0.7 g) and l-benzyl-4-dimethylamino-3-ethyl-3-methyl piperidine (6 g, 23 mmol) in methanol (50 ml) was stirred in hydrogen atmosphere (1 atm.) for 48 hr at room temperature. The catalyst was filtered off, washed with methanol and filtrate was concentrated to afford 4-dimethylamino-3-ethyl-3-methylpiperidine. Yield 2.8 g (72%),C10H22N2,m/z 171 (M+l). Preparation 24 4-Amino-3,3-diethvlpiperidine Ammonium acetate (7.85 g, 102 mmol) was added to the stirred solution of l-benzyl-3,3- diethyl piperidin-4-one (5.0 g, 20.40 mmol) in methanol (100 ml) and stirring was continued for 3 hr at ambient temperature. The resulting mixture was cooled at 0°C and sodium 96 cyanoborohydride (1.3 g, 20.40 mmol) was added to it. Cooling was removed after 10 min. and resulting mixture was stirred for 6 hr at ambient temperature. The reaction mixture was concentrated to dryness, triturated with water, acidified with cone. HCl (pH 3-4) and extracted with ethyl acetate to remove impurities. The aqueous layer was basified with 1 M sodium hydroxide solution (pH -10) and extracted with ethyl acetate. Ethyl acetate extract was dried (Na2S04) and concentrated to dryness to furnish 4-amino-l-benzyl-3,3-diethyl piperidine. Yield 8.2 g (82 %), Ci6H26N2, m/z 247 (M+l), PMR (CDC13): 0.84 (s, 3H), 0.98 (s, 3H), 1.48 (bs, 2H, D20 exchangeable), 1.66 (m, 2H), 2.04 (m, 2H), 2.42 (m, 2H), 2.86 (m, 1H), 3.46 (dd, 2H), 7.32 (m, 5H). A mixture of 20% Pd(OH)2 on carbon (0.8 g) and 4-amino-l-benzyl-3,3-diethylpiperidine (8.0g, 32.52 mmol) in methanol (100 ml) was stirred in hydrogen atmosphere (1 atm.) at 30°C for 6 hr. The catalyst was filtered off, washed with methanol and filtrate was concentrated to dryness to afford 4-amino-3,3-diethylpiperidine. Yield 4.8g (94.60 %), C9H20N2, m/z 157 (M+l), PMR (CDC13): 0.9 (s, 6H), 1.5 (m, 2H), 1.58 (bs, 2H, D20 exchangeable), 2.26 - 2.68 (m, 4H), 3.06 (m, 1H), 3.52 (bs, 1H, D20 exchangeable). Preparation 25 4-Amino-3.5-dimethylpiperidine Step-1: Mixture of isomers of 4-amino-l-carbethoxy-3.5-dimethvlpiperidine: Ethyl chloroformate (10.0 g, 90 mmol) was added to a stirred solution of l-benzyl-3,5-dimethyl-4-piperidinone (5.0 g, 24 mmol) in benzene (20 ml), refluxed with stirring for 6 hr and concentrated to dryness to give l-carbethoxy-3,5-dirnethyl-4-piperidinone as oil. Yield 4.51 g (90 %), CioHi7N03,m/z 200 (M+l). Ammonium acetate (20 g) was added to the stirred solution of l-carbethoxy-3,5-dimethyl-4-piperidinone (4.5 g, 22.5 mmol) in methanol (200 ml) and stirred for 3 hr. The resulting mixture was cooled at 0°C and sodium cyanoborohydride (1.4 g, 22.5 mmol) was added to it. Cooling was removed and stirring was for 3 hr at 35°C. The reaction mixture was concentrated, triturated with water, acidified with cone. HCl (pH 3 ~ 4) and extracted with ethyl acetate to remove impurities. The aqueous layer was basified with 1 M sodium hydroxide solution (pH -10) and extracted with ethyl acetate. Ethyl acetate extract was dried (Na2S04) and concentrated to give 4-amino-l-carbetfroxy-3,5-dimethylpiperidine. The obtained 4-amino-l-carbethoxy-3,5-dimethylpiperidine was subjected to silica gel column chromatography. Elution with 5% methanol in chloroform furnished a solid, which was a mixture of stereoisomers, conformational analysis of which was not obtained. Yield 3.5 g (77 %), m.p. 218-20°C, Ci0Hi8N2O2,m/z 201 (M+1). Step-2: Separation of isomers of 4-amino-l-carbethoxy-3.5~dimethylpiperidine: 4~ Amino- l-carbethoxy-3,5-dimethylpi peri dine obtained as per procedure described in Step-1 was subjected to silica gel column chromatography. Elution with chloroform gave "upper" mixture of isomers of 4-amino-l-carbethoxy-3,5-dimethylpiperidine m.p. 248-50°C, Ci0H18N2O2, m/z 201 (M+1), PMR (CDC13): 0.94 (m, 6H), 1.16 (t, 3H), 1.78 (m, IH), 2.02 < (m, IH), 2.06 (bs, 2H, D20 exchangeable), 2.72 (m, 2H), 2.86 (m, IH), 3.74 (m, 2H), 4.12 (q, 2H). Further elution with 5 % methanol in chloroform furnished "lower" mixture of isomers of 4-amino-l-carbethoxy-3,5-dimethylpiperidine m.p. 236-40°C, Ci0Hi8N2O2, m/z 201 (M+1), PMR (CD3OD): 0.88 (m, 6H), 1.16 (t, 3H), 1.82 (m, IH), 2.1 (m, IH), 2.5 (m, 2H), 2.94 -3.15 (m,3H), 3.96 (q,2H). Step-3: Mixture of isomers of 4-amino-3,5-dimethylpiperidine (Mixtures A+B): A mixture of isomers of 4-amino-l-carbethoxy-3,5-dimethylpiperidine (10 g, 51 mmol) obtained by a procedure as described in step-1, was stirred in 5 M NaOH solution (100 ml) at 100°C for 48 hr, cooled, extracted with ethyl acetate, dried (Na2S04) and concentrated to afford mixture of isomers of 4-amino-3,5-dimethylpiperidine as oil as "mixture A + B". Yield 5.1 g (80 %), C7Hi6N2,m/z 129 (M+1). Step-4: "Upper" mixture of isomers of 4-amino-3.5-dimethylpiperidine (Mixture A of isomers): A "upper" mixture of isomers of 4-amino-l-carbethoxy-3,5-dimethylpiperidine (1.5 g, 7.5 mmol) obtained as described in Step-2, was stirred in 5 M NaOH solution (10 ml) at 100°C for 48 hr, cooled, extracted with ethyl acetate, dried (Na2S04) and concentrated to afford "upper" mixture of isomers of 4-amino-3,5-dimethyl piperidine as oil as mixture A of isomers, of which the conformational analysis was not obtained. Yield 0.72 g (76 %), 98 C7Hi6N2, m/z 129 (M+l), PMR (CDC13): 0.94 (m, 6H), 1.7 (bs, 3H, D20 exchangeable), 1.78 (m, 1H), 2.02 (m, 1H), 2.5 - 2.8 (m, 4H), 2.86 (m,lH). Step-5: "Lower" mixture of isomers of 4-amino-3,5-dimethvfpiperidine (Mixture B of isomers): A "lower" mixture of isomers of 4-amino-l-carbethoxy-3,5-dimethylpiperidine (1.0 g, 5.0 mmol) obtained by a procedure as described in step-2, was stirred in 5 M NaOH solution (10 ml) at 100°C for 48 hr, cooled, extracted with ethyl acetate, dried (Na2S04) and concentrated to afford "lower" mixture of isomers of 4-amino-3,5-dimethylpiperidine as an oil as mixture B of isomers, of which the conformational analysis was not obtained. Yield 0.51 g (80 %), C7Hl6N2,m/zl29(M+l). Preparation 26 4-Methylamino-3,5-Dimethylpiperidine Powdered KOH (0,92 g, 16.44 mmol) was added in portions to the stirred solution of methylamine hydrochloride (1.11 g, 16.44 mmol) in methanol (20 ml) at 0-5°C and 1-carbethoxy-3,5-dimethyl-4-piperidinone (2.2 g, 1.1 mmol),obtained by a procedure as described in Example 25 (Step-1), was added in portions to it. The resulting reaction mixture was stirred for 45 min at 10°C and a solution of sodium cyanoboro-hydride (0.7 g, 1.1 mmol) in methanol (5 ml) was added dropwise to it. Cooling was removed and stirring was for 24 hr at 30°C. The reaction mixture was basified with 20% KOH solution, filtered (to remove insoluble impurities) and filtrate was concentrated to dryness. The obtained residue was dissolved in water and extracted with chloroform. Chloroform layer was extracted with 50% HC1 and acid layer was basified with 20% KOH solution. The separated oil was extracted with chloroform, dried (Na2S04) and concentrated to give a Mixtures A+B of 4-methylamino-l-carbethoxy-3,5-dimethylpiperidine. Yield 1.34 g (60 %), CiiH22N202, m/z 214 (M+l). Mixtures A+B of 4-methylamino-l-carbethoxy-3,5-dimethylpiperidine (1.3 g, 0.6 mmol) was stirred in a mixture of 10% NaOH solution (20 ml) and ethyl alcohol (10 ml) at 100°C for 120 hr, cooled, extracted with ethyl acetate, dried (Na2S04) and concentrated to afford a Mixtures A+B of 4-methylamino-3,5-dimethylpiperidine. Yield 0.61 g (70 %), C8Hi8N2, m/z 143 (M+l). Mixture A of isomers and Mixture B of isomers of 4-methylamino-3,5-dimethylpiperidine were prepared by separation technique at 4-methylamino-l-carbethoxy-3,5- dimethylpiperidine stage by using silica gel column chromatography similar as described in Preparation 25 (Step-2) followed by aqueous sodium hydroxide mediated hydrolysis. Preparation 27 4-Emylamino-3,5-dimethylpiperidine Powdered KOH (2.8g, 50 mmol) was added in portions to the stirred solution of ethylamine hydrochloride (4.0 g, 50 mmol) in methanol (50 ml) and l-carbethoxy-3,5-dimethyl-4-piperidinone (5.0 g, 25.12 mmol) obtained by a procedure as described in Example 25 (Step-1), was added to it. The resulting reaction mixture was stirred for 6 hr. A solution of sodium cyanoborohydride (1.6 g, 25.12 mmol) in methanol (10 ml) was added dropwise to it and stirring was continued for 16 hr. The reaction mixture was concentrated to dryness. The obtained residue was dissolved in water and extracted with chloroform. Chloroform layer was extracted with 50% HC1 and acid layer was basified with KOH (20%) solution. The oil thus separated was extracted with chloroform, dried (Na2S04) and concentrated to give Mixtures A +B of 4-ethylamino-l-carbethoxy-3,5-dimethylpiperidine as an oil. Yield 5.6 g (97.7 %), Q2H24N2O2, m/z 229 (M+l). The similarly obtained Mixtures A+B of 4-ethylamino-l-carbethoxy-3,5-dimethylpiperidine was separated over silica gel column chromatography. Elution from 5% methanol in chloroform gave Mixture A of isomers of 4-ethylamino-l-carbethoxy-3,5-dimethylpiperidine as oil. Yield 2.1 g (36 %), C^^^Oj, m/z 229 (M+l), PMR (CDC13): 0.94 (dd, 6H), 1.25 (t, 3H), 1.5 - 2.1 (3H, m, D20 exchangeable), 2.38 (m, 1H), 2.72 (m, 2H), 3.3 - 3.8 (m, 3H), 3.64 (s, lH),4.12(q, 2H). Further elution from 5 % methanol in chloroform furnished Mixture B of isomers of 4-ethylamino-l-carbethoxy-3,5-dimethylpiperidine as oil. Yield 2.1 g (36 %), C12H24N2O2, m/z 229 (M+l), PMR (CDCI3): 0.92 (dd, 6H), 1.18 (t, 3H), 1.48 (bs,lH, D20 exchangeable), 1.68 (m, 1H), 2.02 (m, 1H), 2.3 (m, 1H), 2.4 - 2.68 (m, 3H), 3.0 (dd, 1H), 3.82 (dd, 1H), 3.95 (m, lH),4.12(m,2H). The Mixture A of isomers of 4-ethylamino-l-carbethoxy-3,5-dimethylpi peri dine (2.1 g, 0.92 mmol) was stirred in 5 N NaOH solution (20 ml) at 100°C for 96 hr, cooled, extracted with ethyl acetate, dried (Na2S04) and concentrated to afford Mixture A of isomers of 4-ethylamino-3,5-dimethyl piperidine as oil. Yield 1.34 g (93.2 %), C9H20N2, m/z 157 (M+l), PMR (CDCI3): 0.94 (dd, 9H), 1.45 (m, 1H), 1.66 (m, 1H), 1.94 (m, 3H, D20 exchangeable), 2.36 (m, 1H), 2.44 - 2.74 (m, 3H), 3.0 (dd, 1H), 3.5 (m, 1H). 100 2 2 MAR 2006 The Mixture B of isomers of 4-ethylamino-l-carbethoxy-3,5-dimethylpiperidine (2.1 g, 0.92 mmol) was stirred in 5 N NaOH solution (20 ml) at 100°C for 96 hr, cooled, extracted with ethyl acetate, dried (Na2S04) and concentrated to afford Mixture B of isomers 4-ethylamino-3,5-dimethylpiperidine as oil. Yield 1.34 g (93.2 %), C9H20N2, m/z 157 (M+l), PMR (CDCI3): 0.94 (dd, 6H), 1.12 (t, 3H), 1.5-1.8 (m, 3H, D20 exchangeable), 1.9 (m, 1H), 2.28 (m, 2H), 2.46 (m, 1H), 2.62 - 3.0 (m, 4H). Preparation 28 4-Cvclopropylamino-3,5-dimethylpiperidine A solution of cyclopropylamine (71.6 g, 126 mmol) and l-carbethoxy-3,5-dimethyl-4-piperidinone (50 g, 26 mmol) obtained by a procedure as described in Example 25 (Step-1), in methanol (500 ml) was stirred for 6 hr at ambient temperature. Sodium cyanoborohydride (16 g, 26 mmol) was added in portions to the resulting mixture and stirring was continued for 16 hr. The reaction mixture was concentrated to dryness. The obtained residue was dissolved in water and extracted with chloroform. Chloroform layer was extracted with 6N HCl and HCl extract was basified with aqueous KOH (20 %) solution. The oil thus separated was extracted with chloroform, dried (Na2S04) and concentrated to give a mixture of Mixtures A+B of l-carbethoxy-4-cyclopropylamino-3,5-dimethylpiperidine as oil. Yield 58 g (96 %), C13H24N202,m/z241 (M+l). The similarly obtained Mixture A+B of l-carbethoxy-4-cyclopropylamino-3,5-dimethylpiperidine was separated over silica gel column chromatography. Elute from 5% ethyl acetate in hexane gave Mixture A of isomers of l-carbethoxy-4-cyclopropyamino-3,5-dimethylpiperidine as oil. C13H24N202, m/z 241 (M+l), PMR (CDC13): 0.88 - 1.17 (m, 10H), 1.3 (t, 3H), 1.74 (bs, 1H, D20 exchangeable), 2.48 - 2.82 (m, 4H), 3.26 - 3.85 (m, 2H), 4.18 (q, 2H), 4.42 (bm, 2H). Further elution from 5% ethyl acetate in hexane furnished Mixture B of isomers of 1-carbethoxy-4-cyclopropylamino-3,5-dimethylpiperidine as oil. C13H24N2O2, m/z 241 (M+l), PMR (CDCI3): 0.78 - 1.08 (m, 10H), 1.15 (t, 3H), 1.48 - 2.1 (m, 4H, D20 exchangeable), 2.32 - 2.82 (m, 2H), 3.24 - 3.82 (m, 2H), 4.04 - 4.25 (m, 3H). 101 Mixture A of isomers of l-carbethoxy-4-cyclopropylamino-3,5-dimethylpiperidine ( 3.5 g, 1.45 mmol) was stirred in 5 N NaOH solution ( 25 ml) at 100°C for hr, cooled, extracted with ethyl acetate, dried (Na2S04) and concentrated to afford Mixture A of isomers of 4-cyclopropylamino-3,5-dimethyl piperidine as oil. Yield 2.1 g ( 85%), Ci0H2oN2, m/z 169 (M+l). The Mixture B of isomers of l-carbethoxy-4-cyclopropylamino-3,5-dimethylpiperidine (2.8 g, 1.16 mmol) was stirred in a mixture 5 N NaOH solution (20 ml) and ethyl alcohol (5 ml) at 100°C for 120 hr, cooled, extracted with ethyl acetate, dried (Na2SC>4) and concentrated to afford Mixture B of isomers of 4-cyclopropylamino-3,5-dimethylpiperidine as an oil. Yield 1.6 g (84 %), C10H20N2, m/z 169 (M+l) PMR (CDC13): 0.82 - 1.05 (m, 10H), 1.5 (m, H), 1.75 (m, H,), 2.16 - 2.38 (m, 3H), 2.65 (m, 1H), 2.78 (m, 1H), 3.02 (m, 1H), 3.41 (m, 1H), 3.64 (m, 1H). Preparation 29 4-Dimethvlamino-3,5-dimethy]piperidine Potassium hydroxide (3.86 g) was added to the stirred solution of N,N-dimethylamine hydrochloride (5.63 g, 69.0 mmol) in methanol (20 ml) and stirring was continued for 30 min at 30 °C. l-benzyl-3,5-methyl-4-piperidinone (3 g, 13.8 mmol) was added to the stirred mixture and refluxed for 48 hr. Reaction mixture was cooled at 30 °C and sodium cyanoborohydride (0.87 g, 13.8 mmol) was added. The resulting reaction mixture was stirred for 24 hr at 70 °C. The reaction mixture was concentrated to dryness, triturated with water, extracted with chloroform, dried (Na2S04) and concentrated to give Mixtures A+B of 1-benzyl-4-dimethylamino-3,5-dimethylpiperidine. Yield 2.7 g (79.4 %), Ci6H26N2, m/z 247 (M+l). A mixture of 20% Pd(OH)2 on carbon (0.5 g) and Mixtures A+B of l-benzyl-4-dimethylamino-3,5-dimethylpiperidine (2.7 g, 10.1 mmol) in methanol (50 ml) was stirred in hydrogen atmosphere (1 atm.) at 60 °C for 48 hr. The catalyst was filtered off, washed with methanol and filtrate was concentrated to dryness to afford Mixtures A +B of 4-dimethylamino-3,5-dimethylpiperidine. Yield 0.9 g (52.6 %), C9H20N2,m/z 157 (M+l). Mixture A of isomers and Mixture B of isomers of 4-dimethylamino-3,5-dimethylpiperidine were prepared by separation technique at l-benzyl-4-dimethylamino-3,5-dimethylpiperidine stage by using silica gel column chromatography followed by debenzylation by using catalytic palladium hydroxide on carbon. 102 Preparation 30 4-Amino-3.5-diethvlpiperidine Ammonium acetate (10 g, 130mmol) was added to the stirred solution of l-benzyl-3,5-diethyI-4-piperidone (3.5 g, 14.3 mmol) in methanol (50 ml) and stirring was continued for 4 hr at ambient temperature. The resulting mixture was cooled at 0°C and sodium cyanoborohydride (0.45 g, 7.14 mmol) was added to it. Cooling was removed after 10 min. and resulting mixture was stirred for 10 hr at ambient temperature. The reaction mixture was concentrated to dryness, triturated with water, acidified with cone. HCl (pH 2) and extracted with ethyl acetate to remove impurities. The aqueous layer was basified with 1M sodium hydroxide solution (pH 10) and extracted with ethyl acetate. Ethyl acetate extract was dried (Na2S04) and concentrated to dryness to furnish 4-amino-l-benzyl-3,5-diethylpiperidine. Yield 3.4 g (97 %), C,6H26N2, m/z 247 (M+l). A mixture of 5% Pd on carbon (0.5 g) and 4-amino-l-benzyl-3,5-diethylpiperidine (3.4 g, 13.82 mmol) in methanol (25 ml) was stirred in hydrogen atmosphere (3 atm.) at 60 °C for 6 hr. The catalyst was filtered off, washed with methanol and filtrate was concentrated to dryness to afford 4-amino-3,5-diethylpiperidine as an oil. Yield 1.4 g (64.5 %), C9H2oN2, m/z 157 (M+l). Preparation 31 4- Amino-3,3,5-trimethylpiperidine A mixture of 20% Pd(OH)2 on carbon (0.3 g) and l-benzyl-3,3,5-trimethyl-4-piperidone (1.5 g, 6.5 mmol) in methanol (20 ml) was stirred in hydrogen atmosphere (1 atm.) at 30°C for 6 hr. The catalyst was filtered off, washed with methanol and filtrate was concentrated to dryness to afford 3,3,5-trimethyl-4-piperidinone. Yield 0.8 g (88 %), C8Hi5NO, m/z 142 (M+l). Ammonium acetate (2.5 g, 32.46mmol) was added to the stirred solution of 3,3,5-trimethyl-4-piperidone (0.8 g, 5.67 mmol) in methanol (20 ml) and stirring was continued for 3 hr at ambient temperature. The resulting mixture was cooled at 0°C and sodium cyanoborohydride (0.25 g, 3.96 mmol) was added to it. Cooling was removed after 10 min. and resulting mixture was stirred for 6 hr at ambient temperature. The reaction mixture was concentrated to dryness, triturated with water, acidified with cone. HCl (pH 3-4) and extracted with ethyl acetate to remove impurities. The aqueous layer was basified with 1 M sodium hydroxide solution (pH -10) and extracted with ethyl acetate. Ethyl acetate extract was dried (Na2S04) 103 2 2 MAR 2006 and concentrated to dryness to furnish 4-amino-3,3,5-trimethylpiperidine. Yield 0.45 g (54 %), C8Hi8N2,m/z 143 (M+l). Preparation 32 4-Amino-3,5-diethyl-3-methylpiperidine Ammonium acetate (8.0 g, 104 mmol) was added to the stirred solution of l-benzyI-3,5-diethyl-3-methyl-4-piperidone (2.5 g, 9.65 mmol) in methanol (25 ml) and stirring was continued for 24 hr at ambient temperature. The resulting mixture was cooled at 0 °C and sodium cyanoborohydride (0.69 g, 11.2 mmol) was added to it. Cooling was removed after 10 min. and resulting mixture was stirred for 20 hr at ambient temperature. The reaction mixture was concentrated to dryness, triturated with water, acidified with cone. HC1 (pH 2) and extracted with ethyl acetate to remove impurities. The aqueous layer was basified with 1M sodium hydroxide solution (pH 9) and extracted with ethyl acetate. Ethyl acetate extract was dried (Na2SC)4) and concentrated to dryness to furnish 4-amino-l-benzyl-3,5-diethyl-3-methylpiperidine as an oil. Yield 2.1 g (84 %), C17H28N2,m/z 261 (M+l). A mixture of 20% Pd(OH)2 on carbon (0.3 g) and 4-amino-l-benzyl-3,5-diethyl-3-methylpiperidine (2.1 g, 8.07 mmol) in methanol (50 ml) was stirred in hydrogen atmosphere (4 atm.) at 45 °C for 4 hr. The catalyst was filtered off, washed with methanol and filtrate was concentrated to dryness to afford 4-amino-3,5-diethyl-3-methyl-piperidine as an oil. Yield 1.2 g (88 %), Ci0H22N2, m/z 171 (M+l). Preparation 33 4-Amino-3.5-dimethyl-3-ethylpiperidine Ammonium acetate (2.5 g, 32.46mmol) was added to the stirred solution of l-benzyl-3,5-dimethyl-3-ethyl-4-piperidone (3.0 g, 12.25 mmol) in methanol (40 ml) and stirring was continued for 20 hr at ambient temperature. The resulting mixture was cooled at 0°C and sodium cyanoborohydride (0.8 g, 12.7 mmol) was added to it. Cooling was removed after 10 mm, and resuhing mixture was stirred for 20 hr at ambient temperature. The reaction mixture was concentrated to dryness, triturated with water, acidified with cone. HC1 (pH 2) and extracted with ethyl acetate to remove impurities. The aqueous layer was basified with 1M sodium hydroxide solution (pH 9) and extracted with ethyl acetate. Ethyl acetate extract was 104 2 2 MAR 2006 cyanoborohydride (0.5 g, 9.2 mmol) was added to it. Then, acetic acid (2 ml) was added to the resulting mixture and stirring was continued for 24 hr at ambient temperature. The reaction mixture was concentrated to dryness, triturated with water, acidified with cone. HCl (pH 3-4) and extracted with ethyl acetate to remove impurities. The aqueous layer was basified with 1 M sodium hydroxide solution (pH -10) and extracted with ethyl acetate. Ethyl acetate extract was dried (Na2S04) and concentrated to give l-benzyl-4-dirnethylamino-3,3-dimethylpiperidine. Yield 1.9 g (84 %), Ci6H26N2,m/z 247 (M+l). A mixture of 20% Pd(OH)2 on carbon (0.3 g) and l-benzyl-4-dimethylamino-3,3-dimethylpiperidine (4.5 g, 6.0 mmol) in methanol (20 ml) was stirred in hydrogen atmosphere (1 atm.) for 48 hr at room temperature. The catalyst was filtered off, washed with methanol and filtrate was concentrated to afford 4-dimethylamino-3,3-dimethylpiperidine. Yield 1.6 g (95 %), C9H20N2,m/z 157 (M+l). Preparation 15 4-Carbethoxyamino-3,3-dimethvlpiperidine Ethyl chloroformate (2 ml) was added to a stirred solution of 4-amino-l-benzyl-3,3-dimethylpiperidine (1.6 g, 7.33 mmol) and triethylamine (2 ml) in methylene chloride (25 ml) at ambient temperature, stirring was continued for 1 hr concentrated to dryness, triturated with water, extracted with ethyl acetate, dried (Na2SC>4) and concentrated to give l-benzyl-4-carbethoxyamino-3,3-dimethyl piperidine as oil. Yield 1.3 g (62 %), Ci7H26N202, m/z 291 (M+l), PMR (CDC13): 0.98 (s, 3H), 1.2 (t, 6H), 1.78 (m, 2H), 2.42 (m, 2H), 2.82 (m, 2H), 3.6 (d, 2H), 3.9 (m, 1H), 4.1 (q, 2H), 4.8 (bs, 1H), 7.54 (m, 5H). A mixture of 20% Pd(OH)2 on carbon (0.3 g) and l-benzyl-4-carbethoxyamino-3,3-dimethylpiperidine (1.3 g, 4.48 mmol) in methanol (15 ml) was stirred in hydrogen atmosphere (1 atm.) at 30°C for 3 hr. The catalyst was filtered off, washed with methanol and filtrate was concentrated to dryness to afford 4-carbethoxyamino-3,3-dimethylpiperidine. Yield 0.8 g (90 %), CioH2oN202,m/z 201 (M+l). Preparation 16 4-Acetylamino-3.3-dimethylpiperidine Acetic anhydride (3 ml) was added to a stirred solution of 4-amino-l-benzyI-3,3- dimethylpiperidine (2.0 g, 9.17 mmol) in pyridine (5 ml) and stirred for 1 hr. The reaction 88 dried (Na2S04) and concentrated to dryness to furnish 4-amino-l-benzyl-3,5-dimethyl-3- ethylpiperidine. Yield 2.2 g (73 %), CI6H26N2, rn/z 247 (M+l). A mixture of 20% Pd(OH)2 on carbon (0.4 g) and 4-amino-l-benzyl-3,5-dimethyl-3- ethylpiperidine (2.2 g, 8.9 mmol) in methanol (15 ml) was stirred in hydrogen atmosphere (1 atm.) at 60°C for 10 hr. The catalyst was filtered off, washed with methanol and filtrate was concentrated to dryness to afford 4-amino-3,5-dirnethyl-3-ethylpiperidine as a semi solid. Yield 1.1 g (79 %), C9H2oN2,m/z 157 (M+l). Preparation 34 cis or f raws-4-t-Butyloxvcarbonvlamino-1 -benzyl-3-methvlpiperidine: Step-1: Ethyl-1 -benzyl-3-methyl-4-oxo-piperidine-3-carboxvlate: Ethyl -l-benzyl-4-oxo-piperidine -3-carboxylate hydrochloride (150 g, 0.504 mol) was suspended in a solvent mixture of 750 ml THF and 750 ml DMF at room temperature. Addition of powdered KOH (56 g, 1.0 mol) was made in two equal lots keeping half an hour interval between two additions. To a clear reaction mixture methyl iodide (78 g, 0.55 mol) was added over period of 10 minutes and it was stirred for three hours at room temperature. The reaction was quenched by adding 4 ltr water followed by 1.5 ltr diethyl ether. Layers were separated. Organic layer was washed with water and dried over Na2S04- Evaporation of organic solvent afforded a liquid, which was passed through a silica gel column to give 86 g (61%), titled compound. mass (ES+) 276, Molecular Formula Ci6H2iN03, H'NMR (CDC13) 1.2 (s, 3H), 1.25 (t, 2H), 2.15 (d, 1H), 2.35-2.5 (m, 2H), 2.9 (d, 2H), 3.45 (d, 1H), 3.6 (s, 2H), 4.12-4.3 (m, 2H), 7.3 (s, 5H). Step -2: 1-Benzyl-3-methvl-4-piperidone: Ethyl-l-benzyl-3-methyl-4-oxo-piperidine-3-carboxylate (85 g, 0.31 mol) was dissolved in cone HC1 (82 ml, 0.77 mol) and the reaction mixture was heated to 100 °C for 32 hrs. Solvent was removed under reduced pressure and the resulting solid was dissolved in the 300 ml CHC13 and 400 ml pet ether was added to this under stirring to provide a solid. The solid was filter and was dissolved in 400 ml ethyl acetate and organic layer was washed with 10% 105 NaOH aqueous solution. Layers were separated and concentration of organic layer afforded 48 g (75%) oil as a titled product. mass (ES+) 204, Molecular Formula C13H17NO, H!NMR (CDCI3) 1.0 (d, 3H), 2.1 (t, 1H), 2.3-2.5 (m, 2H), 2.6-2.8 (m, 2H), 3.0-3.2 (m, 2H), 3.6 (s, 2H), 7.4 (s, 5H). Step-3: 4-Amino-l-benzyl-3-methvlpiperidine: Ammonium acetate (178.3 g, 2.31 mol) was charged to a solution of l-benzyl-3-methyl-4- piperidone (47 g, 0.232 mol) in 500 ml methanol. The suspension was stirred for 4 hours at room temperature. Sodium cyanoborohydride (7.3 g, 0.116 mol) was added in lots at 10 °C and it was stirred for 1 hour. Solvent was removed under vacuum and resultant solid was suspended in 500 ml water and acidified with dilute aqueous HC1. It was extracted with 200ml X 2 chloroform and layers were separated. Aqueous layer was basified with ammonia solution to pH 9 and extracted with 500 ml X 3 CHCI3. Drying of organic layer over Na2S04 and evaporation afforded 44 g (92%) titled product as an oil, which was used directly for further reaction. Step -4: cis or ?mn5,-4-t-Butvloxycarbonvlamino-l-benzvl-3-methvlpiperidine: Di-tert-butyloxydicarbonate (45 g, 0.206 mol) was charged in lots to a solution of 4-amino-l-benzyl-3-methylpiperidine (42 g, 0.206 mol) and 300 ml CH2C12 followed by 5 ml triethylamine. Reaction was worked up after 90 minutes by adding 300 ml water and layers were separated Drying of organic layer over Na2S04 and evaporation yielded mixture of cis and trans isomers in unequal proportion which when subjected to silica gel column chromatography with 10% ethyl acetate and hexane yielded 14 g of cis isomer and 11 g trans isomer and 19 gm mixture of both isomers of titled compound. For cis isomer: mass (ES+) 305, Molecular Formula C18H28N2O2, H'NMR (CDCI3) 0.95 (d, 3H), 1.45 (s, 9H), 1.7-1.8 (m, 2H), 2.0-2.2 (m, 2H), 2.35-2.5 (m, 2H), 3.5 (d, 2H), 3.7-3.8(bs, 1H), 4.5 (bs, 1H), 7.3 (s, 5H). For trans isomer: mass (ES+) 305, Molecular Formula C]8H28N202, H'NMR (CDCI3) 0.90 (d, 3H), 1.45 (s, 9H), 1.7-1.8 (t, 2H), 1.9-2.1 (m, 2H), 2.8-2.9 (m, 2H), 3.1 (m, 1H), 3.45(s, 2H), 4.3 (m, 1H), 7.3 (s, 5H). 106 Preparation 35 cis-4-t-Butyloxvcarbonylamino-3-methylpiperidine: cis-4-t-Butyloxycarbonylamino-l-benzyl-3-methylpiperidine(13 g, .042 mol) was dissolved in 170 ml methanol and transferred to the Parr pressure reactor after addition of 1.3 g of Pd(OH)2 on carbon. The rqcytoion mixture stirred for 6 hrs at 400 psi pressure at 50 °C. Catalyst was removed by filtration and eavaporation of the solvent afforded 8.7 g ( 95%) of titled compound. mass (ES+) 215, Molecular Formula C11H22N2O2, HJNMR (CDCI3) 0.90 (d, 3H), 1.45 (s, 9H), 1.7 (m, 2H), 2.0 (m, 2H), 2.8 (m, 2H), 3.8 (bs, 1H), 4.7 (bs, 1H). Preparation 36 trans-4-t-Butvloxycarbonvlamino-3-methylpiperidine: trans-4-t-Butyloxycarbonylamino-3-methylpiperidine was obtained as per procedure depicted in preparation 000 by using trans-4-t-Butyloxycarbonylamino-l-benzyl-3-methylpiperidine in the place of cis-4-t-Butyloxycarbonylamino-l-benzyl-3-methylpiperidine in 96% yield, mass (ES+) 215, Molecular Formula C11H22N2O2, Fi'NMR (CDCI3) 0.90 (d, 3H), 1.40 (s, 9H), 1.9 (m, 2H), 2.8 (m, 2H), 3.1 (m, 2H), 3.4 (s, 1H), 4.3 (m, 1H). Example 1 l-Cvclopropyl-6-fluoro-l,4-dihvdb-o-8-memoxv-7-(4-amino-3-methvl-l-piperidinvlV4-oxo- quinoline-3-carboxylic acid A mixture of [l-cyclopropyl-6,7-difluoro-l,4-dihydro-8-methoxy-4-oxo-quinoline-3-carboxylate-03,04]difluoroboron chelate (0.1 g, 0.29 mmol) and 4-amino-3-methylpiperidine (0.2 g, 1.75 mmol) in acetonitrile (20 ml) was refluxed for 6 hr. The reaction mixture was concentrated to dryness. The obtained residue was treated with triethylamine (3 ml) and ethanol (15 ml) and refluxed for 16 hr. The resulting mixture was concentrated to dryness; the solid thus obtained was triturated with water (10 ml), filtered, washed with water, dried and purified by preparative HPLC to furnish the required product. Yield 0.04 g (35%), m.p.238-40°C, C2oH24FN304, m/z 390 (M+l), PMR (CD3OD): 0.84-1.42 (m, 7H), 1.8-2.4 (m, 3H), 3.02 (m, 1H), 3.18-3.72 (m, 4H), 3.8 (s, 3H), 4.18 (m, 1H), 7.82 (d, 1H), 8.9 (s, 1H). 107 Example 2 trans- l-Cyclopropvl-6-fluoro-1.4-dihvdro-8-methoxv-7-f4-amino-3-methvl-1 -piperidinvlM- oxo-quinoline-3-carboxylic acid It was prepared in a similar manner as described in Example 1, where fr«/w-4-amino-3-methylpiperidine was used in place of 4-amino-3-methylpiperidine. Yield 35%, m.p.240-42°C, C20H24FN3O4, m/z 390 (M+l). Example 3 c/5,-l-cvclopropvl-6-fluoro-l,4-dihvdro-8-methoxv-7-(4-amino-3-methyl-l-piperidinvl')-4- oxo-quinoline-3-carboxvlic acid It was prepared in a similar manner as described in Example 1, where cw-4-amino-3-methylpiperidine was used in place of 4-amino-3-methylpiperidine Yield 35%, m.p.246-50°C, C20H24N3O4F, m/z 390 (M+l), Example 4 l-Cyclopropvl-6-fluoro-l,4-dihvdro-8-methoxy-7-(4-methylamino-3-methvl-l-piperidinvlV 4-oxo-quinoline-3-carboxylic acid It was prepared in a similar manner as described in Example 1, where 4-methylamino-3-methylpiperidine was used in place of 4-amino-3-methylpiperidine. Yield 50 %, m.p.240°C (decomp.), C23H28FN304, m/z 404 (M+l). Example 5 1 -Cyclopropvl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-emylamino-3-methyl- l-piperidinvl)-4- oxo-quinoline-3-carboxylic acid It was prepared in a similar manner as described in Example 1, where 4-ethylamino-3-methylpiperidine was used in place of 4-amino-3-methylpiperidine. Yield 52 %, m.p.160-62°C, C23H28FN304, m/z 418 (M+l). Example 6 l-Cyclopropvl-6-fluoro-l,4-dihvdro-8-methoxy-7-(4-cyclopropylamino-3-methyl-l- piperidinyl)-4-oxo-quinoline-3-carboxylic acid It was prepared in a similar manner as described in Example 1, where 4-cyclopropyl amino- 3-methylpiperidine was used in place of 4-amino-3-methylpiperidine. Yield 60 %, m.p.182- 84°C, C23H28FN304, m/z 430 (M+l). Example 7 1 -Cvclopropvl-6-fluoro-1,4-dihvdro-8-methoxy-7-(4-dimethylamino-3-methvl'l-piperidinvl)- 4-oxo-quinoline-3-carboxylic acid 108 It was prepared in a similar manner as described in Example 1, where 4-dimethyl amino-3-methylpiperidine was used in place of 4-arnino-3-methylpiperidine. Yield 74 %, m.p.180-82°C, C22H28FN304, m/z 418 (M+l), PMR (CD3OD): 0.88-1.28 (m, 7H), 1.8-2.3 (m, 3H), 2.92 (s, 6H), 2.66-3.32 (m, 5H), 3.76 (s, 3H), 4.14 (m, 1H), 7.68(d, l'H), 8.78 (s, 1H). Example 8 l-Cvclopropvl-6-fluoro-l,4-dihydro-8-methoxy-7-(4-ethoxvcarbonylamino-3,3-dimethvl-l- piperidinvl)-4-oxo-quinoline-3-carboxylic acid It was prepared in a similar manner as described in Example 1, where 4-1-carbethoxy amino- 3,3-dimethyl piperidine was used in place of 4-amino-3-methyl-piperidine. Yield 16 %, m.p.222°C, C24H3oFN306, m/z 476 (M+l), PMR (CDCI3): 1.04 (m, 9H), 1.26 (m, 4H), 1.86 (m, 2H), 3.02 - 3.68 (m, 4H), 3.72 (s, 3H), 4.02 (m, 1H), 4.16 (q, 2H), 4.58 (m, 1H), 7.86 (d, 1H), 8.82 (s, 1H), 14.8 (s, 1H, D20 exchangeable). Example 9 (+)-l-Cyclopropyl-6-fluoro-l,4-dihydro-8-methoxy-7-(4-benzyloxvcarbonvlamino-3,3-dimethyl-1 -piperidinyl)-4-oxo-quinoline-3-carboxylic acid It was prepared in a similar manner as described in Example 1, where 4-(±)-benzyloxy carbonylamino-3,3-dimethylpiperidine was used in place of 4-amino-3-methylpiperidine. Yield 47 %, m.p.l58-60°C, C29H32FN3O6, m/z 538 (M+l), PMR (CDC13): 1.0 (s, 6H), 1.26 (m, 4H), 1.84 (m, 2H), 3.04 - 3.7 (m, 4H), 3.76 (s, 3H), 4.06 (m, 1H), 4.72 (m, 1H), 5.18 (s, 1H), 7.4 (m, 5H), 7.86 (d, 1H), 8.84 (s, 1H), 14.8 (s, 1H, D20 exchangeable). Example-10 (±)-l-Cvclopropyl-6-fluoro-l,4-dihydro-8-methoxy-7-('4-amino-3,3-dimethyl-l-piperidinyl)- 4-oxo-quinoline-3-carboxylic acid 4-Benzyloxycarbonylamino-3,3-dimethyl piperidine (100 g, 0.381 mol) was suspended in 200 ml acetonitrile under stirring. To the solution was added (l-cyclopropyl-6, 7-difIuoro-8-methoxy-1, 4-dihydro-4-oxo-quinoline-3-carboxylate O3, O4) difluoroboron chelate (65 g, 0.189 mol) and stirring was started at temperature between 25-35°C. The reaction mixture was stirred for 4-5 hrs at this temperature. After the reaction was completed, the solvent was removed under vacuum to dryness to obtain a solid. To the solid was charged 200 ml ethyl alcohol followed by triethylamine (20 g, 0.198 mol). The reaction mixture was stirred at 109 reflux temperature for 2-3 hrs. The solution was left overnight at 25-35°C. The solid separated in the reaction mixture was filtered and washed with 50 ml ethanol. The filtered solid was stirred with reflux at 100-110 °C in concentrated hydrochloric acid (250 ml) for 2 hr. The resulting solution was taken to dryness by evaporating the acid under vacuum to obtain a residue. To the residue was added 1 L acetone and the suspension stirred for 1 hr. The resulting solid was filtered and washed with acetone. The residue was suspended in 600 ml chloroform and was refluxed for 30 minutes. The suspension was filtered and the residue washed with chloroform. The residue was suspended in methanol (600 ml) and was stirred at 30-35°C for 30 minutes. The suspension was filtered to obtain a solid, which was dissolved in 1 L water under stirring at 60- 70 °C. The pH of the solution was adjusted between 8.0-9.0 by adding 30% aqueous sodium hydroxide solution. The reaction mixture was extracted with 600 ml X 2 chloroform. The organic layers were combined and washed with water, dried over Na2S04 and evaporated under reduced pressure to afford a solid which was further triturated with methyl alcohol and filtered to give 43 g (56 %) titled compound, m/z (M+l) 404, mp 222-224 °C NMR (CDC13): 0.95-1.3 (m, 10H); 1.7-1.8 (m, 2H); 2.6 (t, 1H); 3.0 (dd, 1H); 3.3 (m,2H); 3.6 (m, 1H), (3.7 s,3H); 4.02 (m, 1H), 7.9 (d,lH); 8.8 (s, 1H). An alternate procedure to prepare this compound is by a method similar to that described in Example 1 where 4-arnino-3,3-dimethylpiperidine was used in place of 4-amino-3-methylpiperidine. A second alternate procedure to prepare this compound is by treating l-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-1 -carbethoxyamino-3,3-dimethyl-1 -piperidinyl)-4-oxo-quinoline-3-carboxylic acid [obtained from condensation of l-cyclopropyl-6,7-difluoro-l,4-dihydro-8-methoxy-4-oxo-quinoline-3-carboxylic acid difluoroborane chelate and 4-1-carbethoxyamino-3,3-dimethylpiperidine] (2.0 g, 4.0 mmol) under reflux with aqueous NaOH (0.6M, 100 ml) for 4 hr with stirring, filtered and the residue dried. The obtained crude product was adjusted to pH 3-5 by 3 N HC1, concentrated, triturated with acetone and crystallisation from methanol furnished the required product. Example-11 (±)-l-Cvclopropvl-6-fluoro-1.4-dihvdro-8-methoxv-7-(4-amino-3.3-dimethvl-l-piperidinvlV 4-oxo-quinoline-3-carboxvlic acid, hydrochloride The hydrochloride salt was obtained by modifying the procedure in Example 10 after obtaining the solid residue from filtration of the suspension in methanol before dissolving in water and adjusting the pH to 8.9 by adding 30% aqueous sodium hydroxide solution. The residue obtained from filtration of the suspension from methanol was dissolved in 2.0 ltr at reflux temperature. It was then filtered hot and concentrated to approximately one fourth of its volume and left overnight. The crystals obtained were filtered at 25-35°C and were dried in an oven at 70-80°C under pump vacuum to yield 38.0 g (48 %) titled compound, mp 256 -260°C, NMR (CD3OD): selected values 1.0-1.5 (m, 2H); 1.20 (d, 6H); 1.21-1.30 (m, 2H); 1.90-2.20 (m, 2H); 3.6-3.7 (m, 1H); 3.8 (s,3H); 4.20 (m, 1H), 7.8 (d,lH); 8.9 (s, 1H). Example 12 f±)-l-Cyclopropyl-6-fluoro-l,4-dihydro-8-methoxy-7-f4-amino-3,3-dimethyl-l-piperidinvl)- 4-oxo-quinoline-3-carboxylic acid methanesulfonate 6.50 Grams (16.13 mol) of l-cyclopropyl-6-fluoro-l,4-dihydro-8-methoxy-7-(4-amino-3,3-dimethyl-l-piperidinyl)-4-oxo-quinoline-3-carboxylic acid were suspended in 65 ml of isopropyl alcohol. The suspension was heated to 70- 80°C under stirring and then 1.90 g (19.79 mol) methanesulfonic acid was added. The reaction mixture was heated at reflux for 30 minutes. It was cooled to 30- 35°C and filtered. The solid was washed with 10 ml isopropyl alcohol and dried for 16 hrs in oven under vacuum at 50°C to give 6.80 g (84%) titled compound, mp286-290°C, NMR (CD3OD): selected values 1.0-1.5 (m, 2H); 1.20 (d, 6H); 1.9-2.2 (m, 2H); 2.7 (s, 3H); 3.2-3.7 (m, 4H); 3.8 (s,3H); 4.20 (m, 1H), 7.8 (d,lH); 8.9 (s, 1H). Example 13 (±)-l-Cvclopropvl-6-fluoro-l,4-dihvdro-8-methoxv-7-(4-amino-3.3-dimethvl-l-piperidinylV 4-oxo-quinoline-3-carboxvlic acid, gluconate To a suspension of 2.50 g (6.20 mol) l-cyclopropyl-6-fluoro-l,4-dihydro-8-methoxy-7-(4- amino-3,3-dimethyl-l-piperidinyl)-4-oxo-quinoline-3-carboxylic acid and 50 ml isopropyl 111 , ■ - - alcohol was added 2.4 ml (1.50 g, 7.64 mol) 50% aqueous D-gluconic acid at 80°C under stirring. The clear solution was stirred for 30 minute at this temperature, and cooled to 30-35°C to give a solid. The solid was filtered and washed with 10ml isopropyl alcohol. The obtained solid was crystallized from methanol to give 2.0 g (54%) of the gluconate salt, mp. 160-162 °C. Example 14 (+)- l-Cvclopropyl-6-fluoro-1.4-dihvdro-8-methoxy-7-(4-amino-3,3-dimethyl-l-piperidinyl)- 4-oxo-quinohne-3-carboxylic acid hydrochloride (+)-3,3-Dimethyl-4-t-butyloxycarbonylamino piperidine (46 g, 0.201mol) was suspended in 200 ml acetonitrile under stirring. To the solution was added (l-cyclopropyl-6,7-difluoro-8-methoxy-l,4-dihydro-4-oxo-quinoline-3-carboxylate O3, O4) difluoroboron chelate (35 g, 0.102 mol) and the reaction mixture was stirred for 24 hrs between 25-35 °C temperature. Triethylamine (10.3 g, 0.102 mol) was added to the reaction mixture and it was stirred at 80-85°C temperature for 4-5 hrs. After reaction was completed, solvent was removed under vacuum to dryness to obtain a residue. To the residue was charged 200 ml ethyl alcohol followed by triethylamine (12.32 g, 0.122 mol). The reaction mixture was stirred at reflux temperature for 5-6 hrs. The solution was left overnight at 25-35°C. The solid separated in the reaction mixture was filtered and washed with 50 ml ethanol. The solid was stirred with concentrated hydrochloric acid (100 ml) for 1 hr. The resulting solution was taken to dryness by evaporating the acid under vacuum to obtain a residue. To the residue was added 600 ml acetone and the suspension stirred for 1 hr. The resulting solid was filtered and washed with acetone. The solid was suspended in 300 ml chloroform and was refluxed for 30 minutes. The suspension was filtered and was washed with chloroform. The wet solid was suspended in methanol 100 ml and was stirred at 30-35°C for 30 minutes. The reaction mixture was filtered. The residue was dissolved in 1.3 L methanol at reflux temperature. It was filtered hot and concentrated to approximately one fourth of its volume and was left overnight. Crystals obtained were filtered at 25-35°C and were dried in an oven at 70-80°C under vacuum to yield 15 g (33.5%) titled compound., mp 256 -260°C, NMR(CD3OD): 0.95-1.3 (m, 10H); 1.90-2.20 (m, 2H); 3.15-3.4(m, 5H); 3.8 (s,3H); 4.20 (m, 1H), 7.8 (d,lH); 8.9 (s, 1H). [a]D25 value +132.0° (c=l, methanol). The enantiomeric purity was established by making N-'-butyloxycarbonylalanine derivative of(+)-1 -cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-amino-3,3-dimethyl-1 -piperidinyl) -4-oxo-quinoline-3-carboxylic acid. This derivative was analyzed on HPLC against N-1-butyloxycarbonylalanine derivative of racemic l-cyclopropyl-6-fluoro-l,4-dihydro-8-methoxy-7-(4-amino-3,3-dimethyl-l-piperidinyl)-4-oxo-quinoline-3-carboxylicacid. The ratio of enantiomers was found to be 98.49:1.50. Example -15 (-)-l-Cyclopropvl-6-fluoro-l,4-dihvdro-8-methoxv-7-(4-amino-3.3-dimethyl-l-piperidinvl)-4-oxo-quinoline-3-carboxylic acid hydrochloride The compound was prepared in 30% yield as per procedure described for its (+) isomer.[cc]D25 value -127.27° (c=l, methanol). Enantiomeric purity was established by making N-'-butyloxycarbonylalanine derivative of (-)-l-cyclopropyl-6-fluoro-l,4-dihydro-8-methoxy-7-(4-amino-3,3-dimethyl-l-piperidinyl)-4-oxo-quinoline-3-carboxylic acid. This derivative was analyzed on HPLC against N-1-butyloxycarbonylalanine derivative of racemic l-cyclopropyl-6-fluoro-l,4-dihydro-8-methoxy-7-(4-amino-3,3-dimethyl-l-piperidinyl)-4-oxo-quinoline-3-carboxylic acid. The ratio of enantiomers was found to be 96.37:3.62. Example -16 (+)- l-Cvclopropvl-6-fluoro-l,4-dihvdro-8-methoxy-7-(4-amino-3,3-dimethvl-l-piperidinvl')- 4-oxo-quinoline-3-carboxylic acid 8.50 Grams (19.34 mmol) of (+)- l-cyclopropyl-6-fluoro-l,4-dihydro-8-methoxy-7-(4-amino-3,3-dimethyl-l-piperidinyl)-4-oxo-quinoline-3-carboxylic acid hydrochloride were dissolved in 250 ml water under stirring. The solution pH was adjusted between 8.0-9.0 by adding 30% aqueous sodium hydroxide solution. The reaction mixture was extracted with 200 ml X 2 chloroform. Combined organic layer was washed with water, dried over Na2SC>4 and evaporated under reduced pressure to afford a solid which was further triturated with isopropyl alcohol and filtered to give 7.34 g (94%) above mentioned compound, mp 221-224°C. NMR (CDC13): 0.95-1.3 (m, 10H); 1.7-1.8 (m, 2H); 2.6 (t, 1H); 3.0 (dd, 1H); 3.3 (m,2H); 3.6 (m, 1H), (3.7 s,3H); 4.02 (m, 1H), 7.9 (d,lH); 8.8 (s, 1H). [oc]D25 value +133.84° (c=l, chloroform). 113 Example -17 (-)- l-Cvclopropvl-6-fluoro-L4-dihvdro-8-methoxv~7-(4-amino-3.3-dimethvl-l-piperidinvD-4-oxo-quinoline-3-carboxvlic acid Similarly, by using the procedure mentioned above, 8.40 g (19.11 mmol) of (-)- 1-cyclopropyl-6-fluoro-l,4-dihydro-8-methoxy-7-(4-amino-3,3-dimethyl-l-piperidinyl)-4-oxo-quinoline-3-carboxylic acid hydrochloride was converted to 6.65 g (86%) titled compound, mp 222-225°C, [cc]D25 value -125.06° (c=l, chloroform). Example -18 (+)-l-Cvclopropvl-6-fluoro-l,4-dihydro-8-methoxy-7-(4-amino-3.3-dimethyl-l-piperidinyl)-4-oxo-quinoline-3-carboxvlic acid, methanesulfonate 6.50 Grams (16.13 mmol) of (+)-l-cyclopropyl-6-fluoro-l,4-dihydro-8-methoxy-7-(4-amino-3,3-dimethyl-l-piperidinyl)-4-oxo-quinoline-3-carboxylic acid were suspended in 65 ml of isopropyl alcohol. The suspension was heated to 70- 80°C under stirring and then 1.90 g ( 19.79 mmol) methanesulfonic acid was added. The reaction mixture became clear for a moment and a solid was separated. The suspension was heated at reflux for 30 minutes. It was cooled to 30- 35°C and filtered. The solid was washed with 10 ml isopropyl alcohol and dried for 16 hrs in oven under vacuum at 50°C to give 6.80 g (84%) titled compound, mp 286 -290°C, NMR (CD3OD): 0.95-1.25 (m, 10H); 1.95-2.20 (m, 2H); 2.7 (s, 3H); 3.2-3.4 (m, 4H); 3.6-3.7 (m, 1H); 3.8 (s, 3H); 4.20 (m, 1H), 7.8 (d,lH); 8.9 (s, 1H). [cc]D25 value +113.97° (c=l, methanol). Example -19 (-)-l-Cvclopropvl-6-fluoro-1.4-dihydro-8-methoxv-7-f4-arnino-3.3-dimethyl-l-piperidinyl)- 4-oxo-quinoline-3-carboxylic acid methanesulfonate Similarly, by using the procedure mentioned above, 6.30 g (15.63 mmol) of (-)- 1-cyclopropyl-6-fluoro-l,4-dihydro-8-methoxy-7-(4-amino-3,3-dimethyl-l-piperidinyl)-4-oxo- quinoline-3-carboxylic acid was converted to 5.60 g (72%) titled compound, mp 288-290°C [ocfo25 value -112.41° (c=l, methanol). Example 20 (+)-l-Cyclopropvl-6-fluoro-l,4-dihydro-8-methoxy-7-(4-amino-3,3-dimethyl-l-piperidinvl)- 4-oxo-quinoline-3-carboxvlic acid gluconate To a suspension of 2.50 g (6.20 mmol) (+>l-cyclopropyl-6-fluoro-l,4-dihydro-8-methoxy-7-(4-amino-3,3-dimethyl-l-piperidinyl)-4-oxo-quinoline-3-carboxylic acid and 50 ml isopropyl alcohol was added 2.4 ml (1.50 g, 7.64 mmol) 50% aqueous D-gluconic acid at 80°C under stirring. The clear solution was stirred for 30 minute at this temperature, cooled to 30-35°C to give a solid. The solid was filtered and washed with 10 ml isopropyl alcohol, he obtained solid was crystallized from methanol to give 2.0 g (54%) gluconate salt of (+)-l-cyclopropyl-6-fluoro-l,4-dihydro-8-methoxy-7-(4-amino-3,3-dimethyl-l-piperidinyl)-4-oxo-quinoline-3-carboxylic acid, mp 158-60°C Example - 21 (-)-l-Cyclopropyl-6-fluoro-l,4-dihvdro-8-methoxv-7-(4-amino-3,3-dimethyl-l-piperidinvl)- 4-oxo-quinoline-3-carboxvlic acid gluconate Similarly, by using the procedure mentioned above, 2.20 g (54.60 mmol) of (-)- 1-cyclopropyl-6-fluoro-l,4-dihydro-8-methoxy-7-(4-amino-3,3-dimethyl-l-piperidinyl)-4-oxo-quinoline-3-carboxylic acid was converted to 1.65 g (50%) titled compound, mp 154-156°C. Example 22 l-Cvclopropvl-6-fluoro-l,4-dihvdro-8-methoxy-7-(4-acetvlamino-3,3-dimethyl-l- piperidinyl)-4-oxo-quinoline-3-carboxvlic acid It was prepared in a similar manner as described in Example 1, where 4-acylamino-3,3- dimethylpiperidine was used in place of 4-amino-3-methylpiperidine. Yield 20%, m.p.194- 96°C, C23H28FN305, m/z 446 (M+l). Example 23 1 -Cyclopropyl-6-fluoro-1,4-dihvdro-8-methoxy-7-(4-t-butvloxvcarbonvlamino-3,3-dimethyl- l-piperidinyl)l-4-oxo-quinoline-3-carboxvlic acid Di-t-butoxycarbonate (0.32 g, 1.1 mmol) was added to a stirred solution of l-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-amino-3,3-dimethyl-1-piped dinyl)} -4-oxo-quinoline-3-carboxylic acid (0.3 g, 7.4 mmol) in dioxane (10 ml) and water (5 ml) at ambient temperature and stirring was continued for 14 hr and concentrated to dryness. The obtained solid was dissolved in ethyl acetate, washed with water, dried (Na2S04) and concentrated to give titled product. Yield 72 %, m.p.218-20°C, C26H34FN3O6 m/z 504 (M+l). 115 ZI MAR ZOW Example 24 l-Cvclopropvl-6-fluoro-h4-dihvdrn-8-methoxv-7-r4-methvlamino-3.3-dimethvl-l-piperidinvl)}-4-oxo-quinoline-3-carboxvlic acid It was prepared in a similar manner as described in Example 1, where 4-methylamino-3,3-dimethylpiperidine'was used in place of 4-amino-3-methylpiperidine Yield 50 %, m.p.246-48°C, C22H28FN304, m/z 418 (M+1). Example 25 l-Cvclopropvl-6-fluoro-l,4-dihvdro-8-methoxv-7-(4-ethvlamino-3,3-dimethvl-l- piperidinvl)}-4-oxo-quinoline-3-carboxylic acid It was prepared in a similar manner as described in Example 1, where 4-ethylamino-3,3- dimethylpiperidine was used in place of 4-amino-3-methylpiperidine Yield 60 %, m.p.230- 32°C, C23H30FN3O4, m/z 432 (M+1). Example 26 l-Cvclopropvl-6-fluoro-l,4-dihvdro-8-methoxv-7-(4-cyclopropylamino-3,3-dimethyl-l-piperidinyl) |-4-oxo-quinoline-3-carboxylic acid It was prepared in a similar manner as described in Example 1, where 4-cyclopropyl amino-3,3-dimethylpiperidine was used in place of 4-amino-3-methylpiperidine Yield 31 %, m.p.l90-92°C, C21H26FN3O4, , m/z 444 (M+1), PMR (CDCI3): 1.22 (6H, s), 0.8-1.48 (8H, m), 1.8.8 (2H, m), 2.28-3.7 (6H, m), 3.72 (s, 3H), 4.06 (m, IH), 7.74 (d, IH), 8.74 (s, IH), 14.7 (bs, IH, D20 exchangeable). Example 27 1 -Cyclopropvl-6-fluoro-1,4-dihydro-8-methoxv-7-(4-dimethylamino-3.3-dimethvl-1 -piperidinyl)-4-oxo-quinoline-3-carboxylic acid It was prepared in a similar manner as described in Example 1, where 4-dimethyl amino-3,3-dimethylpiperidine was used in place of 4-amino-3-methylpiperidine Yield 35 %, m.p.210°C, C23H30FN3O4, m/z 432 (M+1), PMR (CDC13): 1.02 (d, 6H), 0.92-1.4 (m, 4H), 1.8 (m, 2H), 2.32 (s, 6H) 2.28-3.65 (m, 5H), 3.68 (s, 3H), 4.01 (m, IH, m), 7.68 (d, IH), 8.86 (s, IH), 14.9 (bs, IH, D20 exchangeable). Example 28 l-Cyclopropyl-6-fluoro-L4-dihvdro-8-methoxy-7-f4-amino-3-ethyl-3-methyl-l-piperidinyl)- 4-oxo-quinoline-3-carboxylic acid 116 It was prepared in a similar manner as described in Example 1, where 4-amino-3-ethyl-3-methylpiperidine was used in place of 4-amino-3-methylpiperidine. m.p. 152-54 °C, C22H28FN304, m/z 418 (M+l). Example 29 l-Cvclopropvl-6-fluoro-L4-dihvdro-8-methoxv-7-(4-methyIamino-3-ethvl-3-methvl-l- piperidinyl) i-4-oxo-quinoline-3-carboxylic acid It was prepared in a similar manner as described in Example 1, where 4-methylamino-3- ethyl-3-methylpiperidine was used in place of 4-amino-3-methylpiperidine m.p. 182-84 °C, C23H3oFN304, m/z 432 (M+l). Example 30 l-CycIopropYl-6-fluoro-l,4-dihvdro-8-methoxy-7-(4-cvclopropylamino-3-ethyl-3-methvl-l- piperidinyl)}-4-oxo-quinorine-3-carboxylicacid It was prepared in a similar manner as described in Example 1, where 4-cyclopropyl amino- 3-ethyl-3-methylpiperidine was used in place of 4-amino-3-methylpiperidine m.p. 210-12°C, C25H32FN3O4, m/z 458 (M+l). Example 31 l-cvclopropyl-6-fluoro-l,4-dihvdro-8-methoxv-7-(4-dimethylamino-3-ethyl-3-methyl-l- piperidinyl')-4-oxo-quinoline-3-carboxylic acid It was prepared in a similar manner as described in Example 1, where 4-dimethyl amino-3- ethyl-3-methylpiperidine was used in place of 4-amino-3-methylpiperidine, m.p.210-12 °C, C24H32FN3O4, m/z 446 (M+l). Example 32 Mixtures A+B of l-cyclopropyl-6-fluoro-l,4-dihvdro-8-methoxy-7-(4-amino-3,5-dimethvl-l- piperidinvl)-4-oxo-quinoline-3-carboxylic acid It was prepared in a similar manner as described in Example 1, where 4-amino-3,5-dimethylpiperidine was used in place of 4-amino-3-methylpiperidine, m.p.l78-80°C, C21H26FN3O4, m/z 404 (M+l). Example 33 Mixture A of isomers of l-cvclopropvl-6-fluoro-l,4-dihydro-8-methoxy-7-(4-amino-3,5- dimethyl-1 -piperidinyl)-4-oxo-quinoline-3-carboxylic acid It was prepared in a similar manner as described in Example 1, where Mixture A of isomers of 4-amino-3,5-dirnethylpiperidine was used in place of 4-amino-3-methylpiperidine, m.p. 238-40°CC21H26FN3O4, 4 m/z 404 (M+l). 117 ' Example 34 Mixture B of isomers of l-cvclopropvl-6-fluoro-1.4-dihydro-8-methoxv-7-(4-amino-3,5- dimethyl-1 -piperidinvl)-4-oxo-quinoline-3-carboxylic acid It was prepared in a similar manner as described in Example 1, where Mixture B of isomers of 4-arnino-3,5-dimethylpiperidine was used in place of 4-amino-3-methylpiperidine, m.p. 200-04°C, C21H26FN3O4, m/z 404 (M+l). Example 35 Mixtures A+B of lcvclopropvl-6-fluoro-l,4-dihvdro-8-methoxv-7-|4-methylamino-3,5- dimethyl-l-piperidinyl)}-4-oxo-quinoline-3-carboxvlic acid It was prepared in a similar manner as described in Example 1, where 4-methylamino-3,5- dimethylpiperidine was used in place of 4-amino-3-methylpiperidine, m.p. 268-72°C, C22H28FN304, m/z 418 (M+l). Example 36 Mixture A of isomers of l-cvclopropyl-6-fluoro-l,4-dihvdro-8-methoxy-7-(4-methylamino- 3,5-dimethvl-l-piperidinyl)-4-oxo-quinoline-3-carboxylic acid It was prepared in a similar manner as described in Example 1, where Mixture A of isomers of 4-methylamino-3,5-dimethylpiperidine was used in place of 4-amino-3-methylpiperidine, C22H28FN3O4, m/z 418 (M+l). Example 37 Mixture B of isomers of l-cvclopropvl-6-fluoro-l,4-dihvdro-8-methoxv-7-(4-methylamino- 3.5-dimethyl-l-piperidinyl)-4-oxo-quinoline-3-carboxvlic acid It was prepared in a similar manner as described in Example 1, where Mixture A of isomers of 4-methylamino-3,5-dimethylpiperidine was used in place of 4-amino-3-methylpiperidine, C22H28FN3O4, m/z 418 (M+l). Example 38 Mixture A of isomers of l-cvclopropyl-6-fluoro-l,4-dihydro-8-methoxv-7-(4-ethylamino- 3,5-dimethyl-l-piperidinyl') -4-oxo-quinoline-3-carboxylic acid It was prepared in a similar manner as described in Example 1, where Mixture A of isomers of 4-methylamino-3,5-dimethylpiperidine was used in place of 4-amino-3-methylpiperidine, m.p. 250-52°C, C23H3oFN304, m/z 432 (M+l). Example 39 Mixture B of isomers of l-eyclopropyl-6-fluoro-l,4-dihvdro-8-methoxy-7-(4-ethylamino-3,5- dimethyl-l-piperidinylM-oxo-quinoline-S-carboxylic acid 118 2 2 MAR 21 It was prepared in a similar manner as described in Example 1, where Mixture B of isomers of 4-methylamino-3,5-dimethylpiperidine was used in place of 4-amino-3-methylpiperidine, m.p. 250-55°C, C23H30FN3O4, m/z 432 (M+l). Example 40 Mixture A of isomers of l-cvclopropvl-6-fluoro-l,4-dihvdro-8-methoxy-7-(4- cvclopropvlamino-3,5-dimethvl-l-piperidinyl)-4-oxo-quinoline-3-carboxylicacid It was prepared in a similar manner as described in Example 1, where Mixture A of isomers of 4-cyclopropyl amino-3,5-dimethylpiperidine was used in place of 4-amino-3-methyl- piperidineC23H30FN3O4, m/z 444 (M+l) Example 41 Mixture B of isomers of l-cvclopropvl-6-fluoro-L4-dihydro-8-methoxv-7-(4- cyclopropylamino-3,5-dimethyl-l-piperidinylV4-oxo-quinoline-3-carboxvlic acid It was prepared in a similar manner as described in Example 1, where Mixture B of isomers of 4-cyclopropyl amino-3,5-dimethylpiperidine was used in place of 4-amino-3-methyl- piperidine, m.p. 240-42°C, C23H30FN3O4, m/z 444 (M+1) Example 42 l-Cyclopropvl-6-fluoro-l14-dihvdro-8-methoxy-7-(4-amino-3,3,5-trimethyl-l-piperidinvl)-4- oxo-quinoline-3-carboxylic acid It was prepared in a similar manner as described in Example 1, where 4-amino-3,3,5-trimethylpiperidine was used in place of 4-amino-3-methylpiperidine, m.p. 218-20°C, C23H30FN3O4, m/z 418 (M+l). Example 43 5-Amino-l-cyclopropyl-6-fluoro-l,4-dihvdro-8-methoxv-7-(4-methvlamino-33-dimethyl-l- piperidinvl)-4-oxo-quinoline-3-carboxylic acid A suspension of 5-amino-l-cyclopropyl-6,7-difluoro-l,4-dihydro-8-methoxy-4-oxo-quinoline-3-carboxylic acid (0.17 g, 0.55 mmol), 3,3-dimethyl-4-methylamino piperidine (0.15 g, 1.06 mmol) and triethylamine (lg, 10 mmol) in a mixture of dimethylsulfoxide (10 ml) and acetonitrile (10 ml) was heated at 70°C for 18 hr. Acetonitrile was distilled off, filtered to remove suspended impurities, diluted with water (5 ml). The precipitate thus separated was filtered, washed with water, dried and purified by silicagel column chromatography. Elute from a mixture of ethyl acetate and methanol furnished the required product. Yield 0.12 g (50 %), m.p.250°C (decomp.), C22H29FN404, m/z 433 (M+l), PMR 119 (DMSO-de): 0.9 (m, 2H), 1.0 (m, 2H), 1.0 (s, 3H), 1.1 (s, 3H), 1.8 - 2.0 (m, 2H), 2.6 (s, 3H), 2.8 - 3.2 (m, 4H), 3.5 (s, 3H), 3.6 (s, 3H), 3.65 (m, IH), 4.0 (m, IH), 7.2 (bs, 2H, D20 exchangeable), 8.6 (s, IH). Example 44 5-Amino-l-cvclopropvl-6-fluoro-1.4-dihydro-8-methoxv-7-(4-amino-3-methvl-l-piperidinyl)-4-oxo-quinoline-3-carboxylic acid It was prepared in a similar manner as described in Example 43, where 4-amino-3-methylpiperidine was used in place of 3,3-dimethyl-4-methylaminopiperidine. Yield 40 %, m.p.260-62°C, C22H29FN4O4,, m/z 405 (M+1), PMR (CD3OD): 0.8-1.18 (m, 7H), 1.8 - 2.2 (m, 3H), 2.82 - 3.54 (m, 5H), 3.6 (s, 3H), 4.01 (m, IH), 8.62 (s, IH). Example 45 5-Amino-1 -cvclopropvl-6-fluoro-1.4-dihydro-8-methoxy-7-(4-methylamino-3-methvl-1 - piperidinyl)-4-oxo-quinoline-3-carboxylic acid It was prepared in a similar manner as described in Example 43, where 4-methylamino-3- methylpiperidine was used in place of 3,3-dimethyl-4-methylamino piperidine. Yield 30 %, m.p.228-30°C (decomp.), C21H27FN4O4, m/z 419 (M+1). Example 46 5-Amino-l-cyclopropyl-6-fluoro-1.4-dihydro-8-methoxv-7-(4-ethvlamino-3-methyl-l- piperidinvP-4-oxo-quinoline-3-carboxvlic acid It was prepared in a similar manner as described in Example 43, where 4-ethyl amino-3- methylpiperidine was used in place of 3,3-dimethyl-4-methylamino piperidine. Yield 35 %, m.p.230-32°C, C22H29FN4O4, m/z 433 (M+1). Example 47 5-Amino- l-cyclopropvl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-cyclopropylamino-3-methyl-1 - piperidinyl)-4-oxo-quinoline-3-carboxylic acid It was prepared in a similar manner as described in Example 43, where 4-cyclo propylamino-3-methylpiperidine was used in place of 3,3-dimethyl-4-methyl aminopiperidine. Yield 35 %, m.p.218-20°C, C22H29FN4O4,, m/z 445 (M+1). 120 Example 48 5-Amino-l-cvclopropvl-6-fluoro-L4-dihydro-8-methoxv-7-(4-dimethylamino-3-methyl-l-piperidinyl)-4-oxo-quinoline-3-carboxylicacid It was prepared in a similar manner as described in Example 43, where 4-dimethylamino-3-methylpiperidine was used in place of 3,3-dimethyl-4-methylamino piperidine. Yield 30 %, m.p.210°C, C22H29FN4O4, m/z 433 (M+1), PMR (CD3OD): 0.81-1.22 (m, 7H), 1.8-2.25 (m, 3H), 2.92 (s, 6H), 2.61-3.52 (m, 5H), 3.61 (s, 3H), 4.04 (m, 1H), 8.62 (s, 1H). Example 49 5-Amino-l-cvclopropvl-6-fluoro-1.4-dihydro-8-methoxy-7-('4-amino-3,3-dimethvl-l-piperidinvl)-4-oxo-quinoline-3 -carboxylic acid It was prepared in a similar manner as described in Example 44, where 4-amino-3,3-dimethylpiperidine was used in place of 3,3-dimethyl-4-methylaminopiperidine, m.p.205°C, C21H27FN4O4, m/z 419 (M+1), PMR (DMSO-dg): 0.8 (m, 2H), 1.0 (m, 2H), 1.0 (s, 3H), 1.1 (s, 3H), 1.4 - 1.6 (m, 2H), 2.6 - 2.8 (m, 4H), 3.6 (s, 3H), 3.65 (m, 1H), 4.0 (m, 1H), 6.2 (bs, 2H, D20 exchangeable), 7.2 (bs, 2H, D20 exchangeable), 8.6 (s, 1H). Example 50 5-Amino-l-cvclopropyl-6-fluoro-l,4-dihvdro-8-methoxv-7-(4-ethylamino-3,3-dimethvl-l-piperidinvl)}-4-oxo-quinolme-3-carboxylic acid It was prepared in a similar manner as described in Example 43, where 4-ethylamino-3,3-dimethylpiperidine was used in place of 3,3-dimethyl-4-methyl-aminopiperidine, m.p.205°C (decomp.), C23H31FN4O4, m/z 447 (M+1), PMR (CDC13): 0.8 (m, 2H), 1.0 (m, 2H), 1.05 (s, 3H), 1.1 (s, 3H), 1.2 (t, 3H), 1.6 - 2.0 (m, 2H), 2.4 - 2.8 (m, 6H), 3.5 (s, 3H), 3.6 (m, 1H), 3.9 (m, 1H), 6.4 (bs, 2H, D20 exchangeable), 8.4 (bs, 1H, D20 exchangeable), 8.8 (s, 1H). Example 51 5-Amino-l-cvclopropvl-6-fluoro-1.4-dihvdro-8-methoxv-7-(4-dimethylamino-3,3-dimethyl- 1 -piperidinvlV4-oxo-quinoline-3-carboxylic acid It was prepared in a similar manner as described in Example 43, where 4-dimethylamino-3,3-dimethylpiperidine was used in place of 3,3-dimethyl-4-methyl-aminopiperidine, m.p.l78°C (decomp.), C22H29FN4O4,, m/z 447 (M+1). 121 Example 52 Mixture A of isomers of 5-amino-l-cvclopropvl-6-fluoro-1.4-dihvdro-8-methoxv-7-(4- amino-3,5-dimethyl-l-piperidinylV4-oxo-quinoline-3-carboxvlic acid It was prepared in a similar manner as described in Example 43, where Mixture A of isomers of 4-amino-3,5-dimethylpiperidine was used in place of 3,3-dimethyl-4-methylamino piperidine, m.p.238-40°C, G21H27FN4O4, m/z 419 (M+l), Example 53 Mixture B of isomers of 5-Amino-l-cyclopropvl-6-iluoro-l,4-dihydro-8-methoxv-7-(4- amino-3,5-dimethyl-l-piperidinvl)-4-oxo-quinoline-3-carboxylic acid It was prepared in a similar manner as described in Example 43, where Mixture B of isomers of 4-amino-3,5-dimethylpiperidine was used in place of 3,3-dimethyl-4-methylamino- piperidine, m.p. 248-50°C (decomp.), C21H27FN4O4, m/z 419 (M+l), . Example 54 5-Amino-l-cyclopropvl-6-fluoro-l,4-dihvdro-8-methoxv-7-C4-methvlamino-3,5-dimethyl-l- piperidinylV4-oxo-quinoline-3-carboxvlic acid It was prepared in a similar manner as described in Example 43, where 4-methylamino-3,5-dimethylpiperidine was used in place of 3,3-dimethyl-4-methylaminopiperidine, m.p. 224-26°C, C22H29FN4O4, m/z 433 (M+l). Example 55 Mixture A of isomers of 5-amino-l-cyclopropvl-6-fluoro-l,4-dihvdro-8-methoxy-7-(4- methylamino-3,5-dimethyl-1 -piperidinviy4-oxo-quinoline-3-carboxylic acid It was prepared in a similar manner as described in Example 43, where Mixture A of isomers of 4-methylamino-3,5-dimethylpiperidine was used in place of 3,3-dimethyl-4- methylaminopiperidine, C22H29FN4O4, m/z 433 (M+l). Example 56 Mixture B of isomers of 5-amino-l-cyclopropvl-6-fluoro-l,4-dihydro-8-methoxv-7-(4- methvlamino-3,5-dimethyl-l-piperidinvl)-4-oxo-quinoline-3-carboxylic acid 122 It was prepared in a similar manner as described in Example 43, where Mixture B of isomers of 4-methylamino-3,5-dimethylpiperidine was used in place of 3,3-dimethyl-4-methyl-aminopiperidine,C22H29FN4O4,, m/z 433 (M+l). Example 57 Mixture A of isomers of 5-amino-l-cvclopropyl-6-fluoro-l,4-dihvdro-8-methoxy-7-(4- ethvlamino-3,5-dimethyl-l-piperidinvl)-4-oxO'quinoline-3-carboxylic acid It was prepared in a similar manner as described in Example 43, where Mixture A of isomers of 4-ethylamino-3,5-dimethylpiperidine was used in place of 3,3-dimethyl-4-methyl- r aminopiperidine. Yield 52%'m.p. 202-4 °C, C22H29FN4O4,, m/z 447 (M+l). Example 58 Mixture B of isomers of 5-amino-l-cvclopropvl-6-fluoro-l,4-dihydro-8-methoxv-7-(4- ethylamino-3,5-dimethyl-l-piperidinyl)-4-oxo-quinoline-3-carboxylic acid It was prepared in a similar manner as described in Example 43, where Mixture B of isomers of 4-ethylamino-3,5-dimethylpiperidine was used in place of 3,3-dimethyl-4-methyl- aminopiperidine. Yield 80 %, m.p. 255-58°C, C22H29FN4O4,, m/z 447 (M+l). Example 59 Mixture A of isomers of 5-amino-l-cyclopropyl-6-fluoro-l,4-dihvdro-8-methoxv-7-(4- cyclopropylamino-3,5-dimethyl-l-piperidinyl)-4-oxo-quinoline-3-carboxylicacid It was prepared in a similar manner as described in Example 43, where Mixture A of isomers of 4-cyclopropylamino-3,5-dimethylpiperidine was used in place of 3,3-dimethyl-4- methylaminopiperidine, C24H31FN4O4, m/z 459 (M+l) Example 60 Mixture B of isomers of 5-Amino-l-cyclopropyl-6-fluoro-l14-dihydro-8-methoxv-7-(4-cyclopropylamino-3,5-dimethyl-l-piperidinyl)-4-oxo-quinoline-3-carboxylic acid It was prepared in a similar manner as described in Example 43, where Mixture B of isomers of 4-cyclopropylamino-3,5-dimethylpiperidine was used in place of 3,3-dimethyl-4-methylaminopiperidine, m.p. 248°C, C22H29FN4O4,, m/z 459 (M+l) m 11 H*R 7006 123 Example 61 5-Amino-l-cvclopropvl6-fluoro-1-4-dihydro8-methoxv-7-4--amino-3-ethyl-3-methyl-l- piperidinvl)-4-oxo-quinoline-3-carboxyric acid It was prepared in a similar manner as described in Example 43, where 4-amino-3-ethyl-3- methylpiperidine was used in place of 3,3-dimethyl-4-methylaminopiperidine, m.p. 210 °C (decompose), C22H29FN4O4, m/z 433 (M+l). Example 62 . 5-Amino-l-cvclopropyl-6-fluoro-l,4-dihydro-8-methoxy-7-(4-methvlamino-3-ethvl-3- methyl-1-piperidinyl) }-4-oxo-quinorine-3-carboxyhc acid It was prepared in a similar manner as described in Example 43, where 4-methylamino-3- ethyl-3-methylpiperidine was used in place of 3,3-dimethyl-4-methylaminopiperidine, m.p. 164-66 °C, C23H31FN4O4, m/z 447 (M+l). Example 63 5-Amino-1 -cyclopropyl-6-fluoro-1,4-dihvdro-8-methoxv-7-(4-cyclopropvlamino-3-ethyl-3- methvl-l-piperidinyl)}-4-oxo-quinoline-3-carboxylic acid It was prepared in a similar manner as described in Example 43, where 4-cyclopropyl amino- 3-ethyl-3-methylpiperidine was used in place of 3,3-dimethyl-4-methylaminopiperidine, m.p. 186-88 °C, C25H33FN4O4, m/z 473 (M+l). Example 64 5-Amino-l-cyclopropyl-6-fluoro-l,4-dihvdro-8-methoxy-7-(4-dimethvlamino-3-ethyl-3- methyl-l-piperidinyl)-4-oxo-quinoline-3-carboxylic acid It was prepared in a similar manner as described in Example 43, where 4-dimethyl amino-3- ethyl-3-methylpiperidine was used in place of 3,3-dimethyl-4-methylaminopiperidine, m.p. 194-96 °C, C22H29FN4O4,, m/z 461 (M+l). Example 65 5 -Amino-1 -c ycloprop vl-6-fluoro-1,4-dihydro- 8 -methox v-7 -(4-amino-3.3,5 -Trimethyl-1 - piperidinv0-4-oxo-quinoline-3-carboxvlic acid It was prepared in a similar manner as described in Example 43, where 4-amino-3,3,5- trimethylpiperidine was used in place of 3,3-dimethyl-4-methylaminopiperidine, m.p. 248-52 °C, C22H29FN4O4, m/z 433 (M+l). Example - 66 trans-1 -Cyclopropyl-6-fluoro-1,4-dihydro-8-methyl -7-(4-amino-3-methyl-1 -piperidinyl) -4- oxo-quinoline-3-carboxylic acid. 124 A mixture of [l-cyclopropyl-6,7-difluoro-8-methyl -l,4-dihydro-4-oxo-quinoline-3-carboxylate-03,04] difluoroboron (0.5 g,1.52 mmol), and /trans -4-arnino-3-methylpiperidine (0.86 g, 7.64 mmol) in 10 ml acetonitrile was heated to reflux for 8 hr. The reaction mixture was concentrated to dryness. The obtained residue was treated withlO ml ethanol and triethylamine (0.154 ml, 1.52 mmol) and refluxed for 3 hr. Solvent was evaporated to dryness under reduced pressure and the residue was purified on preparative HPLC to give titled product, m. p. 223-225°C C2oH24FN303, m/z 374 (M+l), PMR (CD30D): 0.85 (m, 2H), 1.05 (d, 3H), 1.2 (m, 2H), 1.7-2.l(m, 3H), 2.8 (s, 3H), 2.9-3.l(m, 3H), 3.3-3.4(m,2H), 4.25 (m, lH),7.8(d,lH), 8.9(s,lH). Example - 67 cis- l-Cyclopropyl-6-fluoro-1,4-dihydro-8-methvl-7-(4-amino-3-methvl-1 -piperidinvl)-4-oxo- Quinoline-3-carboxvlic acid. The compound was prepared by a procedure as described in Example 66, by using cis-4-amino-3-methylpiperidine, m. p. 224-228 °C, C20H24FN3O3, m/z 374 (M+l), PMR (CD30D): 0.8-1.0 (m, 2H), 1.15 (d,3H), 1.15-1.25(m, 2H),1.8-2.3(m, 3H), 2.8 (s, 3H),3.1-3.4(m, 3H), 3.4-3.6(m,2H), 4.25 (m, lH),7.8(d,lH), 8.9(s,lH). Example - 68 (±)-l-Cyclopropvl-6-fluoro-l,4-dihydro-8-methvl-7-(,4-amino-3.3-dimethyl-l-piperidinyl)-4- oxo-quinoline-3-carboxvlic acid. The compound was prepared by a procedure as described in Example 66, by using (±)-4-amino-3,3-dimethylpiperidine, m. p. 198 - 200 °C C22H28FN3O3, m/z 388 (M+l), PMR (CD30D): 0.8-1.1 (m, 2H), 1.10 (d, 6H), 1.1-1.4 (m, 2H),1.9-2.2 (m, 2H), 2.8 (s, 3H), 2.9-3.1(m, 1H), 3.2-3.4 (m,3H), 4.3 (m, 1H),7.8 (d,lH), 8.9 (s,lH). Example - 69 (-)-l-Cyclopropvl-6-fluoro-l,4-dihvdro-8-methvl-7-(4-amino-3,3-dimethyl-l-piperidinylV4- oxo-quinoline-3-carboxvlic acid. The compound was prepared by a procedure as described in Example 66, by using (-)-4-amino-3,3-dimethylpiperidine, m. p. 195-198 °CC22H28FN3O3, m/z 388 (M+l). 125 Example - 70 (+)-l-Cvclopropvl-6-fluoro-l,4-dihvdro-8-methvl-7-(4-amino-3.3-dimethvl-l-piperidinvl)4- oxo-quinoline-3-carboxylic acid. The compound was prepared by a procedure as described in Example 66, by using (+)-4-amino-3,3-dimethylpiperidine, m. p. 195-198 °C, C21H26FN3O3, m/z 388 (M+1). Example - 71 1 -Cvclopropyl-6-fluoro-1,4-dihydro 8-methvl -7-(4-methvlamino-3-methvl-1 -piperidinvl)-4- oxo-quinoline-3-carboxvlic acid. The compound was prepared by a procedure as described in Example 66, by using 4-methylamino-3-methylpiperidine, m. p 233-235 °C, C21H26FN3O3, m/z 388 (M+1), PMR (CD30D): 0.8-1.4 (m, 7H), 1.9-2.4 (m, 3H), 2.8 (s, 3H), 2.9 (s, 3H), 3.2-3.7 (m, 5H), 4.3 (m, lH),7.9(d,lH),8.9(s,lH). Example - 72 1 -Cyclopropvl-6-fluoro-1,4-dihydro -8-methvl -7-(4-dimethylarnino-3-methyl-1 -piperidinyl)- 4-oxo-quinoline-3-carboxylic acid. The compound was prepared by a procedure as described in Example 66, by using 4-dimethylamino-3-methylpiperidine, m. p. 221 °C, C22H28FN3O3, m/z 402 (M+1), PMR (CD30D): 0.8-1.4 (m, 7H), 2.0-2.2 (m, 2H),2.5 (m, 2H), 2.8 (s, 3H), 3.0 (s, 6H), 3.2-3.7 (m,4H), 4.4 (m, 1H),7.8 (d,lH), 8.95 (s,lH). Example - 73 ' l-Cyclopropyl-6-fluoro-l,4-dihvdro-8-methyl -7-(4-ethylamino-3,3-dimethyl-l-piperidinvl)- 4-oxo-quinoline-3-carboxylic acid. The compound was prepared by a procedure as described in Example 66, by using 4-ethylamino-3,3-dimethylpiperidine, m. p. 201-203 °C, C22H28FN3O3, , m/z 416 (M+1), PMR (CD30D): 0.8-1.1 (m, 2H), 1.2-1.5 (m, HH),2.0-2.2 (m, 2H), 2.8 (s, 3H), 2.9-3.5 (m, 7H), 4.3 (m, 1H),7.9 (d,lH), 9.0 (s,lH). Example - 74 1 -CyclopropyI-6-fluoro-1,4-dihvdro -8-methvl -7-(4-dimethvlamino-3,3-dimethyl-1 - piperidinvl)-4-oxo-quinoline-3-carboxylic acid. The compound was prepared by a procedure as described in Example 66, by using 4- dimethylamino-3,3-dimethylpiperidine, m. p. 209-210 °C, C22H28FN3O3, , m/z 416 (M+1), 126 22 MAR 288 PMR (CD30D): 0.8-1.0 (m, 2H), 1.05-1.40 (m, 8H),2.0-2.2 (m, 2H), 2.8-3.1 (m, 10H), 3.2-3.6 (m, 3H), 4.3 (m,lH), 7.9 (d,lH), 9.0 (s,lH). Example - 75 ^an5-l-Cvclopropyl-6-fluoro-l,4-dihvdro-8-ethvl-7-(4-amino-3-methyl-l-piperidinvn-4- oxo-quinoline-3-carboxylic acid. A mixture of [l-cyclopropyl-6,7-difluoro-8-ethyl -l,4-dihydro-4-oxo-quinoline-3-carboxylate-03,04] difluoroboron (0.5 g,1.49 mmol), and trarcs-4-amino-3-methylpiperidine (0.86 g, 7.64 mmol) in 10 ml acetonitrile was heated to reflux for 8 hr. The reaction mixture was concentrated to dryness. The obtained residue was treated withlO ml ethanol and triethylamine (0.154 ml, 1.52 mmol) and refluxed for 3 hr. Solvent was evaporated to dryness under reduced pressure and the residue was purified on preparative HPLC to give titled product, C22H28FN3O3, , m/z 388 (M+l), PMR (CD30D): 0.9-1.3 (m, 10H), 1.8-2.2 (m, 2H), 2.9-3.7 (m, 8H), 4.2 (m, 1H), 7.9 (d,lH), 9.0 (s,lH). Example - 76 c/5,-l-Cvclopropvl-6-fluoro-l,4-dihydro-8-ethvl-7-(4-amino-3-methyl-l-piperidinvl)-4-oxo- quinoline-3-carboxylic acid. The compound was prepared by a procedure as described in Example 75, by using cis-4-amino-3-methylpiperidine, C22H28FN3O3, m/z 388 (M+l), PMR (CD30D): 0.8-1.4 (m, 10H), 1.8-2.4 (m, 3H), 3.0-3.8 (m, 9H), 4.2 (m, 1H), 7.9 (d,lH), 9.0 (s,lH). Example - 77 (+)- l-Cvclopropvl-6-fluoro-1,4-dihydro-8-ethyl-7-(4-amino-3,3-dimethyl-1 -piperidinyl)-4- oxo-quinoline-3-carboxylic acid. The compound was prepared by a procedure as described in Example 75, by using (±)-4-amino-3,3-dimethylpiperidine, C22H28FN3O3, , m/z 402 (M+l), PMR (CD30D): 0.8-1.3 (m, 13H), 1.6-2.0 (m, 2H), 2.7-3.0 (m, 2H), 3.0-3.8 (m, 5H), 4.1 (m, 1H), 7.8 (d,lH), 8.9 (s,lH). Example - 78 (-)-l-Cvclopropvl-6-fluoro-l,4-dihvdro-8-ethyl-7-(4-amino-3,3-dimethyl-l-piperidinvl)-4- oxo-quinoline-3-carboxylic acid. The compound was prepared by a procedure as described in Example 75, by using 127 (-)-4-amino-3,3-dimethylpiperidine, C22H28FN3O3, m/z 402 (M+l). Example - 79 (+)-1 -Cyclopropvl-6-fluoro-1,4-dihvdro-8-ethyl-7-(4-amino-3,3-dimethyl- l-piperidinyl)4- oxo-quinoline-3-carboxvlic acid. The compound was prepared by a procedure as described in Example 75, by using (+)-4-amino-3,3-dimethylpiperidine, C22H28FN3O3, m/z 402 (M+l). Example - 80 l-Cvclopropvl-6-fluoro-l,4-dihvdrO'8-ethyl-7-(4-amino-l-piperidinyl)-4-oxo-quinoline-3- carboxylic acid. The compound was prepared by a procedure as described in Example 75, by using 4-aminopiperidine, m.p. 248-249°C22H28FN3O3, 3, m/z 374 (M+l), PMR (CD30D):selected values 0.9 (m, 2H), 1.1 (t, 3H), 1.3 (m, 2H), 1.7-2.2 (m, 4H), 3.6 (m, 2H), 4.2 (m,lH), 7.9(d,lH), 9.0 (s, 1H). Example 81 trans-5-Amino-l-cyclopropyl-6-fluoro-1,4-dihydro-8-methvl -7-(4-amino-3-methyl-1 -piperidinyl) -4-oxo-quinoline-3-carboxvlic acid. A mixture of [l-cyclopropyl-6,7-difluoro-8-methyl -l,4-dihydro-4-oxo-quinoline-3-carboxylate-03,04] difluoroboron (0.5 g, 1.46 mmol), and rrans-4-amino-3-methylpiperidine (0.86 g, 7.64 mmol) in 10 ml acetonitrile was heated to reflux for 8 hr. The reaction mixture was concentrated to dryness. The obtained residue was treated withlO ml ethanol and triethylamine (0.154 ml, 1.52 mmol) and refluxed for 3 hr. Solvent was evaporated to dryness under reduced pressure and the residue was purified on preparative HPLC to give titled product, C20H25FN4O3, m/z 389 (M+l), Example 82 c?i,-5-Amino-l-cyclopropvl-6-fluoro-l,4-dihydro-8-methvl-7-(4-amino-3-methvl-l- piperidinvl)-4-oxo-quinoline-3-carboxvlic acid. The compound was prepared by a procedure as described in Example 81, by using cis-A- amino-3-methylpiperidine, C20H25FN4O3, m/z 389 (M+l). 128 2 MAR 20061 Example 83 (+)-5-Amino-l-cyclopropvl-6-fluoro-l,4-dihydro-8-methyl-7-('4-amino-3.3-dimethyl-l- piperidinvl)-4-oxo-quinoline-3-carboxvlic acid. The compound was prepared by a procedure as described in Example 81, by using (±)-4- amino-3,3-dimethylpiperidine, C21H27FN4O3, m/z 403 (M+l). Example 84 r-)-5-Amino-l-cvclopropvl-6-fluoro-l,4-dihydro-8-methyl-7-(4-amino-3,3-dimethyl-l-piperidinvl)-4-oxo-quinoline-3-carboxvlic acid. The compound was prepared by a procedure as described in Example 81, by using (-)-4-amino-3,3-dimethylpiperidine, C21H27FN7O3, m/z 403 (M+l). Example 85 (+V5-Amino-l-cvclopropvl-6-fluoro-l,4-dihvdro-8-methvl-7-(4-amino-3,3-dimethyl-l- piperidinvl)4-oxo-quinoline-3-carboxylic acid. The compound was prepared by a procedure as described in Example 81, by using -(+)-4- amino-3,3-dimethylpiperidine, C21H27FN7Ch3, m/z 403 (M+l). Example 86 cis- l-Cvclopropyl-6-fluoro-1.4-dihydro-8-methyl-7-(4-amino-3-methvl-1 -piperidinyl)-4-oxo- quinoline-3-carboxylic acid hydrochloride:. A mixture of [l-cyclopropyl-6,7-difluoro-8-methyl -l,4-dihydro-4-oxo-quinoline-3-carboxylate-03,04] difluoroboron (2.4 g, 7.34 mmol), and cis-4-t-butyloxycarbonylamino-3-methylpiperidine (4.45 g, 20.8 mmol) in 10 ml acetonitrile was stirred at 50 °C for 30 hr. The reaction mixture was concentrated to dryness. The obtained residue was treated with 10 ml ethanol and 1 ml triethylamine and refluxed for 1 hr. Solvent was evaporated to dryness under vacuum and the residue was purified by silica gel column chromatoghraphy using 3% methanol chloroform solvent mixture as an eluent to give a crude product. The crude product was dissolved in 10 ml cone HCl and stirred for 30 minutes. The solvent was evaporated under vacuum. The resultant solid was dissolved in methanol and re-crystallized by adding ethyl acetate to provide titled compound 1.56 g (52%) yield as a solid, m. p. 255-260 °C C20H25FN3O3CI, m/z 374 (M+l), 129 ' PMR (CD3OD): 0.95 (m, 2H)7 1.2 (d, 3H), 1.2-1.4 (m, 2H), 1.8-2.4 (m, 3H), 2.8 (s, 3H), 3.2-3.4 (m, 3H), 3.5-3.7 (m, 2H), 4.3 (m, 1H),7.8 (d,lH), 9.0 (s,lH). Example 87 fran^-l-Cvclopropvl-6-fluoro-l,4~dihvdro-8-methvl-7-('4-amino-3-methvl-l-piperidinvl)-4-oxo-quinoline-3-carboxylic acid hydrochloride:. The compound was prepared by a procedure described in Example 86 by using trans-4-t-butyloxycarbonylamino-3-methylpiperidine instead . ds-4-t-butyloxycarbonylamino-3-methylpiperidine. Yield : 56% m. p. 262-265 °C C2oH25FN303Cl, m/z 374 (M+l). Example 88 cis/trans-1 -Cvclopropyl-6-fluoro-8-methvl-7-(4-hydroxv-3-methyl- 1-piperidinyl)-1,4- dihvdro-4-oxoquinoline-3-carboxylic acid. The compound was prepared by a procedure described in Example 86 by using cis/trans-4- hydroxy-3-methylpiperidine instead of trarcs-4-amino-3-methyrpieridine and product was purified on preparative HPLC to give titled product. M. p. 202-206 °C, mass (ES+) 375, Molecular Formula C20H23FN2O5, H'NMR (CD3OD) 0.92 (s, 2H), 1.04 (d, 3H), 1.22-1.38 (m, 2H), 1.62-1.82 (m, 2H), 1.82-2.10 (m, 2H), 2.8 (s, 3H), 2.90-3.24 (m, 4H), 3.95 (q, 1H), 4.30 (m, 1H), 7.80*7.88 (d, 1H), 8.95 (s, 1H). Example 89 c^-l-Cvclopropvl-6-fluoro-8-methyl-7-(4-hydroxv-3-methyl-l-piperidinyl)-l,4-dihvdro-4- oxoquinoline-3-carboxvlic acid. The compound was prepared by a procedure described in Example 86 by using cis-4-hydroxy-3-methylpiperidine instead of trans-4-amino-3-methylpieridine and product was purified on preparative HPLC to give titled product. M. p. 206-210 °C, mass (ES+) 375, Molecular FormulaC20H23FN2O4 H'NMR (CD3OD) 0.92 (s, 2H), 1.04 (d, 3H), 1.22-1.38 (m, 2H), 1.62-1.82 (m, 2H), 1.82-2.10 (m, 2H), 2.8 (s, 3H), 3.0-3.15 (s, 1H), 3.22-3.40 (s, 1H), 3.50-3.62 (m, 2H), 4.0-4.10 (q, 1H), 4.10-4.20 (m, 1H), 7.80-7.88 (d, 1H), 8.95 (s, 1H). 130 Example 90 trans -l-Cvclopropyl-6-fluoro-8-methvl-7-(4-hvdroxy-3-methvl-l-piperidinvl)-l,4-dihydro- 4-oxoquinoline-3-carboxylic acid. The compound was prepared by a procedure described in Example 86 by using trans-4- hydroxy-3-methylpiperidine instead of ?rans-4-amino-3-methylpieridine and product was purified on preparative HPLC to give titled product. M. p. 214-216 °C, mass (ES+) 375, Molecular Formula C20H23FN2O5, H'NMR (CD3OD) 0.92 (s, 2H), 1.04 (d, 3H), 1.22-1.38 (m, 2H), 1.62-1.82 (m, 2H), 1.82- 2.10 (m, 2H), 2.8 (s, 3H), 3.0-3.15 (s, 1H), 3.22-3.40 (s, 1H), 3.50-3.62 (m, 2H), 4.0-4.10 (q, 1H), 4.10-4.20 (m, 1H), 7.80-7.88 (d, 1H), 8.95 (s, 1H). Example 91 cis/trans -l-Cvclopropvl-6-fluoro-8-methyl-7- (4-hydroxy-3-ethvl-l-piperidinyl)-1.4- dihvdro-4-oxoquinoline-3-carboxylic acid. The compound was prepared by a procedure described in Example 86 by using cis/trans-4- hydroxy-3-ethylpiperidine instead of rrans-4-amino-3-methylpieridine and product was purified on preparative HPLC to give titled product. m. p. 185-190 °C, mass (ES+) 389, Molecular Formula C20H23FN2O5 H'NMR (CD3OD) 0.92-1.02 (m, 7H), 1.22-2.18 (m, 4H), 2.78 (s, 3H), 2.90-3.72 (m, 4H), 4.15 (q, 1H), 7.85-7.98 (d, 1H), 8.95 (s, 1H). Example 92 c^/?ran5-l-Cyclopropvl-6-fluoro-8-ethvl-7-(4-hvdroxy-3-ethvl-l-piperidinyl)-l,4-dihydro- 4-oxoquinoline-3-carboxylic acid. The compound was prepared by a procedure described in Example 86 by using cis/trans-4- hydroxy-3-ethylpiperidine instead of rrans-4-amino-3-methylpieridine and product was purified on preparative HPLC to give titled product. m. p. 170-172 °C, mass (ES+) 403, Molecular Formula C22H27FN2O4, H'NMR (CD3OD) 0.92-1.02 (m, 10H), 1.22-2.18 (m, 6H), 2.80-3.62 (m, 4H), 4.0-4.22 (m, 2H), 7.86-8.02 (d, 1H), 8.95 (s, 1H). 131 Example 93 cis /trans -l-Cyclopropvl-6-fluoro-8-methoxy-(4-hvdroxy-3-methvl-l- piperidinylH ,4- dihvdro-4-oxoquinoline-3-carboxylic acid. The compound was prepared by a procedure described in Example 1 by using cis/trans-4- hydroxy-3-methylpiperidine instead of 4-amino-3-methylpiperidine and product was purified on preparative HPLC to give titled product. m. p. 114-216 °C, mass (ES+) 391, Molecular Formula C20H23FN2O5, H'NMR (CDC13) 1.00-1.12 (m, 4H), 1.20-1.32 (d, 3H), 1.78-2.22 (m, 3H), 2.20-2.70 (m, 4H), 3.58-3.80 (s,3H), 4.00- 4.18 (m, 1H), 7.82-8.0 (d, 1H), 8.82 (s, 1H). Example 94 cis /trans -l-Cyclopropyl-6-fluoro-8-methoxy-7- (4-hydroxy-3-ethyl-l-piperidinvl)-l,4- dihydro-4-oxoquinoline-3-carboxylic acid. The compound was prepared by a procedure described in Example 1 by using cis/trans-4- hydroxy-3-ethylpiperidine instead of 4-amino-3-methylpiperidine and product was purified on preparative HPLC to give titled product. m. p. 188-190 °C, mass (ES+) 405, Molecular Formula C20H23FN2O5 H'NMR (CHCI3) 0.98-1.05 (t, 3H), 1.06-1.58 (m, 4H), 1.60-2.02 (m, 3H), 3.30 (s, 3H), 3.60- 3.75 (m, 4H), 3.75-3.90 (q, 3H), 4.00- 4.20 (m, 2H), 7.85-7.98 (d, 1H), 8.80 (s, 1H). Example 95 cis/trans -5-Amino-l-cvclopropyl-6-fluoro-8-methoxv-7- (4-hydroxv-3-methvl-l- piperidinvD-l,4-dihydro-4-oxoquinoline-3-carboxylic acid. The above compound was prepared by a procedure described in Example 43 by using cis/trans-4-hydroxy-3-methylpiperidine instead of 3,3-dimethyl-4-methylarninopiperidine and product was purified on preparative HPLC to give titled product, m. p. 240-244 °C, mass (ES+) 406, Molecular Formula C20H24FN3O5. 132 2 2 MAR 2006 Example 96 cis / trans -5-Amino-l-cyclopropyl-6-fluoro-8-methoxv-7-(4-hvdroxy-3-ethyl-l-piperidinyl)- 1,4-dihvdro-4-oxoquinoline-3-carboxvlic acid. The above compound was prepared by a procedure described in Example 43 by using cis/trans-4-hydroxy-3-ethylpiperidine instead of 3,3-dimethyl-4-methylaminopiperidine and product was purified on preparative HPLC to give titled product. m. p. 217-19 °C, mass (ES+) 420, Molecular Formula C21H26FN3O5, H'NMR (CDCI3) 0.82 (d, 2H), 1.02 (t, 3H),L18 (d, 2H), 3.18-3.40 (m, 4H), 3.60 (s, 3H), 3.90-4.02 (q, 2H), 4.18 (m, 1H), 8.70 (s, 1H). BIOLOGICAL EXAMPLES Microbiological and pharmacological studies can be used to determine the relative potency, and the profile of specificity of the compounds of the invention as antibacterial agent with a spectrum of activity as described in the specification above. In the following examples, the compounds of the invention are numbered as per the list of the specific compounds of the invention described earlier in the text. BIOLOGICAL EXAMPLE 1 In-vitro Antimicrobial Tests The comparative antimicrobial activity of representative compounds of the invention and reference compounds against various sensitive and resistant microorganisms is given in Tables 17 to 20. The test method was in accordance with the standard NCCLS protocol (Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that grow Aerobicially, Approved Standards, M7-A5, Fifth Edition, January 2000). The antibacterial activities (minimum inhibitory concentration: MIC, mcg/ml) were determined by using the two-fold serial agar dilution method recommended, by NCCLS. The media used for preculture and main culture were Tryptic Soya broth (Difco) and Mueller Hinton medium (Difco), respectively. The Mueller Hinton agar was supplemented with 5% 133 sheep blood for streptococci. Overnight cultures were diluted with buffered saline (pH 7.2) to the final cell density of 5 x 106-107 CFU/ml, and each bacterial suspension was applied with a replicator (Denley's multipoint inoculator, UK) onto a series of Mueller-Hinton agar plates containing antibacterial agents at various concentrations. Final inoculum was approximately 104 CFU/spot. The plates were incubated for 18 hrs at 37° C. The MIC was defined as the lowest concentration of an antibacterial agent that inhibits the development of visible microbial growth on agar. The results obtained are shown in tables 17 to 20. Table 17 Activity Against Fluoroquinolone Sensitive Strains. Compound No. MSSA ATCC 25923 S. pneumoniae ATCC 49619 S. sanguis ATCC 10556* E. faecalis ATCC 29212 E.coli ATCC 25922 P. aeruginosa 27853 MICs (|ig / ml) 1 0.05 0.2 - - 0.05 - 17 0.4 1.56 - - 0.4 - 18 0.05 0.05 0.1 0.1 0.2 6.25 19 0.05 0.05 0.1 0.1 0.2 6.25 20 0.05 0.1 0.1 0.1 0.2 6.25 21 0.05 0.1 - - 0.05 - 37 0.05 0.1 - - 0.1 - 39 1,56 >6.25 - - 6,25 - 61 0.05 0.2 - - 0.4 - 66 0.05 0.2 - - 0.2 - 83 0.1 - . - 0.05 - 84 0.003 0.025 0.05 0.05 0.2 3.12 85 0.003 0.025 0.025 0.1 0.2 3.12 86 0.003 0.025 0.025 0.05 0.2 3.12 88 0.012 0.1 0.2 0.2 0.4 12.5 89 0.025 0.05 0.025 0.1 0.006 1.56 90 0.025 0.05 0.025 0.1 0.0012 3.12 91 0.025 0.025 0.025 0.05 0.025 3.12 92 0.025 0.1 0.1 0.2 0.05 6.25 93 0.025 0.025 0.05 0.05 0.025 1.56 94 0.05 0.05 - - 0.05 - 100 0.1 0.8 - - 0.8 - HI 0.8 - - - 1.56 - 116 0.025 0.2 - - 0.4 - 125 0.025 0.4 - - 1.56 - 127 <0.006 0.1 - - 0.4 - Levofloxacin 0.2 0.8 1.56 0.8 0.025 3.12 Moxifloxacin 0.05 0.2 0.4 0.2 0.05 6.25 * S.sanguis 10556 belongs to the group of Viridans Streptococci. 3 other strains of the group S.oralis 900, S.salivaris 1062 and S.mitis 1303 provided similar MICs ranging from 0.025 -0.40 u.g / ml in comparison to the reference compounds which had MIC values ranging from 0.1-3.12. Table 18 Activity Against FIuoroquinolone-Resistant Strains. Compound No. MRSA 032 FQM S. pneumoniae 718 Cipro" S. sanguis 941 Cipro" S. mitis 938 MICs (ug/ml) 18 0.8 0.8 0.4 1.56 19 0.8 0.4 0.2 0.8 20 0.8 0.8 0.4 1.56 84 0.2 0.8 0,4 0.4 85 0.2 0.8 0.4 0.4 86 0.2 0.8 0.4 0.4 88 0.8 3.12 3.12 3.12 89 1.56 1.56 3.12 1.56 90 1.56 1.56 3.12 1.56 91 0.8 0.8 1.56 1.56 92 1.56 1.56 6.25 6.25 93 0.4 0.4 1.56 0.8 Levofloxacin 6.25 12.5 12.5 25.0 Moxifloxacin 3.12 3.12 6.25 6.25 Table 19 Activity Against Trovafloxacin-Resistant and Vancomvcin-Resistant Enterococci Compound No. Trova-Resist MRSE**110 V R E*** 336 MICs (ng /ml) 84 0.4 3.12 85 0.4 3.12 86 0.4 3.12 Ref.comp.l* 1.56 6.25 v Ref.comp.2* 1.56 6.25 Ref.comp.3* 1.56 6.25 * Ref. Comp. 1, 2 and 3 are reference compounds cited in our pending US patent application 09/850,669 and WO 01/85728 Ref. Comp.l is S-(-)-9-fluoro-6,7-dihydro-8-(4-hydroxy-3-methylpiperidin-l-yl)-5-methyl-l-oxo-lH,5H-benzo[i, j]quinolizine-2-carboxylic acid (mixture of cis racemate and trans racemate) Ref. Comp. 2 is S-(-)-9-fluoro-6,7-dihydro-8-{cis-4-(RS)-hydroxy-3-(RS)-methylpiperidin-1- yl}-5-methyl-l-oxo-lH,5H-benzo[i,j]quinolizine-2-carboxylic acid. Ref. Comp. 3 is S-(-)-9-fluoro-6,7-dihydro-8-{trans-4-(RS)-hydroxy-3-(RS)- 135 22 MAR 2006 methylpiperidin-1-yl }-5-methyl-l-oxo-lH,5H-benzo[i, j]quinolizine-2-carboxylic acid ** MRSE stands for methicillin-resistant S. epidermidis *** VRE stands for vancomycin-resistant Enterococcus faecium Table 20 Activity Against Clinical Isolate MRSA 5076 with Mutations in DNA Gyrase and Topoisomerase IV as well as bearing an Efflux Pump Compound No. S. aureus (sensitive) ATCC 25293 MRSA 5076 (triple resistance) MRSA 5076 + efflux inhibitor reserpine MICs (ng / ml) 18 0.05 3.12 1.56 19 0.05 1.56 1.56 20 0.05 3.12 1.56 86 0.003 0.2 0.2 93 0.05 0.8 0.8 Ciprofloxacin 0.8 100 25.0 Moxifloxacin 0.05 12.5 6.25 The data shows that the reference compounds, which although are active against sensitive staphylococci, are rendered quite unattractive due to serious loss in their potency against clinical isolate MRSA 5076 expressing triple fluoroquinolone-resistance mechanisms. The fold difference between the MIC values for each compound in the last two columns indicates the effect of the efflux pump mechanism on the susceptibility of the strains to the respective compounds. The compounds of the invention are 4-fold to 500-fold more potent than the reference compounds against the resistant strain as seen in column 3. Resistance to Resistance Development Compound No. 18 was evaluated in comparison with Moxifloxacin and Trovafloxacin in terms of resistance to resistance development on sequential transfer / passages through respective drug-containing media. Initially all the three drugs had comparable activity against MRSA 5027 (0.4 ng/ml). However, after 10 passage in drug containing medium, MIC for Moxifloxacin and Trovafloxacin was 6.25 fig/ml and 50 u,g/ml respectively, while compound No. 18 showed no elevation and remained 0.4 (j,g/ml. The data indicates that compound No. 18 has a remarkable property of resisting the development and selection of MRSA strains resistant to it and is significantly less likely to select resistant mutants in a clinical scenario, thus obviating the risk of treatment failure in patients. 136 BIOLOGICAL EXAMPLE 2 In-vivo Antimicrobial Tests Protocol for Systemic Infection Model The in vivo efficacy was studied through mouse septicemia model of infection in Swiss male and female mice (4 weeks old, 20 + 2g weight) using 6 animals in each group. Infective organisms were inoculated intraperitonially. Compound were administered by oral route 1 hour and 5 hours post-infection. By Probit analysis protective doses were calculated from the survival rate on day 7 in terms of ED5o (50% survival dose) values. Appropriate comparators were included in the study. Table 22 In-vivo Activity Against Multidrug-Resistant (MDR) Pneumococcal Infections COMPOUND ED50 p-o. (mg/kg) MDR S. pneumoniae 718* 18 30 19 20 20 50 90 30 91 30 93 20 Levofloxacin >100 Moxifloxacin >100 Gatifloxacin >100 * Resistant to B-lactams, macrolides and fluoroquinolones BIOLOGICAL EXAMPLE 3 ' Acute Toxicity Each test compound or reference compound was administered orally to groups of 10 swiss mice (body weight: 22-26 gms) each, whereby its acute toxicity was investigated. The compounds were administered in solution form. As a result it was found that the median lethal dose (LD50) values of compounds 18, 19 and 20 were 650 mg/kg, 600 mg/kg and 650 mg/kg respectively. The LD50 of reference compound moxifloxacin was 600 mg/kg. On 137 the basis of data of ED50 values (provided in table 22) the therapeutic index (LD50/ED50) for the test compounds is 3.0 to 7.5 times higher than that for moxifloxacin. BIOLOGICAL EXAMPLE 4 Cytotoxicity Protocol for cytotoxicity test Compounds were evaluated for their cytotoxic potential against two celllines viz. J 744 (mouse macrophage) and V79 (Chinese Hamster Lung). Cells were grown for 3 - 4 days in a culture flask using D-MEM (Dulbecco's Modified Eagle Medium) supplemented with 10% fetal bovine serum (FBS). Freshly grown cells were distributed in microtiter plates at a cell density of 10 -10 cells / well and allowed to adhere and form monolayer by incubating the microtiter plate at 37°C for 24 hrs. Medium from each well was aspirated and replaced with fresh D-MEM (supplemented with 2.5% FBS) containing various concentrations of compounds. Following 3 hrs. of drug exposure, cells were washed with D-MEM and incubated further for 96 hrs. Cytotoxic effects of drugs were monitored through daily microscopic observation and by ascertaining the metabolic status through redox indicator Alamar blue. Healthy actively metabolising cells bring about colour change of Alamar blue from blue to pink within an overnight incubation. Cytotoxic drugs inhibit this reaction resulting into blue coloured wells. Minimum drug concentration inhibiting Alamar blue color change i.e. resulting into blue coloured wells for a given drug is considered cytotoxic concentration. Table 23 Compound No. J 744 Macrophage V79CHL (Cytotoxic concentration mcg/ml) 18 >1000 >1000 19 >1000 1000 20 >1000 >1000 84 >1000 >1000 85 >1000 >1000 86 >1000 >1000 88 >1000 >1000 89 1000 250 90 1000 125 91 1000 750 92 >1000 >1000 93 1000 250 Trovafloxacin 500 62.5-120 138 BIOLOGICAL EXAMPLE 5 Phototoxicity Six groups of healthy Swiss Albino mice consisting of 6 males per group were orally administered with a single dose of a compound of the invention or a reference compound at dose levels of 50, 100, 200, 300 and 400 mg/kg. The stock solutions for different doses were prepared freshly on the day of experimentation. Appropriate concentration of each dose was chosen to give a, constant dosage volume of 0.3-0.4 ml/20g body weight of mouse. The treated mice were exposed to UVA light source immediately after dosing for 4 hours and for 4 consecutive days. The mean light intensity in the UVA chamber was adjusted to 0.9-1.2 mW/cm^. The total irradiation dose was approximately 18 Joules/cm^ /day. A phototoxic dose is one which causes ear erythema and oeadema. The phototoxic doses of compounds 18, 19 and 20 of the present invention were greater than 500 mg/kg, whereas the phototoxic dose for reference compound sparfloxacin was 25 mg/kg, thus indicating that the compounds of the present invention induced no phototoxicity. We claim: 1. A fluoroquinolone compound of the formula I wherein Ri is C 1.5 alkyl, substituted C1-5 alkyl C3-6 cycloalkyl, substituted C3.6 cycloalkyl, aryl; substituted aryl; or when Q is CH and the nitrogen atom to which R1 is linked forms an optionally substituted 5-, 6- or 7-membered ring with the carbon atom of Q, the ring optionally containing one or more hetero atoms selected from nitrogen, oxygen or sulfuiv atoms, said heteroatom(s) represented by T, preferably Ri is CH2CH2-, CH2T-, CH2CH2CH2-, CH2CH2T-, CH2TCH2-, TCH2T-, TCH2CH2CH2CH2- CH2CH2CH2T-, CH2TCH2CH2-, and TCH2CH2T- where T represents NH, O, or S. If the ring is substituted, the substituent is as defined above for Ri. Y is OR3 where R3 is hydrogen; or C1-C20 alkyl, such as straight chain or branched chain aliphatic residues; or aralkyl; or CH2CH(NH2)COOH; or (CH2)n-CHRio-OCORn or (CH2)n-CHR10-OCO2Rii wherein R10 is H, or CH3; n is 0-3 and R]i is C1-C20 alkylor substituted C1-C6 alkyl or aralkyl or Rn is or R3 is an alkanoylalkyl group; or R3 is —(CH2)P— A wherein A is CH or N, and when A is CH, Z is NH or NCH3, and when A is N, Z is CH, O, NH, S, or NCH3 ; p is 0 - 2 ; q is 0 - 2; or Y is NHR2, wherein R2 is H, C1.20 alkyl, C3.6 cycloalkyl, substituted C3.6 cycloalkyl, aryl or substituted aryl, heteroaryl, all of which heteroaryl residues may be further substituted or unsubstituted; or R2 is the amino acid residue derived from one of the 20 naturally occurring amino acids, or the optically active isomers thereof, or the racemic mixtures thereof; R5 is H, Ci-5 alkyl, C1.5 alkoxy, amino, C1.5 alkylamino, or C1.5 acylamino; Q is -N-, -C(R8)- (Rg being H, F, CI, bromo, CM alkyl or unsubstituted or substituted CM alkoxy, wherein when the alkoxy group is substituted it ^substituted by one or more halogen atoms such as F, CI, or Br), or when Q is CH and the nitrogen atom to which R\ is linked forms an optionally substituted 5-, 6- or 7-membered ring with the carbon atom of Q, the ring optionally containing one or more hetero atoms selected from nitrogen, oxygen or sulfur atoms, said heteroatom(s) represented by T, preferably R, is CH2CH2-, CH2T-, CH2CH2CH2-, CH2CH2T-, CH2TCH2-, TCH2T-, TCH2CH2CH2CH2- CH2CH2CH2T-, CH2TCH2CH2_, and TCH2CH2T- where T represents NH, O, or S. If the ring is substituted, the substituent is as defined above for Rj. X is OR4, wherein R4 is hydrogen, or C]-C20 alkyl, or glycosyl, or aralkyl, or C)-C6 alkanoyl or aminoalkanoyl or an acid residue derived from one of the 20 naturally occurring amino acids, or the optically active isomers thereof, or the racemic mixtures thereof, or R4 is 1- aminocyclohexylcarbonyl or COORn wherein Rn is as hereinbefore defined or R4 is - (CH2)n-CHRio-OCOORn where Rio and Rn are as hereinbefore defined, or R4 is C6Hii06, P02(CH3)H, P03H2, P02(OCH3)H or SO3H thus giving respectively the gluconic acid, phosphonic acid, phosphoric acid and sulfonic acid ester derivatives of the compounds; or X is NR6R7, 2 2 MAR IBM' wherein R6 is H, C1-20 alkyl, C3.6 cycloalkyl, aralkyl; C1-20 alkanoyl, or C1-20 alkoxycarbonyl, aralkyloxycarbonyl, amino(C1-20)alkanoyl, or an amino acid residue derived from one of the 20 naturally occurring amino acids or the optically active isomers thereof, or the racemic mixtures thereof. The amino acid residue is derived from a single amino acid or from combinations of amino acids that form dipeptide, tripeptide or polypeptide amino acid unit residues, wherein a terminal carboxy group is optionally protected by CM alkyl or aralkyl groups and a terminal amino group is optionally protected by a 4-Boc (tertiarybutyloxycarbonyl), F-Moc (fluorenylmethoxycarbonyl) or Cbz (benzyloxycarbonyl) group R$ may also be COORi 1 wherein R11 as hereinbefore defined or R6 is C6H11O6 thus giving the gluconic acid ester derivative of the compounds. R7 is H, C1-6 alkyl, C3-6 cycloalkyl, aralkyl; C1-6 alkanoyl, aralkyloxycarbonyl or amino C1-20 alkanoyl; or an amino acid residue derived from one of the 20 naturally occurring amino acids or the optically active isomers thereof, or the racemic mixtures thereof. The amino acid residue is derived from a single amino acid or from combinations of amino acids that form dipeptide, tripeptide or polypeptide amino acid unit residues, or R7 may be C6H1 iCV Rg/Rg' are substituents at the 3/3-position ofthe piperidino ring and are the same or different and represent H, C1-6 alkyl, substituted C1-6 alkyl, alkylamino, or aralkyl. R9 is a substituent at the 4-position or 5-position ofthe piperidino ring and represents H, C1.6 alkyl, C1-5 alkylamino, C1.3 dialkylamino or aryl or aralkyl or a trihaloalkyl with the provisos that Q is not C-CH3 or C-CH2CH3 when X is hydroxy, Ri is cyclopropyl and Rg, R8- and R9 are all hydrogen; the heteroatom in the ring T is not sulfur, when X, R5, Rg, Rss and R9 are all hydrogen and Y is OR3 where R3 is hydrogen; when Rg, Rg' and R5 are hydrogen R\ is c-propyl and Q is N, or when Rg, Rg' and R5 are hydrogen Ri is c-propyl, Q is COMe and R5 is NH2 or when Rg, R8> and Rs are hydrogen the ring T is pyrido[l,2,3-de]-l,4-benzoxazine the X is not NRgRy where R6 and R7 are hydrogen or R6 is CH3 and R7 is hydrogen or Re is hydrogen and R7 is CH3; when the nitrogen atom to which Ri is linked forms methyl substituted 6-membered ring with the carbon atom of Q, and Rg, Rg- and R9 is hydrogen, then X is not hydroxy and amino; when R5 is CrC5 alkyl Q is not C-H. 142 CO,H 2. A compound according to claim 1 wherein the fluoroquinolone moiety is selected from CH3 C2H5 0 0 NH2 0 ° 0 0 0 F^ ^ J^ ^C02H F^ ^C J^ v-C02H F^^^JI^^C02H C2 H5 C2 H5 F^ ^^ J^ ^C02H F^ JL JL ^C02H F^^v.^V^-c°2H C02H F CO,H OCH3 C2H5 CO,H NH2 0 143 2 2 MAR 2006 COb.H o CH3 144 taM^ii NHc-C H 3 5 3. The compound according to claim 1 wherein the amine is selected from CH 145 2 2 MAR 2006' 4. A compound as claimed in claim 1, which can be of the following: 1 -Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-amino-3-methyl-1 -piperidinyl)-4-oxo- quinoline-3-carboxylic acid (mixture of cis and trans isomers) and its salts; trans -1 -Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-amino-3 -methyl-1 -piperidinyl)-4- oxo-quinoline-3-carboxylic acid (racemic mixture of 4R, 3R and 4S, 3S) and its salts; trans-1 -Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-amino-3-methyl-1 -piperidinyl)-4- oxo-quinoline-3-carboxylic acid (4R, 3R) and its salts; trans-1 -Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-amino-3 -methyl-1 -piperidinyl)-4- oxo-quinoline-3-carboxylic acid (4S, 3S) and its salts; cis-1 -Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-amino-3-methyl-1 -piperidinyl)-4- oxo-quinoline-3-carboxylic acid (racemic mixture of 4S, 3R and 4R, 3S) and its salts; cis-1 -Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-amino-3-methyl-1 -piperidinyl)-4- oxo-quinoline-3-carboxylic acid (4S, 3R) and its salts; cis-1 -Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-amino-3-methyl-1 -piperidinyl)-4- oxo-quinoline-3-carboxylic acid (4R, 3S) and its salts; 1 -Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-amino-3 -ethyl-1 -piperidinyl)-4-oxo- quinoline-3-carboxylic acid (mixture of cis and trans isomers) and its salts; l-Cyclopropyl-6-fluoro-l,4-dihydro-8-methoxy-7-(4-methylamino-3-methyl-l-piperidinyl)- 4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; 1 -Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-methylamino-3-ethyl-1 -piperidinyl)-4- oxo-quinoline-3-carboxylic acid and its isomers and its salts; 146 2 2 MAR MS 1 -Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-ethylamino-3-methyl-1 -piperidinyl)-4- oxo-quinoline-3-carboxylic acid and its isomers and its salts;. 1 -Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-cyclopropylamino-3 -methyl-1 - piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; 1 -Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-cyclopropylamino-3 -ethyl-1 - piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its isomers and its saltsL; l-Cyclopropyl-6-fluoro-l,4-dihydro-8-methoxy-7-(4-dimethylamino-3-methyl-l- piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; 1 -Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-dimethylamino-3-ethyl-1 -piperidinyl)- 4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; 1 -Ethyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-amino-3,3-dimethyl-1 -piperidinyl)-4-oxo- quinoline-3-carboxylic acid and its isomers and its salts; 1 -(2,4-Difluorophenyl)-6-fluoro-l ,4-dihydro-8-methoxy-7-(4-amino-3,3-dimethyl-l - piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; (±)-1 -Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-amino-3,3-dimethyl-1 -piperidinyl)- 4-oxo-quinoline-3-carboxylic acid and its salts; " *?■ (+)-1 -Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-amino-3,3-dimethyl-1 -piperidinyl)- 4-oxo-quinoline-3-carboxylic acid and its salts; (-)-1 -Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-amino-3,3 -dimethyl-1 -piperidinyl)- 4-oxo-quinoline-3-carboxylic acid and its salts; 1 -Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-acetylamino-3,3 -dimethyl-1 - piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; 1 -Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-carbethoxyamino-3,3-dimethyl-1 - piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; l-Cyclopropyl-6-fluoro-l,4-dihydro-8-methoxy-7-(4-t-butyloxycarbonylamino-3,3-dimethyl- l-piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; (±)-l-Cyclopropyl-6-fluoro-l,4-dihydro-8-methoxy-7-(4-benzyloxycarbonylamino-3,3- dimethyl-l-piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its salts; (+)-1 -Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-benzyloxycarbonylamino-3,3 - dimethyl-l-piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its salts; (-)-l-Cyclopropyl-6-fluoro-l,4-dihydro-8-methoxy-7-(4-benzyloxycarbonylamino-3,3- dimethyl-l-piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its salts; 147 l-Cyclopropyl-6-fluoro-l,4-dihydro-8-methoxy-7-(4-methylamino-3,3-dimethyl-l- piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its isomers and its saltsl; 1 -Cyclopropyl-6-fluoro-l ,4-dihydro-8-methoxy-7-(4-ethylamino-3,3-dimethyl-l - piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; 1 -Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-cyclopropylamino-3,3-dimethyl-1 - piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; 1 -Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-dimethylamino-3,3-dimethyl-1 - piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; 1 -Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-amino-3-ethyl-3-methyl-1 -piperidinyl)- 4-oxo-quinoline-3-carboxylic acid, its isomers, and its salts; 1 -Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-methylamino-3-ethyl-3 -methyl-1 - piperidinyl)-4-oxo-quinoline-3-carboxylic acid, its isomers, and its salts; l-Cyclopropyl-6-fluoro-l,4-dihydro-8-methoxy-7-(4-cyclopropylamino-3-ethyl-3-methyl-l- piperidinyl)-4-oxo-quinoline-3-carboxylic acid, its isomers, and its salts; 1 -Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-dimethyamino-3-ethyl-3-methyl-1 - piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts. 1 -Cyclopropyl-6-fluoro-1,4-dihydro-8-metnoxy-7-(4-amino-3,3 -diethyl-1 - piperidinyl)-4- oxo-quinoline-3-carboxylic acid and its isomers and its salts. 1 -Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-amino-3,5-dimethyl-1 -piperidinyl)-4- oxo-quinoline-3-carboxylic acid and its isomers and its salts. l-Cyclopropyl-6-fluoro-l,4-dihydro-8-methoxy-7-(4-methylamino-3,5-dimethyl-l- piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts. 1 -Ethyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-methylamino-3,5-dimethyl-1 -piperidinyl)-4- oxo-quinoline-3-carboxylic acid and its isomers and its salts. 1 -Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-ethylamino-3,5-dimethyl-1 - piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts. 1 -Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-cyclopropylamino-3,5-dimethyl-1 - piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts. l-Cyclopropyl-6-fluoro-l,4-dihydro-8-methoxy-7-(4-dimethylamino-3,5-dimethyl-l- piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts. 1 -Cyclopropyl-6-fluoro-l ,4-dihydro-8-methoxy-7-(4-amino-3,3,5-trimethyl-1 -piperidinyl)-4- oxo-quinoline-3-carboxylic acid and its isomers and its salts. 148 l-Cyclopropyl-6-fluoro-l,4-dihydro-8-methoxy-7-(4-amino-3-ethyl-3,5-dimethyl-l-piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts. 1 -Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-amino-3-methyl-3,5-diethyl-1 -piperidinyl)-4-oxo-quinoline-3-carboxylic acid, its isomers, and its salts; 5-Amino-1 -cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-amino-3-methyl-1 -piperidinyl)-4-oxo-quinoline-3-carboxylic acid (mixture of cis and trans isomers) and its salts; trans-5 -Amino-1 -cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-amino-3 -methyl-1 -piperidinyl)-4-oxo-quinoline-3-carboxylic acid (racemic mixture of 4R, 3R and 4S, 3S) and its salts; trans-5-Aramo-1 -cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-amino-3-methyl-1 -piperidinyl)-4-oxo-quinoline-3-carboxylic acid (4R, 3R) and its salts; trans-5-Amino-1 -cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-amino-3-methyl-1 -piperidinyl)-4-oxo-quinoline-3-carboxylic acid (4S, 3S) and its salts; cis-5-Amino-1 -cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-amino-3-methyl-1 -piperidinyl)-4-oxo-quinoline-3-carboxylic acid (racemic mixture of 4S, 3R and 4R, 3S) and its salts; cis-5 -Amino-1 -cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-amino-3-methyl-1 -piperidinyl)-4-oxo-quinoline-3-carboxylic acid (4S, 3R) and its salts; cis-5- Amino-1 -cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-amino-3-methyl-1 -piperidinyl)-4-oxo-quinoline-3-carboxylic acid (4R, 3S) and its salts; 5-Amino-1 -cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-methylamino-3 -methyl-1 -piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; 5-Amino-1 -cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-ethylamino-3 -methyl-1 -piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; 5-Amino-1 -cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-cyclopropylamino-3 -methyl-1 -piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; 5-Amino-1 -cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-dimethylamino-3 -methyl-1 -piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; 5-Amino-l-cyclopropyl-6-fluoro-l,4-dihydro-8-methoxy-7-(4-amino-3-ethyl-l-piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; 5-Amino-1 -cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-methylamino-3 -ethyl-1 -piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; 149 5-Amino-1 -cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-cyclopropylamino-3 -ethyl-1 - piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; 5-Amino-l-cyclopropyl-6-fluoro-l,4-dihydro-8-methoxy-7-(4-dimethylamino-3-ethyl-l- piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; 5-Amino-1 -cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-amino-3,3 -dimethyl-1 - piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; 5-Amino-1 -cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-acetylamino-3,3 -dimethyl-1 - piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; 5-Amino-1 -cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-ethoxycarbonylamino-3,3 - dimethyl-l-piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; 5-Amino-l-cyclopropyl-6-fluoro-l54-dihydro-8-methoxy-7-(4-t-butoxycarbonyl amino-3,3- dimethyl-l-piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; 5-Amino-1 -cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-benzyloxycarbonyl amino-3,3 - dimethyl-l-piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; 5-Amino-l-cyclopropyl-6-fluoro-l,4-dihydro-8-methoxy-7-(4-methylamino-3,3-dimethyl-l- piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; 5-Amino-1 -cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-ethylamino-3,3-dimethyl-1 - piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; 5-Amino-l-cyclopropyl-6-fluoro-l,4-dihydro-8-methoxy-7-(4-cyclopropylamino-3,3- dimethyl-l-piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; 5-Amino-l-cyclopropyl-6-fluoro-l,4-dihydro-8-methoxy-7-(4-dimethylamino-3,3-dimethyl- l-piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; 5-Amino-1 -cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-amino-3 -ethyl-3 -methyl-1 - piperidinyl)-4-oxo-quinoline-3-carboxylic acid, its isomers, and its salts; 5-Amino-l-cyclopropyl-6-fluoro-l,4-dihydro-8-methoxy-7-(4-methylamino-3-ethyl-3- methyl-l-piperidinyl)-4-oxo-quinoline-3-carboxylic acid, its isomers, and its salts; 5-Amino-l-cyclopropyl-6-fluoro-l,4-dihydro-8-methoxy-7-(4-cyclopropylamino-3-methyl-3- ethyl-1- piperidinyl)-4-oxo-quinoline-3-carboxylic acid, its isomers, and its salts; 5-Amino-l-cyclopropyl-6-fluoro-l,4-dihydro-8-methoxy-7-(4-dimethylamino-3-methyl-3- ethyl-1- piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; 5-Amino-l-cyclopropyl-6-fluoro-l,4-dihydro-8-methoxy-7-(4-amino-3,3-diethyl-l- piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; 150 5-Amino-1 -cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-amino-3,5-dimethyl-1 -piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; 5-Amino-1 -cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-methylamino-3,5-dimethyl-1 -piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; 5-Amino-1 -cyclopropyl-6-fluoro-l ,4-dihydro-8-methoxy-7-(4-ethylamino-3,5-dimethyl-1 -piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; 5-Amino-l-cyclopropyl-6-fluoro-l,4-dihydro-8-methoxy-7-(4-cyclopropylamino-3,5-dimethyl-l-piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; 5-Amino-l-cyclopropyl-6-fluoro-l,4-dihydro-8-methoxy-7-(4-dimethylamino-3,5-dimethyl-l-piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; 5-Amino-1 -cyclopropyl-6-fluoro-l ,4-dihydro-8-methoxy-7-(4-amino-3,3,5-trimethyl-l -piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; 5-Amino-1 -cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-amino-3-ethyl-3,5-dimethyl-1 -piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; 5-Amino-1 -cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-amino-3-methyl-3,5-diethyl-1 -piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; 1 -Cyclopropyl-6-fluoro-1,4-dihydro-8-methyl -7-(4-amino-1 -piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its salts; cis/trans-1 - Cyclopropyl -6-fluoro-8-methyl-7-(4-hydroxy-3 -methyl-1 -piperidinyl)-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; cis-1 - Cyclopropyl -6-fluoro-8-methyl-7-(4-hydroxy-3 -methyl-1 -piperidinyl)-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; trans-1 - Cyclopropyl -6-fluoro-8-methyl-7-(4-hydroxy-3-methyl-1 -piperidinyl)-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; (±)-1 - Cyclopropyl -6-fluoro-8-methyl-7-(4-hydroxy-3,3-dimethyl-1 -piperidinyl)-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; cis/trans-1 - Cyclopropyl -6-fluoro-8-methyl-7-(4-hydroxy-3-ethyl-1 -piperidinyl)-1,4-dihydro-4-oxo-quinolme-3-carboxylic acid and its isomers and its salts; trans-1 -Cyclopropyl-6-fluoro-1,4-dihydro-8-methyl -7-(4-amino-3 -methyl-1 -piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; cis-1 -Cyclopropyl-6-fluoro-1,4-dihydro-8-methyl-7-(4-amino-3 -methyl-1 -piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; 151 (+) 1 -Cyclopropyl-6-fluoro-1,4-dihydro-8-methyl-7-(4-amino-3,3 -dimethyl-1 -piperidinyl)-4- oxo-quinoline-3-carboxylic acid and its salts; (+)-1 -Cyclopropyl-6-fluoro-1,4-dihydro-8-methy]-7-(4-amino~3,3-dimethyl-1 -piperidinyl)-4- oxo-quinoline-3-carboxylic acid and its salts; (-)-l-Cyclopropyl-6-fluoro-l,4-dihydro-8-methyl-7-(4-amino-3,3-dimethyl-l-piperidinyl)-4- oxo-quinoline-3-carboxylic acid and its salts; 1 -Cyclopropyl-6-fluoro-1,4-dihydro 8-methyl -7-(4-methylamino-3 -methyl-1 -piperidinyl)-4- oxo-quinoline-3-carboxylic acid and its isomers and its salts; 1 -Cyclopropyl-6-fluoro-1,4-dihydro -8-methyl -7-(4-dimethylamino-3 -methyl-1 -piperidinyl)- 4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; 1 -Cyclopropyl-6-fluoro-1,4-dihydro-8-methyl -7-(4-ethylamino-3,3 -dimethyl-1 -piperidinyl)- 4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; 1 -Cyclopropyl-6-fluoro-1,4-dihydro -8-methyl -7-(4-dimethylamino-3,3 -dimethyl-1 - piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; 1 -Cyclopropyl-6-fluoro-8-ethyl-7-(4-amino-1 -piperidinyl)-1,4-dihydro-4-oxo-quinoline-3 - carboxylic acid and its isomers and its salts; cis/trans-1 - Cyclopropyl -6-fluoro-8-ethyl-7-(4-hydroxy-3 -methyl-1 -piperidinyl)-1,4- dihydro-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; cis-1 - Cyclopropyl -6-fluoro-8-ethyl-7-(4-hydroxy-3 -methyl-1 -piperidinyl)-1,4-dihydro-4- oxo-quinoline-3-carboxylic acid and its isomers and its salts; trans-1 - Cyclopropyl -6-fluoro-8-ethyl-7-(4-hydroxy-3-methyl-1 -piperidinyl)-1,4-dihydro-4- oxo-quinoline-3-carboxylic acid and its isomers and its salts; (+)-1 - Cyclopropyl -6-fluoro-8-ethyl-7-(4-hydroxy-3,3 -dimethyl-1 -piperidinyl)-1,4-dihydro- 4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; cis/trans-1 - Cyclopropyl -6-fluoro-8-ethyl-7-(4-hydroxy-3-ethyl-1 -piperidinyl)-1,4-dihydro- 4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; trans-1 -Cyclopropyl-6-fluoro-1,4-dihydro-8-ethyl -7-(4-amino-3-methyl-1 -piperidinyl)-4- oxo-quinoline-3-carboxylic acid and its isomers and its salts; cis-1 -Cyclopropyl-6-fluoro-1,4-dihydro-8-ethyl-7-(4-amino-3-methyl-1 -piperidinyl)-4-oxo- quinoline-3-carboxylic acid and its isomers and its salts; (±)-1 -Cyclopropyl-6-fluoro-1,4-dihydro-8-ethyl-7-(4-amino-3,3 -dimethyl-1 -piperidinyl)-4- oxo-quinoline-3 -carboxylic acid and its salts; 152 (+)-1 -Cyclopropyl-6-fluoro-1,4-dihydro-8-ethyl-7-(4-amino-3,3 -dimethyl-1 -piperidinyl)-4- oxo-quinoline-3-carboxylic acid and its salts; (-)-1 -Cyclopropyl-6-fluoro-1,4-dihydro-8-ethyl-7-(4-amino-3,3 -dimethyl-1 -piperidinyl)-4- oxo-quinoline-3-carboxylic acid and its salts; trans-5-Amino-1 -cyclopropyl-6-fluoro-1,4-dihydro-8-methyl -7-(4-amino-3-methyl-1 - piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; cis-1 -5-Amino-i -cyclopropyl-6-fluoro-1,4-dihydro-8-methyl-7-(4-amino-3-methyl-1 - piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; (± )-5-Amino-1 -cyclopropyl-6-fluoro-1,4-dihydro-8-methyl-7-(4-amino-3,3 -dimethyl-1 - piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its salts; (+)-5-Amino-1 -cyclopropyl-6-fluoro-1,4-dihydro-8-methyl-7-(4-amino-3,3-dimethyl-1 - piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its salts; (-)-5-Amino-1 -cyclopropyl-6-fluoro-1,4-dihydro-8-methyl-7-(4-amino-3,3 -dimethyl-1 - piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its salts; 1 -Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-hydroxy-3 -methyl-1 -piperidinyl)-4- oxo-quinoline-3-carboxylic acid and its isomers and its'salts; 5-Amino-1 -cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-hydroxy-3 -methyl-1 - piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; 1 -Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-hydroxy-3 -ethyl-1 -piperidinyl)-4-oxo- quinoline-3-carboxylic acid and its isomers and its salts; 5-Amino-1 -cyclopropyl-6-fluoro-l ,4-dihydro-8-methoxy-7-(4-hydroxy-3-ethyl-1 - piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; 1 -Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-hydroxy-3-n-propyl-1 -piperidinyl)-4- oxo-quinoline-3-carboxylic acid and its isomers and its salts; 5-Amino-1 -cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-hydroxy-3 -isopropyl 1-1 - piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; 5-Amino-l-cyclopropyl-6-fluoro-l,4-dihydro-8-methoxy-7-(4-hydroxy-3-isobutyll-l- piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; 1 -Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-hydroxy-3 -aminomethylene-1 - piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; 5-Amino-1 -cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-hydroxy-3-aminomethyl-1 - piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; 153 l-Cyclopropyl-6-fluoro-l,4-dihydro-8-methoxy-7-(4-hydroxy-3,3-dimethyl-l-piperidinyl)-4- oxo-quinoline-3-carboxylic acid and its isomers and its salts; 5-Amino-1 -cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-hydroxy-3,3-dimethyl-1 - piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; 1 -Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-hydroxy-3,5-dimethyl-1 -piperidinyl)-4- oxo-quinoline-3-carboxylic acid and its isomers and its salts; 5-Amino-1 -cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-hydroxy-3,5-dimethyl-1 - piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; l-Cyclopropyl-6-fluoro-l,4-dihydro-8-methoxy-7-(4-hydroxy-353,5-trimethyl-l-piperidinyl)- 4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; 5-Amino-1 -cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-hydroxy-3,3,5-trimethyl-1 - piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; 1 -Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-hydroxy-4-methyl-1 -piperidinyl)-4- oxo-quinoline-3-carboxylic acid and isomers and its salts; 5-Amino-1 -cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-hydroxy-4-methyl-1 - piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; 1 -Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-hydroxy-4-trifluoro methyl-1 - piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; 5-Amino-1 -cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-hydroxy-4-trifluoro methyl-1 - piperidinyl)-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; l-Ethyl-6-fluoro-8-methyl-7-(4-amino-l-piperidinyl)-l,4-dihydro-4-oxo-quinoline-3- carboxylic acid and its isomers and its salts; 1 -Ethyl-6-fluoro-8-methyl-7-(4-hydroxy-1 -piperidinyl)-1,4-dihydro-4-oxo-quinoline-3 - carboxylic acid and its isomers and its salts; cis/trans-1 -Ethyl-6-fluoro-8-methyl-7-(4-amino-3 -methyl-1 -piperidinyl)-1,4-dihydro-4-oxo- quinoline-3-carboxylic acid and its isomers and its salts; cis-1 -Ethyl-6-fluoro-8-methyl-7-(4-amino-3 -methyl-1 -piperidinyl)-1,4-dihydro-4-oxo- quinoline-3-carboxylic acid and its isomers and its salts; trans-1 -Ethyl-6-fluoro-8-methyl-7-(4-amino-3-methyl-1 -piperidinyl)-1,4-dihydro-4-oxo- quinoline-3-carboxylic acid and its isomers and its salts; cis/trans-1 -Ethyl-6-fluoro- 8 -methyl-7-(4-hydroxy-3 -methyl-1 -piperidinyl)-1,4-dihydro-4- oxo-quinoline-3 -carboxylic acid and its isomers and its salts; cis-1 -Ethyl-6-fluoro-8-methyl-7-(4-hydroxy-3 -methyl-1 -piperidinyl)-1,4-dihydro-4-oxo- quinoline-3-carboxylic acid and its isomers and its salts; trans-1 -Ethyl-6-fluoro-8-methyl-7-(4-hydroxy-3-methyl-1 -piperidinyl)-1,4-dihydro-4-oxo- quinoline-3-carboxylic acid and its isomers and its salts; (±)-1 -Ethyl-6-fluoro-8-methyl-7-(4-amino-3,3-dimethyl-1 -piperidinyl)-1,4-dihydro-4-oxo- quinoline-3-carboxylic acid and its salts; (+)-1 -Ethyl-6-fluoro-8-methyl-7-(4-amino-3,3 -dimethyl-1 -piperidinyl)-1,4-dihydro-4-oxo- quinoline-3-carboxylic acid and its salts; (-)-1 -Ethyl-6-fluoro-8-methyl-7-(4-amino-3,3-dimethyl-1 -piperidinyl)-1,4-dihydro-4-oxo- quinoline-3-carboxylic acid and its salts; (+)-1 -Ethyl-6-fluoro-8-methyl-7-(4-hydroxy-3,3 -dimethyl-1 -piperidinyl)-1,4-dihydro-4-oxo- quinoline-3-carboxylic acid and its isomers and its salts; cis/trans-l-Ethyl-6-fluoro-8-methyl-7-(4-hydroxy-3-ethyl-l-piperidinyl)-l,4-dihydro-4-oxo- quinoline-3-carboxylic acid and its isomers and its salts; cis/trans-1 -Ethyl-6-fluoro-8-methyl-7-(4-amino-3-ethyl-1 -piperidinyl)-1,4-dihydro-4-oxo- ^ quinoline-3-carboxylic acid and its isomers and its salts; 1 -(2,4-Difluorophenyl)-6-fluoro-8-methyl-7-(4-amino-1 -piperidinyl)-1,4-dihydro-4-oxo- quinoline-3-carboxylic acid and its isomers and its salts; 1 -(2,4-Difluorophenyl)-6-fluoro-8-methyl-7-(4-hydroxy-1 -piperidinyl)-1,4-dihydro-4-oxo- quinoline-3-carboxylic acid and its isomers and its salts; cis/trans-l-(2,4-Difluorophenyl)-6-fluoro-8-methyl-7-(4-amino-3-methyl-l-:piperidinyl)-l,4- dihydro-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; cis-1 -(2,4-Difluorophenyl)-6-fluoro-8-methyl-7-(4-amino-3-methyl-1 -piperidinyl)-1,4- dihydro-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; trans-1 -(2,4-Difluorophenyl)-6-fluoro-8-methyl-7-(4-amino-3-methyl-1 -piperidinyl)-1,4- dihydro-4-Oxo-quinoline-3-carboxylic acid and its isomers and its salts; cis/trans-1 -(2,4-Difluorophenyl)-6-fluoro-8-methyl-7-(4-hydroxy-3 -methyl-1 -piperidinyl)- l,4-dihydro-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; cis-1 -(2,4-Difluorophenyl)-6-fluoro-8-methyl-7-(4-hydroxy-3 -methyl-1 -piperidinyl)-1,4- dihydro-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; trans-1 -(2,4-Difluorophenyl)-6Tfluoro-8-methyl-7-(4-hydroxy-3 -methyl-1 -piperidinyl)-1,4- dihydro-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; (±)-1 -(2,4-Difluorophenyl)-6-fluoro-8-methyl-7-(4-amino-3,3 -dimethyl-1 -piperidinyl)-1,4- dihydro-4-oxo-quinoline-3-carboxylic acid and its salts; (+)-1 -(2,4-Difluorophenyl)-6-fluoro-8-methyl-7-(4-amino-3,3-dimethyl-1 -piperidinyl)-1,4- dihydro-4-oxo-quinoline-3-carboxylic acid and its salts; (-)-l-(2,4-Difluorophenyl)-6-fluoro-8-methyl-7-(4-amino-3,3-dimethyl-l-piperidinyl)-l,4- dihydro-4-oxo-quinoline-3-carboxylic acid and its salts; (±)-1 -(2,4-Difluorophenyl)-6-fluoro-8-methyl-7-(4-hydroxy-3,3-dimethyl-1 -piperidinyl)-1,4- dihydro-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; cis/trans-1 -(2,4-Difluorophenyl)-6-fluoro-8-methyl-7-(4-hydroxy-3-ethyl-1 -piperidinyl)-1,4- dihydro-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; cis/trans-1 -(2,4-Difluorophenyl)-6-fluoro-8-methyl-7-(4-amino-3-ethyl-1 -piperidinyl)-1,4- dihydro-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; 1,8-Diethyl-6-fluoro -7-(4-amino-1 -piperidinyl)-1,4-dihydro-4-oxo-quinoline-3 -carboxylic acid and its isomers and its salts; 1,8-Diethyl-6-fluoro -7-(4-hydroxy-1 -piperidinyl)-1,4-dihydro-4-oxo-quinoline-3 -carboxylic acid and its isomers and its salts; cis/trans-1,8-Diethyl-6-fluoro -7-(4-amino-3-methyl-1 -piperidinyl)-1,4-dihydro-4-oxo- quinoline-3-carboxylic acid and itsisoniers and its salts; cis-1,8-Diethyl-6-fluoro -7-(4-amino-3-methyl-1 -piperidinyl)-1,4-dihydro-4-oxo-quinoline-3- carboxylic acid and its isomers and its salts; trans-1,8-Diethyl-6-fluoro -7-(4-amino-3-methyl-1 -piperidinyl)-1,4-dihydro-4-oxo-quinoline- 3-carboxylic acid and its isomers and its salts; cis/trans-l,8-Diethyl-6-fluoro -7-(4-hydroxy-3-methyl-l-piperidinyl)-l,4-dihydro-4-oxo- quinoline-3-carboxylic acid and its isomers and its salts; cis-1,8-Diethyl-6-fluoro -7-(4-hydroxy-3-methyl-1 -piperidinyl)-1,4-dihydro-4-oxo-quinoline- 3-carboxylic acid and its isomers and its salts; trans-l,8-Diethyl-6-fluoro-7-(4-hydroxy-3-methyl-l-piperidinyl)-l,4-dihydro-4-oxo- quinoline-3-carboxylic acid and its isomers and its salts; (+)-1,8-Diethyl -6-fluoro -7-(4-amino-3,3-dimethyl-1 -piperidinyl)-1,4-dihydro-4-oxo- quinoline-3-carboxylic acid and its salts; (+)-1,8-Diethyl -6-fluoro -7-(4-amino-3,3-dimethyl-1 -piperidinyl)-1,4-dihydro-4-oxo- quinoline-3-carboxylic acid and its salts; ' 22 MAR 2006 156 (-)-1,8-Diethyl -6-fluoro -7-(4-amino-3,3-dimethyl-1 -piperidinyl)-1,4-dihydro-4-oxo- quinoline-3-carboxylic acid and its salts; (±)-1,8-Diethyl -6-fluoro-7-(4-hydroxy-3,3-dimethyl-1 -piperidinyl)-1,4-dihydro-4-oxo- quinoline-3-carboxylic acid and its isomers and its salts; cis/trans-1,8-Diethyl -6-fluoro -7-(4-hydroxy-3-ethyl-1 -piperidinyl)-1,4-dihydro-4-oxo- quinoline-3-carboxylic acid and its isomers and its salts; cis/trans-1,8-Diethyl -6-fluoro- -7-(4-amino-3 -ethyl-1 -piperidinyl)-1,4-dihydro-4-oxo- quinoline-3-carboxylic acid and its isomers and its salts; 1 -(2,4-Difluorophenyl)-6-fluoro-8-ethyl-7-(4-amino-1 -piperidinyl)-1,4-dihydro-4-oxo- quinoline-3-carboxylic acid and its isomers and its salts; 1 -(2,4-Difluorophenyl)-6-fluoro-8-ethyl-7-(4-hydroxy-1 -piperidinyl)-! ,4-dihydro-4-oxo- quinoline-3-carboxylic acid and its isomers and its salts; cis/trans-1 -(2,4-Difluorophenyl)-6-fluoro-8-ethyl-7-(4-amino-3-methyl-1 -piperidinyl)-1,4- dihydro-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; cis-1 -(2,4-Difluorophenyl)-6-fluoro-8-ethyl-7-(4-amino-3 -methyl-1 -piperidinyl)-1,4-dihydro- 4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; trans-1 -(2,4-Difluorophenyl)-6-fluoro-8-ethyl-7-(4-amino-3-methyl-1 -piperidinyl)-1,4- dihydro-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; cis/trans-1 -(2,4-Difluorophenyl)-6-fluoro-8-ethyl-7-(4-hydroxy-3-methyl-1 -piperidinyl)-1,4- dihydro-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; cis-1 -(2,4-Difluorophenyl)-6-fluoro-8-ethyl-7-(4-hydroxy-3-methyl-1 -piperidinyl)-1,4- dihydro-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; trans-1 -(2,4-Difluorophenyl)-6-fluoro-8-ethyl-7-(4-hydroxy-3 -methyl-1 -piperidinyl)-1,4- dihydro-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; (±)-1 -(2,4-Difluorophenyl)-6-fluoro-8-ethyl-7-(4-amino-3,3-dimethyl-1 -piperidinyl)-1,4- dihydro-4-oxo-quinoline-3-carboxylic acid and its salts; (+)-1 -(2,4-Difluorophenyl)-6-fluoro-8-ethyl-7-(4-amino-3,3 -dimethyl-1 -piperidinyl)-1,4- dihydro-4-oxo-quinoline-3-carboxylic acid and its salts; (-)-1 -(2,4-Difluorophenyl)-6-fluoro-8-ethyl-7-(4-amino-3,3-dimethyl-1 -piperidinyl)-1,4- dihydro-4-oxo-quinoline-3-carboxylic acid and its salts; (+)-1 -(2,4-Difluorophenyl)-6-fluoro-8-ethyl-7-(4-hydroxy-3,3 -dimethyl-1 -piperidinyl)-1,4- dihydro-4-oxo-quinoline-3-carboxylic acid and its isomers and its salts; 157 2 2 MAR 2006